<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.0 20120330//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 1.0?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Mem Inst Oswaldo Cruz</journal-id><journal-id journal-id-type="iso-abbrev">Mem Inst Oswaldo Cruz</journal-id><journal-id journal-id-type="publisher-id">mioc</journal-id><journal-title-group><journal-title>Mem&#x000f3;rias do Instituto Oswaldo Cruz</journal-title></journal-title-group><issn pub-type="ppub">0074-0276</issn><issn pub-type="epub">1678-8060</issn><publisher><publisher-name>Instituto Oswaldo Cruz, Minist&#x000e9;rio da Sa&#x000fa;de</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7534958</article-id><article-id pub-id-type="doi">10.1590/0074-02760200254</article-id><article-id pub-id-type="other">00202</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>COVID-19: molecular targets, drug repurposing and new avenues for
drug discovery</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Senger</surname><given-names>Mario Roberto</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Evangelista</surname><given-names>Tereza Cristina Santos</given-names></name><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Dantas</surname><given-names>Rafael Ferreira</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Santana</surname><given-names>Marcos Vinicius da Silva</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Gon&#x000e7;alves</surname><given-names>Luiz Carlos Saramago</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>de Souza Neto</surname><given-names>Lauro Ribeiro</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Ferreira</surname><given-names>Sabrina Baptista</given-names></name><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-4560-1291</contrib-id><name><surname>Silva-Junior</surname><given-names>Floriano Paes</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref><xref ref-type="corresp" rid="c">
<sup>+</sup>
</xref></contrib></contrib-group><aff id="aff1">
<label>1</label>Funda&#x000e7;&#x000e3;o Oswaldo Cruz-Fiocruz, Instituto Oswaldo Cruz, Laborat&#x000f3;rio
de Bioqu&#x000ed;mica Experimental e Computacional de F&#x000e1;rmacos, Rio de Janeiro, RJ,
Brasil</aff><aff id="aff2">
<label>2</label>Universidade Federal do Rio de Janeiro, Instituto de Qu&#x000ed;mica,
Laborat&#x000f3;rio de S&#x000ed;ntese Org&#x000e2;nica e Prospec&#x000e7;&#x000e3;o Biol&#x000f3;gica, Rio de Janeiro, RJ,
Brasil</aff><author-notes><corresp id="c">+ Corresponding author: <email>floriano@ioc.fiocruz.br</email></corresp><fn fn-type="equal" id="fn2"><p>MRS, TCSE and RFD contributed equally to this work.</p></fn><fn fn-type="con" id="fn3"><p>All authors contributed to writing, reviewing and editing the manuscript.
MRS, TCSE and RFD contributed equally to this manuscript; FPS-Jr performed
the manuscript conceptualisation and final review. The authors declare no
conflict of interest concerning this manuscript.</p></fn></author-notes><pub-date pub-type="epub"><day>02</day><month>10</month><year>2020</year></pub-date><pub-date pub-type="collection"><year>2020</year></pub-date><volume>115</volume><elocation-id>e200254</elocation-id><history><date date-type="received"><day>22</day><month>5</month><year>2020</year></date><date date-type="accepted"><day>01</day><month>9</month><year>2020</year></date></history><permissions><license license-type="open-access" xlink:href="https://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the
Creative Commons Attribution License</license-p></license></permissions><abstract><p>Coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) is a highly contagious infection that may
break the healthcare system of several countries. Here, we aimed at presenting a
critical view of ongoing drug repurposing efforts for COVID-19 as well as
discussing opportunities for development of new treatments based on current
knowledge of the mechanism of infection and potential targets within. Finally,
we also discuss patent protection issues, cost effectiveness and scalability of
synthetic routes for some of the most studied repurposing candidates since these
are key aspects to meet global demand for COVID-19 treatment.</p></abstract><kwd-group><title>Key words:</title><kwd>COVID-19</kwd><kwd>SARS-CoV-2</kwd><kwd>drug repurposing</kwd><kwd>drug discovery</kwd><kwd>replication cycle</kwd><kwd>drug targets</kwd></kwd-group><counts><fig-count count="17"/><table-count count="3"/><ref-count count="253"/></counts></article-meta></front><body><p>Epidemiology</p><p>Coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) is a highly contagious disease that may break the healthcare
system of several countries. On January 22, the numbers of confirmed COVID-19 cases were
580 but, at the present date (August 5), these numbers increased to 18.3 million
worldwide.<xref rid="B1" ref-type="bibr">
<sup>1</sup>
</xref> The transmission can occur among humans via oral and nasal respiratory droplets
and contact with contaminated surfaces.<xref rid="B2" ref-type="bibr">
<sup>2</sup>
</xref> For instance, droplets in aerosol from a cough can spread 4 to 5 m and a sneeze
can spread droplets up to 8 m away.<xref rid="B3" ref-type="bibr">
<sup>3</sup>
</xref>
</p><p>Recently the aerodynamic nature of SARS-CoV-2 was also investigated in two Wuhan
hospitals in China.<xref rid="B4" ref-type="bibr">
<sup>4</sup>
</xref> The results showed that the viral RNA level in ventilated patient wards was low
because of segregation and high air exchange rate. Conversely, in toilets, which were
not ventilated, and medical staff areas had elevated concentrations of airborne viral
RNA. After rigorous sanitisation procedures these levels were reduced. Therefore the
authors showed that room ventilation, disinfection and sanitisation are important
measures to be implemented in hospitals.<xref rid="B4" ref-type="bibr">
<sup>4</sup>
</xref> Furthermore, SARS-CoV-2 was detected in wastewater in many countries around the
world.<xref rid="B5" ref-type="bibr">
<sup>5</sup>
</xref>
<sup>,</sup>
<xref rid="B6" ref-type="bibr">
<sup>6</sup>
</xref>
<sup>,</sup>
<xref rid="B7" ref-type="bibr">
<sup>7</sup>
</xref>
</p><p>At the moment, the prevention aimed at reducing transmission in the community is the best
alternative, indicating that enhanced public health interventions, including social
distancing, use of masks and movement restrictions should be implemented to bring the
COVID-19 pandemic under control. Aggressive isolation measures including travel
restriction in China, have successfully led to a progressive reduction of COVID-19
cases.<xref rid="B8" ref-type="bibr">
<sup>8</sup>
</xref> Kissler and colleagues, simulated the relaxation of the protective measures
using a post-pandemic mathematical model.<xref rid="B9" ref-type="bibr">
<sup>9</sup>
</xref> The authors demonstrated that social isolation will be necessary at the best
scenario until 2021, and reaffirmed the need and importance of maintaining social
isolation. They also suggested that in the absence of such restrictions, the pandemic
could last until 2024. Thus, in this context, the search for new medicines available to
combat this disease is urgent.</p><p>Etiological agent</p><p>Coronaviruses are members of the family Coronaviridae that present crown-like spikes on
their surface visualised by electron microscopy. The subfamily Coronavirinae contains
the four genera Alpha, Beta, Gamma, and Deltacoronavirus. Coronaviruses infect birds
(gamma and deltacoronaviruses) and several mammalian species (mainly alpha and
betacoronaviruses), including humans.<xref rid="B10" ref-type="bibr">
<sup>10</sup>
</xref>
<sup>,</sup>
<xref rid="B11" ref-type="bibr">
<sup>11</sup>
</xref>
</p><p>Coronaviruses have been isolated from diverse species, including mammals like bats,
rodents, bovines, swine, felines, pangolins, horses and others.<xref rid="B12" ref-type="bibr">
<sup>12</sup>
</xref>
<sup>,</sup>
<xref rid="B13" ref-type="bibr">
<sup>13</sup>
</xref> Human coronavirus was first identified in 1966 by Tyrrell and Bynoe.<xref rid="B14" ref-type="bibr">
<sup>14</sup>
</xref> Nowadays the seven coronaviruses that can infect humans (HCoVs) are classified
in alpha coronavirus (229E, NL63) or beta coronavirus [OC43, HKU1, Middle East
respiratory syndrome coronavirus (MERS-CoV), severe acute respiratory syndrome
coronavirus (SARS-CoV) and more recently the SARS-CoV-2]. 229E, NL63, OC43, and HKU1 can
cause upper and lower respiratory tract infection in adults and children. After the
2000s, two epidemic CoVs have arisen in humans: the SARS-CoV and the MERS-CoV which were
reported in 2003 and 2012, respectively.<xref rid="B15" ref-type="bibr">
<sup>15</sup>
</xref>
<sup>,</sup>
<xref rid="B16" ref-type="bibr">
<sup>16</sup>
</xref> In 2019, after the first report of novel pneumonia (COVID-19) in Wuhan, China,
the seventh hCoV was described. It also causes severe acute respiratory syndrome
(therefore called SARS-CoV-2) and spreads very quickly worldwide .</p><p>Coronavirus are single-stranded positive-sense RNA viruses and their genome size is
approximately 30 kb, which encodes some important structural proteins.<xref rid="B17" ref-type="bibr">
<sup>17</sup>
</xref> The spike (S) glycoprotein is a well characterised protein that mediates
coronavirus entry into host cells via fusion of the viral and cellular membranes through
a pre to post fusion conformation transition.<xref rid="B18" ref-type="bibr">
<sup>18</sup>
</xref> The S protein S1-S2 subunits bind to cellular receptors that vary according to
the coronavirus species: angiotensin-converting enzyme 2 (ACE2) in SARS-CoV, SARS-CoV-2
and HCoV-NL63; and dipeptidyl peptidase 4 (DPP4) and aminopeptidase N (APN) in MERS or
others alphacoronaviruses like TGEV (porcine transmissible gastroenteritis coronavirus)
and porcine respiratory coronavirus (PRCH).<xref rid="B18" ref-type="bibr">
<sup>18</sup>
</xref>
<sup>,</sup>
<xref rid="B19" ref-type="bibr">
<sup>19</sup>
</xref>
<sup>,</sup>
<xref rid="B20" ref-type="bibr">
<sup>20</sup>
</xref>
</p><p>Other structural proteins are mandatory to assemble the complete viral particle like
nucleocapsid protein (N), membrane protein (M) and the envelope protein (E).
Furthermore, they can be involved in other processes like morphogenesis, envelope
formation, budding or pathogenesis.<xref rid="B17" ref-type="bibr">
<sup>17</sup>
</xref>
<sup>,</sup>
<xref rid="B21" ref-type="bibr">
<sup>21</sup>
</xref>
<sup>,</sup>
<xref rid="B22" ref-type="bibr">
<sup>22</sup>
</xref>
</p><p>By genomic sequencing analysis of other coronavirus strains and SARS-CoV-2, Andersen and
collaborators demonstrated that SARS-CoV-2 has mutations resulting in six different
amino acids at the receptor-binding domain (RBD) that appears to be optimised for
binding to the human receptor ACE2.<xref rid="B23" ref-type="bibr">
<sup>23</sup>
</xref> They also showed that the gene encoding the Spike protein has an insertion of 12
nucleotides giving it a polybasic (furin) cleavage site at the S1-S2. In this way, the
high-affinity of the SARS-CoV-2 spike protein to the human ACE2 is a consequence of
natural selection on a human or human-like ACE2. They suggest some possibilities to
explain that: emergence in an animal host before zoonotic transfer; natural selection in
humans following zoonotic transfer; or natural selection during the passage.<xref rid="B23" ref-type="bibr">
<sup>23</sup>
</xref> Other researchers did a phylogenetic analysis of 160 genomes of SARS-CoV-2.<xref rid="B24" ref-type="bibr">
<sup>24</sup>
</xref> They showed 3 important variations in the composition of amino acids that
allowed them to classify into different groups. Group A has two subclusters that are
distinguished by the synonymous mutation T29095C. While B is derived from A by two
mutations T8782C and C28144T, type C differs from its parent type B by mutation of
G26144T. The A and C types are found more often outside East Asia, in Europeans and
Americans. While the B type is the most common type in East Asia.<xref rid="B24" ref-type="bibr">
<sup>24</sup>
</xref>
</p><p>Clinical aspects of pathology</p><p>In December 2019, COVID-19 was initially reported as a new viral pneumonia, due to the
clinical characteristics of the large number of cases that emerged in Wuhan, China.<xref rid="B25" ref-type="bibr">
<sup>25</sup>
</xref>
<sup>,</sup>
<xref rid="B26" ref-type="bibr">
<sup>26</sup>
</xref> SARS-CoV-2 typically causes respiratory sickness, the major clinical
characteristics observed in infected patients are high fever, dry cough and dyspnea
(shortness of breath or difficulty in breathing). Minor symptoms include headache,
diarrhea, nausea, vomiting, loss of smell and taste.<xref rid="B27" ref-type="bibr">
<sup>27</sup>
</xref> This clinical condition can progress to moderate or severe pneumonia.<xref rid="B28" ref-type="bibr">
<sup>28</sup>
</xref> In this case, first there is an accumulation of macrophages in alveoli, followed
by release of cytokines and accumulation of fluids. Neutrophils can also be recruited by
the immune system leading to the destruction of type I and type II alveolar epithelial
cells causing a collapse of the alveoli function and consequently the acute respiratory
distress syndrome (ARDS). In the severe condition, with an increase of the inflammation,
the protein rich fluid from lungs enter in the bloodstream causing the systemic
inflammatory syndrome (SIRS).<xref rid="B29" ref-type="bibr">
<sup>29</sup>
</xref>
<sup>,</sup>
<xref rid="B30" ref-type="bibr">
<sup>30</sup>
</xref> These complicating factors can lead to a multi-organ failure and septic shock,
causing patient death.</p><p>Furthermore, some pre-existing conditions can enhance the risk to develop the severe form
of the disease, including age over 60 years and a history of chronic diseases like
chronic lung disease, asthma, heart diseases, immunosuppressed patients, cancer,
diabetes or chronic kidney disease.<xref rid="B31" ref-type="bibr">
<sup>31</sup>
</xref>
<sup>,</sup>
<xref rid="B32" ref-type="bibr">
<sup>32</sup>
</xref>
<sup>,</sup>
<xref rid="B33" ref-type="bibr">
<sup>33</sup>
</xref>
<sup>,</sup>
<xref rid="B34" ref-type="bibr">
<sup>34</sup>
</xref>
<sup>,</sup>
<xref rid="B35" ref-type="bibr">
<sup>35</sup>
</xref> Finally, the vast majority of people have mild symptoms or are asymptomatic,
which is a big problem because they can also transmit the virus to the non-infected
population.<xref rid="B36" ref-type="bibr">
<sup>36</sup>
</xref>
</p><p>Drug repositioning</p><p>Drug repositioning, repurposing, reprofiling or re-tasking is the evaluation of existing
drugs for new therapeutic purposes.<xref rid="B37" ref-type="bibr">
<sup>37</sup>
</xref> A candidate drug (investigational or approved) for repurposing efforts already
has a known safety and toxicity profile, based on at least successful Phase I or Phase
II clinical trials.<xref rid="B38" ref-type="bibr">
<sup>38</sup>
</xref> Considering the whole process, costs of bringing a repurposed drug to the market
have been estimated to be ten times lower and the time is shortened by around a half,
compared with a new drug.<xref rid="B38" ref-type="bibr">
<sup>38</sup>
</xref> Even though the clinical phase III and regulatory aspects remain similar for
developing a new drug, drug repurposing possesses many advantages over developing a new
drug from scratch: the reduced time and financial investment for development, the lower
risk of failure and a consolidated pharmaceutical supply chain for production and
distribution to the patients that effectively need treatment.<xref rid="B39" ref-type="bibr">
<sup>39</sup>
</xref>
</p><p>Emerging or reemerging viruses pose major public health concerns globally.<xref rid="B40" ref-type="bibr">
<sup>40</sup>
</xref> For several pathogenic viruses, considerable efforts have focused on vaccine
development and other therapies, like transfusion of convalescent plasma.<xref rid="B41" ref-type="bibr">
<sup>41</sup>
</xref>
<sup>,</sup>
<xref rid="B42" ref-type="bibr">
<sup>42</sup>
</xref> However, during pandemics infected individuals need urgently to be treated on a
large scale. A medicine armamentarium for the COVID-19 outbreak is needed immediately
and drug repurposing could be one of the best strategies to deal with this
pandemic.<xref rid="B43" ref-type="bibr">
<sup>43</sup>
</xref>
<sup>,</sup>
<xref rid="B44" ref-type="bibr">
<sup>44</sup>
</xref> Computational and experimental approaches can be used, alone or combined, to
achieve a more holistic point of view and increased chance of success in drug
repurposing.</p><p>In the following topic, we will review SARS-CoV-2 structure and mechanism of infection in
order to discuss molecular targets from the virus or its human host that are being
considered for drug repurposing and perhaps future development of new drugs. Ongoing
drug repurposing efforts will be described in more details later in this article, along
with some clinical trials that have been carried out so far for COVID-19 treatment.
Finally, as treatment availability is of utmost importance when dealing with a pandemic,
we bring a discussion on patent protection and ease of large-scale production of some of
the drugs that are more advanced in clinical studies.</p><p>SARS-CoV-2: structure, mechanism of infection and drug targets</p><p>
<italic>SARS-CoV-2 structure</italic> - Electron microscopy imaging of SARS-CoV-2
virions indicates that they have a spherical or pleomorphic shape, with diameters
ranging from 60 to 140 nm, showing prominent spikes of 9-12 nm in their surfaces that
resemble a solar corona, hence the name &#x0201c;coronavirus&#x0201d;.<xref rid="B45" ref-type="bibr">
<sup>45</sup>
</xref>
<sup>,</sup>
<xref rid="B46" ref-type="bibr">
<sup>46</sup>
</xref>
<sup>,</sup>
<xref rid="B47" ref-type="bibr">
<sup>47</sup>
</xref>
<sup>,</sup>
<xref rid="B48" ref-type="bibr">
<sup>48</sup>
</xref> SARS-CoV-2 is an enveloped virus with a single-stranded positive sense (5&#x02019;-3&#x02019;)
RNA (+ssRNA) (~ 30 kb) containing a 5&#x02019;-cap structure and a 3&#x02019;-poly-A tail.<xref rid="B49" ref-type="bibr">
<sup>49</sup>
</xref>
<sup>,</sup>
<xref rid="B50" ref-type="bibr">
<sup>50</sup>
</xref> Its genomic RNA (gRNA) has a variable number of open reading frames (ORFs) that
are predicted to encode 16 non-structural (Nsp), 4 structural and several accessory
proteins (<xref ref-type="fig" rid="f1">Fig. 1</xref>).<xref rid="B26" ref-type="bibr">
<sup>26</sup>
</xref>
<sup>,</sup>
<xref rid="B51" ref-type="bibr">
<sup>51</sup>
</xref>
<sup>,</sup>
<xref rid="B52" ref-type="bibr">
<sup>52</sup>
</xref>
<sup>,</sup>
<xref rid="B53" ref-type="bibr">
<sup>53</sup>
</xref>
<sup>,</sup>
<xref rid="B54" ref-type="bibr">
<sup>54</sup>
</xref> ORF1a and ORF1b represent more than 2/3 of the whole length of gRNA, and encode
two polyproteins: pp1a (440-500 kDa) and pp1ab (740-810 kDa).<xref rid="B53" ref-type="bibr">
<sup>53</sup>
</xref>
<sup>,</sup>
<xref rid="B55" ref-type="bibr">
<sup>55</sup>
</xref> The polyprotein pp1a is translated from ORF1a while pp1ab from ORF1a/ORF1b using
a -1 ribosomal frameshift mechanism that occurs near the 3&#x02019; end of ORF1a which allows
continued translation of ORF1b.<xref rid="B53" ref-type="bibr">
<sup>53</sup>
</xref> Together, pp1a and pp1ab originate all Nsps (1-16), such as M<sup>pro</sup>
(Nsp5) protease and RdRp (Nsp12) RNA polymerase, which form viral
replicase/transcriptase complexes (RTCs), and are encapsulated in double-layered
vesicles originated from the endoplasmic reticulum (ER).<xref rid="B56" ref-type="bibr">
<sup>56</sup>
</xref>
<sup>,</sup>
<xref rid="B57" ref-type="bibr">
<sup>57</sup>
</xref>
<sup>,</sup>
<xref rid="B58" ref-type="bibr">
<sup>58</sup>
</xref>
</p><p>
<fig id="f1" orientation="portrait" position="float"><label>Fig. 1:</label><caption><title>genomic structure of severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) and its encoded proteins. Together, open reading frames (ORFs)
1a and 1b are translated into all 16 non-structural proteins (Nsp1-16) while
the remaining ORFs encode the structural (S, E, M, N) and accessory proteins
(here represented as nine individual proteins). Adapted from Gordon et
al.<xref rid="B54" ref-type="bibr">
<sup>54</sup>
</xref>
</title></caption><graphic xlink:href="1678-8060-mioc-115-e200254-gf1"/></fig>
</p><p>The ORFs near the 3&#x02019; end of the gRNA encode the structural and accessory proteins of
SARS-CoVs.<xref rid="B58" ref-type="bibr">
<sup>58</sup>
</xref> The first ones have a crucial role in the assembly of viral particles and virus
invasion.<xref rid="B56" ref-type="bibr">
<sup>56</sup>
</xref>
<sup>,</sup>
<xref rid="B58" ref-type="bibr">
<sup>58</sup>
</xref> The main structural proteins are named: spike (S), envelope (E), nucleocapsid
(N) and membrane (M) proteins. Most of them reside on the virion surface (S, E, M
proteins) while N proteins are found in the core of the particle bound to gRNA.<xref rid="B59" ref-type="bibr">
<sup>59</sup>
</xref> S proteins are essential for virus attachment and entry into the host cells,
tissue tropism and pathogenesis.<xref rid="B58" ref-type="bibr">
<sup>58</sup>
</xref>
<sup>,</sup>
<xref rid="B60" ref-type="bibr">
<sup>60</sup>
</xref> E proteins exert several roles in virus infection, such as helping in virus
assembly and release from infected cells, creating ion channels in cell membranes and
suppressing host stress response.<xref rid="B58" ref-type="bibr">
<sup>58</sup>
</xref>
<sup>,</sup>
<xref rid="B61" ref-type="bibr">
<sup>61</sup>
</xref>
<sup>,</sup>
<xref rid="B62" ref-type="bibr">
<sup>62</sup>
</xref> N proteins interact with gRNA to form the ribonucleoprotein.<xref rid="B56" ref-type="bibr">
<sup>56</sup>
</xref>
<sup>,</sup>
<xref rid="B62" ref-type="bibr">
<sup>62</sup>
</xref> M proteins have a role in virion assembly and in determining the shape of the
envelope. They also bind to all other structural proteins promoting, for instance, the
stabilisation of N protein-RNA complexes.<xref rid="B56" ref-type="bibr">
<sup>56</sup>
</xref>
<sup>,</sup>
<xref rid="B63" ref-type="bibr">
<sup>63</sup>
</xref>
</p><p>
<italic>SARS-CoV-2 mechanism of infection</italic> - At present, the mechanisms that
underlie SARS-CoV-2 infection have not been directly described. Nonetheless, they seem
to be similar to those proposed for other coronaviruses.<xref rid="B58" ref-type="bibr">
<sup>58</sup>
</xref> In one proposal, virus infection starts with the binding of its S proteins to
host receptor ACE2, a membrane protein largely expressed in the lung and small intestine
cells (<xref ref-type="fig" rid="f2">Fig. 2</xref>).<xref rid="B44" ref-type="bibr">
<sup>44</sup>
</xref>
<sup>,</sup>
<xref rid="B59" ref-type="bibr">
<sup>59</sup>
</xref>
<sup>,</sup>
<xref rid="B64" ref-type="bibr">
<sup>64</sup>
</xref> After attachment, S protein is cleaved by host proteases initiating the fusion
of virus and cell membranes that culminates in viral gRNA release into the cytoplasm.
This event is proposed to occur through two distinct ways: via plasma membrane (early
pathway) or via endosomes (late pathway). In the early pathway, S protein is cleaved by
host plasma membrane proteases (e. g., TMPRSS2) while in the late pathway by endosomal
proteases (e. g., cathepsin L). The route taken by the virus to enter the cell appears
to be dependent on the availability of these proteases.<xref rid="B59" ref-type="bibr">
<sup>59</sup>
</xref>
<sup>,</sup>
<xref rid="B64" ref-type="bibr">
<sup>64</sup>
</xref>
<sup>,</sup>
<xref rid="B65" ref-type="bibr">
<sup>65</sup>
</xref>
</p><p>
<fig id="f2" orientation="portrait" position="float"><label>Fig. 2:</label><caption><title>severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) replication
cycle and potential targets for drug repurposing. (1) Virus infection
initiates with the binding of virus S proteins to the ACE2 cellular
receptors. After attachment, the virus may enter the cell through two
distinct mechanisms: early and late pathways. (2) In the early pathway the
genomic ssRNA (gRNA) is liberated into the cytoplasm after the fusion
between viral and cell cytoplasmic membranes, an event triggered by membrane
proteases (e. g., TMPRSS2). (3) The gRNA is immediately translated into two
polyproteins that undergo proteolytic cleavage giving rise to all
nonstructural proteins (Nsps). (4) The Nsps form the
replication-transcription complexes (RTCs) where the gRNA (blue ribbon) is
replicated and the subgenomic RNAs (red ribbon) are transcribed. (5) The
subgenomic RNAs are translated into viral structural and accessory proteins
in the cytosol. (6) Upon translation, E, M and S structural proteins are
inserted into ER and follow the secretory pathway to the ER-Golgi
intermediate compartment (ERGIC). (7) Meanwhile, a copy of the gRNA binds to
N proteins in the cytoplasm forming the nucleocapsid, which is transported
to the ERGIC. (8) Virion assembly in the ERGIC. (9) The new virion travels
through the cytoplasm inside a vesicle and leaves the cell by exocytosis.
(10) Alternatively, in the late pathway, the virus can undergo endocytosis
to initiate the infection. (11) The virion membrane merges with the endosome
membrane after S protein proteolysis by endosomal proteases (e. g.,
cathepsin L), allowing the gRNA to be released into the cytoplasm. From this
point on, the cycle follows the same pathway described in 3-9 steps. The red
arrows indicate the general replication pathway and the blue arrows indicate
the gRNA movement through the cycle. Some viral and host proteins have been
explored as potential targets for drug repurposing. Some of these drug
candidates are shown with their site of action indicated in the cycle.<xref rid="B44" ref-type="bibr">
<sup>44</sup>
</xref>
<sup>,</sup>
<xref rid="B59" ref-type="bibr">
<sup>59</sup>
</xref>
<sup>,</sup>
<xref rid="B66" ref-type="bibr">
<sup>66</sup>
</xref>
<sup>,</sup>
<xref rid="B67" ref-type="bibr">
<sup>67</sup>
</xref>
</title></caption><graphic xlink:href="1678-8060-mioc-115-e200254-gf2"/></fig>
</p><p>Once in the cytoplasm, gRNA is readily translated into viral polyproteins (pp1a/pp1ab),
which are cleaved into the individual Nsps that compose the RTCs (<xref ref-type="fig" rid="f2">Fig. 2</xref>). These complexes recognise transcriptional regulator
sequences in gRNA and begin to transcribe a series of subgenomic RNAs that encode
structural and accessory proteins, otherwise the whole gRNA is replicated.<xref rid="B57" ref-type="bibr">
<sup>57</sup>
</xref>
<sup>,</sup>
<xref rid="B58" ref-type="bibr">
<sup>58</sup>
</xref>
<sup>,</sup>
<xref rid="B59" ref-type="bibr">
<sup>59</sup>
</xref> Upon translation, S, E and M structural proteins are driven to the ER-Golgi
intermediate compartment (ERGIC) where S proteins go through post-translational
modifications (e. g., proteolysis, N-glycosylation). In parallel, a copy of the gRNA and
N proteins bind in the cytoplasm to form the nucleocapsid and move into the ERGIC. In
this compartment, nucleocapsid and the other viral proteins are assembled into a virion
which travels through the cytoplasm inside a vesicle and leaves the cell by
exocytosis.<xref rid="B48" ref-type="bibr">
<sup>48</sup>
</xref>
<sup>,</sup>
<xref rid="B56" ref-type="bibr">
<sup>56</sup>
</xref>
<sup>,</sup>
<xref rid="B59" ref-type="bibr">
<sup>59</sup>
</xref>
</p><p>
<italic>Candidate drug targets</italic> - In the search for a treatment for COVID-19,
several viral and host molecular proteins have been explored as potential drug targets.
Overall, they participate in key events of the virus infection cycle, such as cell entry
and replication, as well in host metabolic pathways and immune response. In the
following topics we will address in more details some of these targets. Drugs under
investigation for blocking the main steps of the SARS-Cov-2 virus replication cycle are
indicated in <xref ref-type="fig" rid="f2">Fig. 2</xref>.</p><p>
<italic>Virus targets</italic> - During SARS-CoV-2 gRNA translation, two proteases,
namely M<sup>pro</sup> and PL<sup>pro</sup>, act in concert to cleave and release from
pp1a/pp1ab the 16 Nsps that compose the RTC.<xref rid="B58" ref-type="bibr">
<sup>58</sup>
</xref> Therefore, these proteases are essential for virus replication and represent
useful targets for therapeutic intervention. Recently, SARS-CoV-2 M<sup>pro</sup> and
PL<sup>pro</sup> had their 3D structures published - PDB 6LU7, 2.16 &#x000c5; and PDB 6W9C,
2.70 &#x000c5;, respectively - which make them particularly useful for computational
structure-based drug design methods.<xref rid="B68" ref-type="bibr">
<sup>68</sup>
</xref>
</p><p>3-chymotrypsin-like protein (synonyms: coronavirus main protease, M<sup>pro</sup>,
3CL<sup>pro</sup>) of SARS-CoV-2 is a 33.8 kDa homodimeric protein (306 aa) that
belongs to the cysteine protease class (possibly from C30 family and PA clan).<xref rid="B68" ref-type="bibr">
<sup>68</sup>
</xref>
<sup>,</sup>
<xref rid="B69" ref-type="bibr">
<sup>69</sup>
</xref> This enzyme catalyses the hydrolysis of peptide bonds of polyproteins (possibly
E.C. 3.4.22.69) at sites whose amino acid sequences generally follow the pattern
Leu-Gln* (Ser, Ala, Gly) (*marks the cleavage site).<xref rid="B70" ref-type="bibr">
<sup>70</sup>
</xref>
<sup>,</sup>
<xref rid="B71" ref-type="bibr">
<sup>71</sup>
</xref> M<sup>pro</sup> is part of pp1a/pp1ab polyproteins (Nsp5).<xref rid="B57" ref-type="bibr">
<sup>57</sup>
</xref> During polyproteins translation, M<sup>pro</sup> suffers autolytic cleavage and
is released from its polyprotein precursor, reaching a mature state that cleaves
pp1a/pp1ab at no less than 11 sites downstream of the Nsp4 coding region.<xref rid="B57" ref-type="bibr">
<sup>57</sup>
</xref>
<sup>,</sup>
<xref rid="B68" ref-type="bibr">
<sup>68</sup>
</xref>
<sup>,</sup>
<xref rid="B70" ref-type="bibr">
<sup>70</sup>
</xref>
<sup>,</sup>
<xref rid="B72" ref-type="bibr">
<sup>72</sup>
</xref> Each protomer of SARS-CoV-2 M<sup>pro</sup> is divided into three domains:
chymotrypsin and picornavirus 3C protease-like I and II domains, composed by
antiparallel &#x003b2;-barrel structures, and domain III which contains five &#x003b1;-helices arranged
into an antiparallel globular cluster responsible for protease dimerisation (<xref ref-type="fig" rid="f3">Fig. 3</xref>A). Domains II and III are connected by a long
loop, where lies a cleft that serves as a substrate binding site and where catalysis
occurs using the Cys<sup>145</sup>-His<sup>41</sup> dyad (<xref ref-type="fig" rid="f3">Fig. 3</xref>B).<xref rid="B68" ref-type="bibr">
<sup>68</sup>
</xref>
<sup>,</sup>
<xref rid="B70" ref-type="bibr">
<sup>70</sup>
</xref>
<sup>,</sup>
<xref rid="B73" ref-type="bibr">
<sup>73</sup>
</xref> M<sup>pro</sup> has been widely explored in drug discovery campaigns using
experimental and/or computational approaches.<xref rid="B68" ref-type="bibr">
<sup>68</sup>
</xref>
<sup>,</sup>
<xref rid="B73" ref-type="bibr">
<sup>73</sup>
</xref>
<sup>,</sup>
<xref rid="B74" ref-type="bibr">
<sup>74</sup>
</xref>
<sup>,</sup>
<xref rid="B75" ref-type="bibr">
<sup>75</sup>
</xref>
<sup>,</sup>
<xref rid="B76" ref-type="bibr">
<sup>76</sup>
</xref>
<sup>,</sup>
<xref rid="B77" ref-type="bibr">
<sup>77</sup>
</xref> Moreover, M<sup>pro</sup> has no human homologue, which reduces the chances of
toxic effects of a given inhibitor.<xref rid="B68" ref-type="bibr">
<sup>68</sup>
</xref> Potential SARS-CoV-2 M<sup>pro</sup> inhibitors include FDA-approved antivirals,
such as inhibitors of HIV-1 [e. g., lopinavir (1) /ritonavir (2)] and HCV [e.g.,
boceprevir (3)] proteases, as well as antineoplastic [e.g. carmofur (4)] and
antibacterial [e.g., doxycycline (5)] drugs.<xref rid="B73" ref-type="bibr">
<sup>73</sup>
</xref>
<sup>,</sup>
<xref rid="B78" ref-type="bibr">
<sup>78</sup>
</xref>
<sup>,</sup>
<xref rid="B79" ref-type="bibr">
<sup>79</sup>
</xref>
<sup>,</sup>
<xref rid="B80" ref-type="bibr">
<sup>80</sup>
</xref>
<sup>,</sup>
<xref rid="B81" ref-type="bibr">
<sup>81</sup>
</xref>
<sup>,</sup>
<xref rid="B82" ref-type="bibr">
<sup>82</sup>
</xref> Chemical structures for compounds 1-14 are shown in <xref ref-type="fig" rid="f4">Fig. 4</xref>.</p><p>
<fig id="f3" orientation="portrait" position="float"><label>Fig. 3:</label><caption><title>severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) main
protease (M<sup>pro</sup>) 3D structure (PDB 6LU7, 2.16 &#x000c5;). (A) Transparent
VdW surface and ribbon representation of M<sup>pro</sup>, coloured by its
three domains: domain I (pink), domain II (green) and domain III (blue). (B)
The catalytic pair formed by Cys145 and His41 (CPK colours with dark blue
carbons). Images created using Maestro, release 2020-1 (Maestro,
Schr&#x000f6;dinger, LLC, New York, NY, 2020).</title></caption><graphic xlink:href="1678-8060-mioc-115-e200254-gf3"/></fig>
</p><p>
<fig id="f4" orientation="portrait" position="float"><label>Fig. 4:</label><caption><title>chemical structures for drug repurposing candidates and compounds 1-14
under investigation against coronavirus disease 2019 (COVID-19).</title></caption><graphic xlink:href="1678-8060-mioc-115-e200254-gf4"/></fig>
</p><p>Nsp3 is the largest protein encoded by CoVs (~200 kDa). In SARS-CoVs it has 16 domains
which include a papain-like proteolytic enzyme from the cysteine protease class (C16
family and CA clan for SARS-CoV).<xref rid="B57" ref-type="bibr">
<sup>57</sup>
</xref>
<sup>,</sup>
<xref rid="B69" ref-type="bibr">
<sup>69</sup>
</xref>
<sup>,</sup>
<xref rid="B83" ref-type="bibr">
<sup>83</sup>
</xref> PL<sup>pro</sup> is composed of a catalytic domain, an extended right-handed
thumb-palm-finger structure with a Cys-His-Asp catalytic triad, and a ubiquitin-like
domain (Ubl) (<xref ref-type="fig" rid="f5">Fig. 5</xref>A). The catalytic Cys is
located in the thumb subdomain while His and Asp in the palm subdomain (<xref ref-type="fig" rid="f5">Fig. 5</xref>B). PL<sup>pro</sup> catalyses the hydrolysis
reaction of peptide bonds of pp1a/pp1ab at three sites (Nsp1/Nsp2, Nsp2/Nsp3 and
Nsp3/Nsp4) that share the XLXGG* pattern (*represents the cleavage site).<xref rid="B57" ref-type="bibr">
<sup>57</sup>
</xref>
<sup>,</sup>
<xref rid="B71" ref-type="bibr">
<sup>71</sup>
</xref>
<sup>,</sup>
<xref rid="B83" ref-type="bibr">
<sup>83</sup>
</xref>
<sup>,</sup>
<xref rid="B84" ref-type="bibr">
<sup>84</sup>
</xref> This activity is responsible for Nsp3 release from polyproteins.
PL<sup>pro</sup> also recognises and hydrolyses ubiquitin and ISG15 from cellular
proteins.<xref rid="B83" ref-type="bibr">
<sup>83</sup>
</xref>
<sup>,</sup>
<xref rid="B84" ref-type="bibr">
<sup>84</sup>
</xref> The deubiquitination and deISGylation activities are proposed to modulate the
post-translational modifications of signaling molecules that trigger innate immune
response of the host.<xref rid="B85" ref-type="bibr">
<sup>85</sup>
</xref> These functions are pivotal for virus infection justifying the search for
SARS-CoVs PL<sup>pro</sup> inhibitors.<xref rid="B84" ref-type="bibr">
<sup>84</sup>
</xref>
<sup>,</sup>
<xref rid="B86" ref-type="bibr">
<sup>86</sup>
</xref>
<sup>,</sup>
<xref rid="B87" ref-type="bibr">
<sup>87</sup>
</xref>
<sup>,</sup>
<xref rid="B88" ref-type="bibr">
<sup>88</sup>
</xref>
<sup>,</sup>
<xref rid="B89" ref-type="bibr">
<sup>89</sup>
</xref>
<sup>,</sup>
<xref rid="B90" ref-type="bibr">
<sup>90</sup>
</xref> Putative inhibitors of SARS-CoV-2 PL<sup>pro</sup> include FDA-approved drugs
such as fostamatinib disodium (6) (a tyrosine kinase inhibitor used in the treatment of
chronic immune thrombocytopenia) and natural products [e.g., platycodin D (7)].<xref rid="B89" ref-type="bibr">
<sup>89</sup>
</xref>
<sup>,</sup>
<xref rid="B91" ref-type="bibr">
<sup>91</sup>
</xref>
</p><p>
<fig id="f5" orientation="portrait" position="float"><label>Fig. 5:</label><caption><title>tertiary structure and catalytic site of severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) PL<sup>pro</sup> (PDB 6W9C, 2.7 &#x000c5;). (A)
The monomer is represented with transparent VdW surface and opaque ribbons,
coloured by domains: finger (cyan), palm (pink) and thumb (green). The Ubl
domain is represented in dark gray ribbon. (B) Amino acid residues of the
catalytic triad (Cys145, His272 and Asp286) are represented in sticks
coloured by CPK (carbons in yellow). The Cys145 is located in the thumb
domain (green) while His272 and Asp286 are located in the palm domain
(pink). Images created using Maestro, release 2020-1 (Maestro, Schr&#x000f6;dinger,
LLC, New York, NY, 2020).</title></caption><graphic xlink:href="1678-8060-mioc-115-e200254-gf5"/></fig>
</p><p>RNA-dependent RNA polymerase (RdRp, Nsp12) is an essential protein responsible for RNA
synthesis during viral RNA transcription and replication cycles.<xref rid="B89" ref-type="bibr">
<sup>89</sup>
</xref> As described for SARS-CoV, the RNA polymerase activity of SAR-CoV-2 RdRp (804
aa) also seems to require the binding of Nsp7 and Nsp8 cofactors to enhance RdRp binding
and processivity.<xref rid="B92" ref-type="bibr">
<sup>92</sup>
</xref>
<sup>,</sup>
<xref rid="B93" ref-type="bibr">
<sup>93</sup>
</xref> The overall RdRp structure has a &#x0201c;right hand&#x0201d; RdRp domain, composed by three
subdomains (palm, fingers and thumb), and a nidovirus-unique N-terminal extension domain
that forms a nidovirus RdRp-associated nucleotidyltransferase (NiRAN) structure. These
domains are connected by an interface domain. Additionally, this protein also has a
N-terminal &#x003b2;-hairpin (<xref ref-type="fig" rid="f6">Fig. 6</xref>A). The active site of
RdRp contains conserved polymerase motifs located in the palm subdomain and its
configuration is similar to other RNA polymerases.<xref rid="B94" ref-type="bibr">
<sup>94</sup>
</xref> RdRp substrates, RNA template/primer and nucleotide triphosphate (NTPs), access
the catalytic centre through the template and NTP entry paths, respectively, while the
product-template hybrid is released through the RNA exit path.<xref rid="B92" ref-type="bibr">
<sup>92</sup>
</xref>
<sup>,</sup>
<xref rid="B94" ref-type="bibr">
<sup>94</sup>
</xref> SARS-CoV-2 RdRp shares 96% identity in amino acid sequence with SARS-CoV
protein.<xref rid="B93" ref-type="bibr">
<sup>93</sup>
</xref> Moreover, the accessory proteins also have a high degree of amino acid sequence
identity between these viruses: 98.1 % for Nsp7 and 97.5 % for Nsp8 - sequences obtained
from PDB 7BV2 (2.5 &#x000c5;) and PDB 6NUR (3.1 &#x000c5;) entries.<xref rid="B92" ref-type="bibr">
<sup>92</sup>
</xref>
<sup>,</sup>
<xref rid="B95" ref-type="bibr">
<sup>95</sup>
</xref> Therefore, it is reasonable to suggest that SARS-CoV RdRp inhibitors may also
bind to the homologous enzyme from SARS-CoV-2, as demonstrated for remdesivir (8) (<xref ref-type="fig" rid="f6">Fig. 6</xref>B), an adenosine triphosphate analog.<xref rid="B92" ref-type="bibr">
<sup>92</sup>
</xref>
<sup>,</sup>
<xref rid="B93" ref-type="bibr">
<sup>93</sup>
</xref>
<sup>,</sup>
<xref rid="B96" ref-type="bibr">
<sup>96</sup>
</xref> Other potential inhibitors include clinically available drugs, such as
favipiravir (9), a purine nucleic acid analog used in the treatment of influenza, and
ribavirin (10), a synthetic guanosine nucleoside indicated for the treatment of
hepatitis C virus (HCV) infection.<xref rid="B97" ref-type="bibr">
<sup>97</sup>
</xref>
<sup>,</sup>
<xref rid="B98" ref-type="bibr">
<sup>98</sup>
</xref> The crucial role of RdRp and the lack of a host homolog turns this enzyme into a
valuable target for anti-CoVs agents.<xref rid="B93" ref-type="bibr">
<sup>93</sup>
</xref>
</p><p>
<fig id="f6" orientation="portrait" position="float"><label>Fig. 6:</label><caption><title>3D structure of severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) RNA-dependent RNA polymerase (PDB 7BV2, 2.5 &#x000c5;, RdRp, Nsp12)
bound to triphosphate form of remdesivir (RTP) and cofactors Nsp7 (pink) and
Nsp8 (purple). (A) Ribbon representation coloured by Nsp12 subdomains:
&#x003b2;-hairpin (cyan), NiRAN (yellow), interface (orange), finger (blue), palm
(red) and thumb (light green). (B) Binding pose of RTP. The sidechain of all
residues (gray) within 5 &#x000c5; of distance and the RTP molecule (pink) are
represented as sticks. Magnesium ions (pink) are represented as space
filling spheres. Images created using Maestro, release 2020-1 (Maestro,
Schr&#x000f6;dinger, LLC, New York, NY, 2020).</title></caption><graphic xlink:href="1678-8060-mioc-115-e200254-gf6"/></fig>
</p><p>Helicase (Nsp13) is a multifunctional protein (predicted to have 596 aa in SARS-CoV-2)
essential for SARS-CoVs RNA replication and proliferation.<xref rid="B74" ref-type="bibr">
<sup>74</sup>
</xref>
<sup>,</sup>
<xref rid="B99" ref-type="bibr">
<sup>99</sup>
</xref> SARS-CoV helicase belongs to helicase superfamily 1 (SF1) and can unwind
double-stranded DNAs/RNAs (helicase activity) in the 5&#x02019;-3&#x02019; direction, an
energy-consuming process that is driven by the hydrolysis of nucleosides triphosphate
(NTPase activity).<xref rid="B57" ref-type="bibr">
<sup>57</sup>
</xref>
<sup>,</sup>
<xref rid="B100" ref-type="bibr">
<sup>100</sup>
</xref>
<sup>,</sup>
<xref rid="B101" ref-type="bibr">
<sup>101</sup>
</xref> Its structure contains five domains arranged in a triangular pyramid-shape: the
triangular base is composed by two &#x0201c;RecA-like&#x0201d; (1A and 2A) and 1B domains whereas the
zinc binding domain (ZBD), in the N-terminal, and the stalk domain are oriented towards
the apex. The ZBD and 1B domains are connected by the stalk domain (<xref ref-type="fig" rid="f7">Fig. 7</xref>).<xref rid="B101" ref-type="bibr">
<sup>101</sup>
</xref> The same domain arrangement is predicted to occur in SARS-CoV-2 enzyme.<xref rid="B74" ref-type="bibr">
<sup>74</sup>
</xref> SARS-CoV helicase has been explored as a potential target for drugs.<xref rid="B99" ref-type="bibr">
<sup>99</sup>
</xref>
<sup>,</sup>
<xref rid="B100" ref-type="bibr">
<sup>100</sup>
</xref>
<sup>,</sup>
<xref rid="B102" ref-type="bibr">
<sup>102</sup>
</xref> Recently, some efforts have also been made to predict inhibitors for SARS-CoV-2
helicase.<xref rid="B74" ref-type="bibr">
<sup>74</sup>
</xref>
<sup>,</sup>
<xref rid="B103" ref-type="bibr">
<sup>103</sup>
</xref>
<sup>,</sup>
<xref rid="B104" ref-type="bibr">
<sup>104</sup>
</xref>
<sup>,</sup>
<xref rid="B105" ref-type="bibr">
<sup>105</sup>
</xref> They include drugs used in the clinics to treat acquired immunodeficiency
syndrome (AIDS), such as vapreotide (11) (somatostatin analog) and atazanavir (12) (HIV
protease inhibitor), as well anti-HCV protease inhibitors [e.g., daclatasvir (13)] and
bismuth salts [e.g., bismuth potassium citrate (14), a compound used in clinical
treatment of gastrointestinal diseases].<xref rid="B103" ref-type="bibr">
<sup>103</sup>
</xref>
<sup>,</sup>
<xref rid="B104" ref-type="bibr">
<sup>104</sup>
</xref>
<sup>,</sup>
<xref rid="B106" ref-type="bibr">
<sup>106</sup>
</xref>
</p><p>
<fig id="f7" orientation="portrait" position="float"><label>Fig. 7:</label><caption><title>tertiary structure of severe acute respiratory syndrome coronavirus
(SARS-CoV) helicase (PDB 6JYT, 2.8 &#x000c5;, Nsp13). The domains are zinc-binding
(ZBD) (light green), stalk (orange), 1B (pink), 1A (cyan) and 2A (blue). The
zinc atoms are shown as gray spheres. Image created using Maestro, release
2020-1 (Maestro, Schr&#x000f6;dinger, LLC, New York, NY, 2020).</title></caption><graphic xlink:href="1678-8060-mioc-115-e200254-gf7"/></fig>
</p><p>SARS-CoVs replication also requires other enzymatic activities including
(guanine-N7)-methyltransferase (N7-MTase), 2&#x02019;-O-methyltransferase (2&#x02019;-OMTase) and
exoribonuclease (ExoN).<xref rid="B57" ref-type="bibr">
<sup>57</sup>
</xref>
<sup>,</sup>
<xref rid="B107" ref-type="bibr">
<sup>107</sup>
</xref>
<sup>,</sup>
<xref rid="B108" ref-type="bibr">
<sup>108</sup>
</xref> The N7-MTase domain at the C-terminus of Nsp14 is responsible for adding a
methyl group in the N7 position of RNA 5&#x02019;-guanosine forming the 5&#x02019;-cap structure of
viral RNAs.<xref rid="B108" ref-type="bibr">
<sup>108</sup>
</xref> Additionally, Nsp14 also has a catalytic domain in its N-terminus with 3&#x02019;-5&#x02019;
ExoN activity, which participates in RNA proofreading mechanism (<xref ref-type="fig" rid="f8">Fig. 8</xref>).<xref rid="B57" ref-type="bibr">
<sup>57</sup>
</xref> 2&#x02019;-OMTase (Nsp16) catalyses the methylation reaction at the ribose 2&#x02019;-O position
of the first and second nucleotide of the mRNAs and it is one of the SARS-CoV-2 proteins
whose 3D structure has already been resolved (PDB: 6W61, 2.0 &#x000c5;) (<xref ref-type="fig" rid="f9">Fig. 9</xref>).<xref rid="B109" ref-type="bibr">
<sup>109</sup>
</xref> Both Nsp14 and 16 use Nsp10 as a cofactor to enhance their 3&#x02019;-5&#x02019; ExoN and
2&#x02019;-OMTase activities, respectively.<xref rid="B110" ref-type="bibr">
<sup>110</sup>
</xref> Together, these proteins are responsible for inducing RNA modifications that are
essential for its stability and translation as well to avoid the activation of host
immune response.<xref rid="B57" ref-type="bibr">
<sup>57</sup>
</xref>
<sup>,</sup>
<xref rid="B107" ref-type="bibr">
<sup>107</sup>
</xref>
<sup>,</sup>
<xref rid="B109" ref-type="bibr">
<sup>109</sup>
</xref> Thus, Nsp14 and 16 have been considered as potential targets for anti-SARS
agents that may affect their functions in a direct or indirect way (e.g., by blocking
Nsp 10 binding).<xref rid="B108" ref-type="bibr">
<sup>108</sup>
</xref>
<sup>,</sup>
<xref rid="B109" ref-type="bibr">
<sup>109</sup>
</xref>
<sup>,</sup>
<xref rid="B110" ref-type="bibr">
<sup>110</sup>
</xref>
<sup>,</sup>
<xref rid="B111" ref-type="bibr">
<sup>111</sup>
</xref>
<sup>,</sup>
<xref rid="B112" ref-type="bibr">
<sup>112</sup>
</xref>
<sup>,</sup>
<xref rid="B113" ref-type="bibr">
<sup>113</sup>
</xref>
<sup>,</sup>
<xref rid="B114" ref-type="bibr">
<sup>114</sup>
</xref>
<sup>,</sup>
<xref rid="B115" ref-type="bibr">
<sup>115</sup>
</xref> Some compounds have been regarded as potential inhibitors of SARS-CoV-2 methyl
transferases, such as adenine dinucleoside S-adenosylmethionine analogs [e.g.,
dinucleoside 13 (15)], predicted for SARS-CoV N7-MTase activity, and some clinically
available drugs [e.g., raltegravir (16) - a HIV integrase inhibitor], predicted for
SARS-CoV-2 2&#x02019;-OMTase activity.<xref rid="B112" ref-type="bibr">
<sup>112</sup>
</xref>
<sup>,</sup>
<xref rid="B115" ref-type="bibr">
<sup>115</sup>
</xref> Chemical structures for compounds 15-29 are shown in <xref ref-type="fig" rid="f10">Fig. 10</xref>.</p><p>
<fig id="f8" orientation="portrait" position="float"><label>Fig. 8:</label><caption><title>tertiary structure of severe acute respiratory syndrome coronavirus
(SARS-CoV) Nsp14 (PDB 5C8S, 3.3 &#x000c5;) in complex with its Nsp10 cofactor
(yellow VdW surface). Nsp14 is represented as ribbons coloured according to
its domains: Methyltransferase (MTD, light green) and exoribonuclease (ExoN,
blue). Zn2+ and Mg2+ ions are shown as gray and magenta spheres,
respectively. The Nsp10 cofactor interacts with the Nsp14 ExoN domain. Image
created using Maestro, release 2020-1 (Maestro, Schr&#x000f6;dinger, LLC, New York,
NY, 2020).</title></caption><graphic xlink:href="1678-8060-mioc-115-e200254-gf8"/></fig>
</p><p>
<fig id="f9" orientation="portrait" position="float"><label>Fig. 9:</label><caption><title>ribbon representation and VdW surface of the severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) 2&#x02019;-O-methyltransferase 3D structure (PDB
6W61, 2.0 &#x000c5;, Nsp16, pink) in complex with its Nsp10 cofactor (light blue).
The zinc and chloride ions are represented as gray and green spheres,
respectively. Image created using Maestro, release 2020-1 (Maestro,
Schr&#x000f6;dinger, LLC, New York, NY, 2020).</title></caption><graphic xlink:href="1678-8060-mioc-115-e200254-gf9"/></fig>
</p><p>
<fig id="f10" orientation="portrait" position="float"><label>Fig. 10:</label><caption><title>chemical structures for drug repurposing candidates and compounds 15-29
under investigation against coronavirus disease 2019 (COVID-19).</title></caption><graphic xlink:href="1678-8060-mioc-115-e200254-gf10"/></fig>
</p><p>Spike protein (S) is a viral type I transmembrane glycoprotein (~180-200 kDa) responsible
for CoVs interaction and invasion of host cells.<xref rid="B59" ref-type="bibr">
<sup>59</sup>
</xref>
<sup>,</sup>
<xref rid="B64" ref-type="bibr">
<sup>64</sup>
</xref> This protein is synthesised as a monomer and suffers post-translational
modifications in the ER before becoming a trimeric glycosylated protein.<xref rid="B59" ref-type="bibr">
<sup>59</sup>
</xref>
<sup>,</sup>
<xref rid="B116" ref-type="bibr">
<sup>116</sup>
</xref> Its structure is divided into three main domains: an extracellular, a
transmembrane and a short intracellular domain (<xref ref-type="fig" rid="f11">Fig.
11</xref>).<xref rid="B117" ref-type="bibr">
<sup>117</sup>
</xref> The former protrudes from the surface of the virus particle creating a
crown-like halo and contains two functional subunits: S1 (bulbous shape), which binds to
cellular receptors (e.g., ACE2), and S2 (stalk shape) that promotes the fusion between
cell and virus membranes.<xref rid="B59" ref-type="bibr">
<sup>59</sup>
</xref> In turn, S1 subunit has two domains: a N-terminal and a C-terminal domain. The
latter serves as a RBD for SARS-CoVs being responsible for ACE2 recognition and
binding.<xref rid="B59" ref-type="bibr">
<sup>59</sup>
</xref>
<sup>,</sup>
<xref rid="B64" ref-type="bibr">
<sup>64</sup>
</xref>
<sup>,</sup>
<xref rid="B117" ref-type="bibr">
<sup>117</sup>
</xref> Apart from S1 and S2, SARS-CoV-2 S protein also has a ganglioside-binding
subdomain at the tip of N-terminal domain, which may allow this protein to interact with
gangliosides on cells&#x02019; surface. In theory, this domain could facilitate virus attachment
to the cell and facilitate the contact with ACE2, being a potential site for drug
interference.<xref rid="B118" ref-type="bibr">
<sup>118</sup>
</xref>
</p><p>
<fig id="f11" orientation="portrait" position="float"><label>Fig. 11:</label><caption><title>tertiary and quaternary structure of extracellular domain of severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) S protein (PDB: 6VXX, 2.8
&#x000c5;). (A) Top view of the protein trimer. Each monomer is distinctly coloured
(blue, light green and red). (B) Side view of the protein. (C) VdW surface
of each monomer. (D) Subunits S1 and S2 (violet) of extracellular domain.
The S1 subunit is further divided into N terminal (NTD, pink) and C-terminal
domains (CTD, green). At the tip of the NTD, the ganglioside-binding domain
(GBD) is coloured in blue. CTD is also the receptor-binding domain
(RBD).</title></caption><graphic xlink:href="1678-8060-mioc-115-e200254-gf11"/></fig>
</p><p>CoVs S proteins require proteolytic priming or cleavage to become fusion competent.<xref rid="B59" ref-type="bibr">
<sup>59</sup>
</xref> This is achieved by host proteases (e.g., TMPRSS2, cathepsin L, furins) which
cleave the S2 subunit of S protein at two main positions: S1/S2 interface and S2&#x02019;. The
latter is located immediately upstream of the fusion peptide (FP), the fusion functional
element of S2. Contrary to SARS-CoV, SARS-CoV-2 S2 subunit also has an additional
cleavage site for furin proteases in the S1/S2 region, something that also occurs in
MERS-CoV.<xref rid="B60" ref-type="bibr">
<sup>60</sup>
</xref> It is still unclear its role in SARS-CoV-2 infection, but it is speculated that
the ubiquitous expression of furins may increase cell and tissue tropism of SARS-CoV-2
in comparison to SARS-CoV, as well altering its transmissibility and pathogenicity.<xref rid="B60" ref-type="bibr">
<sup>60</sup>
</xref>
<sup>,</sup>
<xref rid="B117" ref-type="bibr">
<sup>117</sup>
</xref> Taken together, host proteases represent potential targets for anti-SARS-CoV-2
drugs, and thus some of them will be discussed in the following topics.<xref rid="B60" ref-type="bibr">
<sup>60</sup>
</xref>
<sup>,</sup>
<xref rid="B64" ref-type="bibr">
<sup>64</sup>
</xref>
<sup>,</sup>
<xref rid="B119" ref-type="bibr">
<sup>119</sup>
</xref>
</p><p>CoVs E proteins are small integral membrane polypeptides (76 - 109 aa) encoded by
subgenomic RNAs. In SARS-CoV, they are found in virions, but also in large amounts in
the ERGIC where they participate in virus budding and trafficking. Their structures are
divided into three main domains: N-terminal, transmembrane (TMD) and C-terminal domain.
TMD is able to form pentameric &#x003b1;-helical bundles creating ion conductive pores in
membranes.<xref rid="B120" ref-type="bibr">
<sup>120</sup>
</xref>
<sup>,</sup>
<xref rid="B121" ref-type="bibr">
<sup>121</sup>
</xref>
<sup>,</sup>
<xref rid="B122" ref-type="bibr">
<sup>122</sup>
</xref> The ion channel (IC) activity of E protein has been proposed to alter ion
homeostasis, as well induce inflammatory response, which may lead to pulmonary
damage.<xref rid="B123" ref-type="bibr">
<sup>123</sup>
</xref>
<sup>,</sup>
<xref rid="B124" ref-type="bibr">
<sup>124</sup>
</xref> Thus, the use of inhibitors of IC activity may represent a possible therapeutic
strategy for CoVs-related diseases, including COVID-19.<xref rid="B67" ref-type="bibr">
<sup>67</sup>
</xref>
<sup>,</sup>
<xref rid="B122" ref-type="bibr">
<sup>122</sup>
</xref>
<sup>,</sup>
<xref rid="B123" ref-type="bibr">
<sup>123</sup>
</xref>
<sup>,</sup>
<xref rid="B125" ref-type="bibr">
<sup>125</sup>
</xref> This can be exemplified by the FDA-approved drugs gliclazide (17), a
sulfonylurea administered to non-insulin-dependent diabetes mellitus patients, and
memantine (18), an N-methyl-D-aspartate receptor antagonist used in the management of
Alzheimer&#x02019;s disease, which have shown IC inhibitory activity in bacteria expressing
SARS-CoV-2 E proteins.<xref rid="B126" ref-type="bibr">
<sup>126</sup>
</xref>
</p><p>
<italic>Host cell targets</italic> - A key step in SARS-CoVs infection is the attachment
of S protein to host angiotensin-converting enzyme 2 (ACE2), a membrane-bound
carboxypeptidase (family: M2, clan: MA).<xref rid="B25" ref-type="bibr">
<sup>25</sup>
</xref>
<sup>,</sup>
<xref rid="B65" ref-type="bibr">
<sup>65</sup>
</xref>
<sup>,</sup>
<xref rid="B69" ref-type="bibr">
<sup>69</sup>
</xref> This enzyme catalyses the hydrolysis of angiotensin I and angiotensin II into
angiotensin-(1-9) and angiotensin-(1-7) peptides, respectively.<xref rid="B127" ref-type="bibr">
<sup>127</sup>
</xref> ACE2 is expressed in the upper respiratory system, type I and II alveolar
epithelial cells in the lungs, heart, endothelial cells, kidney tubular epithelium and
other tissues.<xref rid="B128" ref-type="bibr">
<sup>128</sup>
</xref> Its role as a functional receptor of SARS-CoV-2 S protein in host cells makes
this protein a potential drug target to treat COVID-19. There are several therapeutic
strategies targeting ACE2 which include: vaccines based on S protein, exogenous
administration of a soluble form of ACE2, and administration of small molecules [e.g.,
arbidol (19), an anti-influenza drug] or antibodies (e.g., STI-1499, an anti-spike
antibody) to block the interaction of ACE2 with S protein.<xref rid="B66" ref-type="bibr">
<sup>66</sup>
</xref>
<sup>,</sup>
<xref rid="B129" ref-type="bibr">
<sup>129</sup>
</xref>
<sup>,</sup>
<xref rid="B130" ref-type="bibr">
<sup>130</sup>
</xref> Additionally, compounds could also have an anti-SARS-CoVs activity by disturbing
ACE2 glycosylation, as proposed for chloroquine (20).<xref rid="B131" ref-type="bibr">
<sup>131</sup>
</xref>
</p><p>Renin-angiotensin-aldosterone system (RAAS) inhibitors, such as ACE inhibitors [ACE-i,
e.g., captopril (21)] and angiotensin receptor blockers [ARB, e.g., losartan (22)], are
commonly used in clinics to treat hypertension and cardiovascular/renal diseases.<xref rid="B132" ref-type="bibr">
<sup>132</sup>
</xref>
<sup>,</sup>
<xref rid="B133" ref-type="bibr">
<sup>133</sup>
</xref> Recently, some researchers have debated over the administration of these drugs
to patients with known or suspected COVID-19.<xref rid="B133" ref-type="bibr">
<sup>133</sup>
</xref>
<sup>,</sup>
<xref rid="B134" ref-type="bibr">
<sup>134</sup>
</xref>
<sup>,</sup>
<xref rid="B135" ref-type="bibr">
<sup>135</sup>
</xref>
<sup>,</sup>
<xref rid="B136" ref-type="bibr">
<sup>136</sup>
</xref> The main reason for this discussion is that RAAS inhibitors may induce ACE2
expression, which, in theory, could increase the severity of the infection.<xref rid="B133" ref-type="bibr">
<sup>133</sup>
</xref>
<sup>,</sup>
<xref rid="B136" ref-type="bibr">
<sup>136</sup>
</xref> Nonetheless, evidence suggests that these drugs may protect patients from lung
injury by suppressing angiotensin II signaling mediated by angiotensin receptor 1
(AT1R).<xref rid="B135" ref-type="bibr">
<sup>135</sup>
</xref>
<sup>,</sup>
<xref rid="B136" ref-type="bibr">
<sup>136</sup>
</xref>
<sup>,</sup>
<xref rid="B137" ref-type="bibr">
<sup>137</sup>
</xref> Further investigation is still required to determine whether ACE-i and ARB have
a beneficial or deleterious role in COVID-19 treatment.<xref rid="B134" ref-type="bibr">
<sup>134</sup>
</xref>
</p><p>In order to become fusion-competent, SAR-CoVs S proteins must be cleaved by host
proteases. In SARS-CoV-2, this process appears to be mediated primarily by TMPRSS2 in
the plasma membrane.<xref rid="B65" ref-type="bibr">
<sup>65</sup>
</xref> TMPRSS2 (transmembrane protease, serine 2) is a transmembrane protein (predicted
to have 492 aa) from the serine protease class (family: S1 clan: PA).<xref rid="B69" ref-type="bibr">
<sup>69</sup>
</xref>
<sup>,</sup>
<xref rid="B138" ref-type="bibr">
<sup>138</sup>
</xref> It is highly expressed in the epithelial cells of the prostate, and relatively
less in lungs, colon, liver, kidney, and pancreas. Its physiological function is still
unclear.<xref rid="B138" ref-type="bibr">
<sup>138</sup>
</xref> TMPRSS2 has a major role in SARS-CoV-2 cell entry and replication, and thus
represents an interesting therapeutic target since its inhibitors could potentially
block virus infection in its initial stages.<xref rid="B65" ref-type="bibr">
<sup>65</sup>
</xref>
<sup>,</sup>
<xref rid="B138" ref-type="bibr">
<sup>138</sup>
</xref> Potential TMPRSS2 blockers include some serine protease inhibitors [e.g.,
camostat mesylate (23)], commercially available compounds [e. g., ZINC64606047 (24),
3-[[5-(3-fluorophenyl)pyrimidin-2-yl]amino~(N)-(4-methyl phenyl)benzamide]] and natural
products [e.g., withanone (25)].<xref rid="B65" ref-type="bibr">
<sup>65</sup>
</xref>
<sup>,</sup>
<xref rid="B139" ref-type="bibr">
<sup>139</sup>
</xref>
<sup>,</sup>
<xref rid="B140" ref-type="bibr">
<sup>140</sup>
</xref>
<sup>,</sup>
<xref rid="B141" ref-type="bibr">
<sup>141</sup>
</xref>
</p><p>In the absence of exogenous or membrane-bound proteases (e g. TMPRSS2) to promote
SARS-CoVs infection on cells&#x02019; surface, the virus can also be internalised via
endocytosis, also known as &#x0201c;late pathway&#x0201d;.<xref rid="B59" ref-type="bibr">
<sup>59</sup>
</xref> This process comprises several factors that operate in a sequential and
partially overlapping fashion.<xref rid="B142" ref-type="bibr">
<sup>142</sup>
</xref> Endocytosis initiates with the recruitment of endocytic coat proteins (e. g.,
clathrins) from the cytosol to gather on the inner leaflet of the plasma membrane. Then,
protein-coated pits bud into vesicles originated from plasma membranes and fuse with
each other or with pre-existing early endosomes.<xref rid="B142" ref-type="bibr">
<sup>142</sup>
</xref>
<sup>,</sup>
<xref rid="B143" ref-type="bibr">
<sup>143</sup>
</xref> Gradually, early endosomes mature to late endosomes which have an acid
environment (approx. pH 5.5), activating endosomal cathepsin L cysteine proteases
(family: C1, clan: CA).<xref rid="B59" ref-type="bibr">
<sup>59</sup>
</xref>
<sup>,</sup>
<xref rid="B69" ref-type="bibr">
<sup>69</sup>
</xref>
<sup>,</sup>
<xref rid="B143" ref-type="bibr">
<sup>143</sup>
</xref> These enzymes are responsible for triggering the fusion activity of S protein
and subsequent insertion of viral SARS-CoV gRNA into the cytosol, especially in cells
with lower expression of TMPRSS2.<xref rid="B64" ref-type="bibr">
<sup>64</sup>
</xref>
<sup>,</sup>
<xref rid="B65" ref-type="bibr">
<sup>65</sup>
</xref> Some key elements of endocytosis have been explored as potential targets for
anti-SARS-CoV drugs, such as agents that increase endosomal pH (avoiding cathepsin L
activation) [e.g., chloroquine (20) and hydroxychloroquine (26)] and cathepsin L
inhibitors [e.g., teicoplanin (27), a glycopeptide antibiotic].<xref rid="B49" ref-type="bibr">
<sup>49</sup>
</xref>
<sup>,</sup>
<xref rid="B131" ref-type="bibr">
<sup>131</sup>
</xref>
<sup>,</sup>
<xref rid="B144" ref-type="bibr">
<sup>144</sup>
</xref>
</p><p>Cytokines are short-lived small size proteins (15-20 kDa) that exert an important role in
autocrine, paracrine, and endocrine signaling controlling the development and function
of several immune and nonimmune cells.<xref rid="B145" ref-type="bibr">
<sup>145</sup>
</xref>
<sup>,</sup>
<xref rid="B146" ref-type="bibr">
<sup>146</sup>
</xref> They are classified in families based on certain properties of their receptor
complexes, such as their structure, specificity and composition.<xref rid="B145" ref-type="bibr">
<sup>145</sup>
</xref> One example is Interleukin (IL)-6 family which includes several cytokines, such
as IL-6, that use the common signaling receptor subunit glycoprotein 130 kDa (gp130).
IL-6 signaling requires the binding of IL-6 to IL-6 receptor (IL-6R) which consists of a
soluble IL-6 binding domain (CD126) and membrane-bound gp130. IL-6 acts as the main
inducer of fever, inflammation and of hepatic acute phase proteins. Therefore,
IL-6/IL-6R antagonists have a therapeutic effect in inflammatory diseases.<xref rid="B145" ref-type="bibr">
<sup>145</sup>
</xref>
<sup>,</sup>
<xref rid="B146" ref-type="bibr">
<sup>146</sup>
</xref> Their use in COVID-19 treatment may be beneficial to avoid the &#x0201c;cytokines storm&#x0201d;
syndrome that some patients with the severe form of the disease may develop.<xref rid="B147" ref-type="bibr">
<sup>147</sup>
</xref> This deleterious event is caused by an amplified immune response and cytokine
release that can damage the organs, including the lungs.<xref rid="B66" ref-type="bibr">
<sup>66</sup>
</xref> Tocilizumab and sarilumab are two examples of humanised monoclonal antibodies
that act as IL-6R antagonists which are currently under clinical trials for COVID-19
treatment.<xref rid="B148" ref-type="bibr">
<sup>148</sup>
</xref>
</p><p>
<italic>Other targets</italic> - Apart from SARS-CoVs infection, some relevant molecular
targets of other viral diseases and host metabolism have also been investigated in
COVID-19 drug discovery, such as viral neuraminidases and the DPP4 cell receptor.
Neuraminidases (NA) or sialidases, are glycoside hydrolases (family: GH34) largely found
attached to the envelope of influenza viruses.<xref rid="B149" ref-type="bibr">
<sup>149</sup>
</xref>
<sup>,</sup>
<xref rid="B150" ref-type="bibr">
<sup>150</sup>
</xref> They catalyse the hydrolysis of glycosidic bonds between sialic acid and
adjacent sugar residues (EC 3.2.1.18) in glycoproteins, glycolipids and
oligosaccharides.<xref rid="B149" ref-type="bibr">
<sup>149</sup>
</xref> NA is mainly responsible for cleaving sialic acid acids from cell receptors and
on carbohydrate side chains of nascent virion, facilitating its release from infected
cells.<xref rid="B150" ref-type="bibr">
<sup>150</sup>
</xref> Its critical role in virus infection and proliferation has been exploited by NA
inhibitors [e.g., oseltamivir (28)] which are administered in clinics to combat
influenza infections. Apparently, this therapeutic strategy was employed at the
beginning of COVID-19 outbreak during the peak of influenza season in China when the
etiologic agent of this disease was yet unknown. So far, there is no evidence that NA
inhibitors may have a role in COVID-19 management.<xref rid="B66" ref-type="bibr">
<sup>66</sup>
</xref>
</p><p>Dipeptidyl peptidase-4 (DDP4), also known as adenosine deaminase complexing protein 2 or
T-cell activation antigen CD26, is a type II transmembrane glycoprotein of 766 aa
largely expressed in many tissues (e.g. lungs and immune cells).<xref rid="B151" ref-type="bibr">
<sup>151</sup>
</xref>
<sup>,</sup>
<xref rid="B152" ref-type="bibr">
<sup>152</sup>
</xref> DDP4 belongs to serine protease group (family: S9, clan: SC) and catalyses the
hydrolysis of N-terminal dipeptide, Xaa-Yaa-|-Zaa-, (preferentially when Yaa is a
proline, as long as Zaa is neither proline or hydroxyproline), from a variety of peptide
substrates (EC 3.4.14.5), such as chemokines, neuropeptides, vasoactive peptides and
growth factors.<xref rid="B69" ref-type="bibr">
<sup>69</sup>
</xref>
<sup>,</sup>
<xref rid="B71" ref-type="bibr">
<sup>71</sup>
</xref>
<sup>,</sup>
<xref rid="B152" ref-type="bibr">
<sup>152</sup>
</xref> Therefore, it participates in many physiologic and pathological processes,
including glucose/insulin metabolism and immune/inflammatory response.<xref rid="B153" ref-type="bibr">
<sup>153</sup>
</xref> In addition, DPP4 acts as the functional cell receptor of MERS-CoV S protein,
helping virus entry into the cell. Theoretically, this role may also be played in
SARS-CoV-2 infection, as predicted by computational analysis.<xref rid="B154" ref-type="bibr">
<sup>154</sup>
</xref> Recently, there has been a discussion about the use of DDP4 inhibitors, such as
sitagliptin (29) (anti-diabetic drug), in the treatment of COVID-19.<xref rid="B152" ref-type="bibr">
<sup>152</sup>
</xref>
<sup>,</sup>
<xref rid="B153" ref-type="bibr">
<sup>153</sup>
</xref>
<sup>,</sup>
<xref rid="B155" ref-type="bibr">
<sup>155</sup>
</xref>
<sup>,</sup>
<xref rid="B156" ref-type="bibr">
<sup>156</sup>
</xref> In principle, these inhibitors could be beneficial for type 2 diabetes patients
(or even without diabetes) with COVID-19 since it could potentially block virus cell
entry/replication, as well suppress inflammatory response.<xref rid="B152" ref-type="bibr">
<sup>152</sup>
</xref>
<sup>,</sup>
<xref rid="B155" ref-type="bibr">
<sup>155</sup>
</xref> However, there is not enough evidence yet to prove this hypothesis.<xref rid="B152" ref-type="bibr">
<sup>152</sup>
</xref>
<sup>,</sup>
<xref rid="B153" ref-type="bibr">
<sup>153</sup>
</xref>
<sup>,</sup>
<xref rid="B156" ref-type="bibr">
<sup>156</sup>
</xref>
</p><p>Repositioning studies in progress for the treatment of COVID-19</p><p>
<italic>Computational approaches</italic> - The SARS-CoV-2 pandemic is creating a
fertile ground for computational approaches to identify viable therapeutic options in
the short-term, with the number of published studies growing rapidly.<xref rid="B157" ref-type="bibr">
<sup>157</sup>
</xref>
<sup>,</sup>
<xref rid="B158" ref-type="bibr">
<sup>158</sup>
</xref> Classical target- and ligand-based strategies (e.g., molecular docking and
similarity analysis), are being applied to FDA-approved drugs and compounds in clinical
trials to explore possible interactions with viral proteins.<xref rid="B75" ref-type="bibr">
<sup>75</sup>
</xref>
<sup>,</sup>
<xref rid="B159" ref-type="bibr">
<sup>159</sup>
</xref>
<sup>,</sup>
<xref rid="B160" ref-type="bibr">
<sup>160</sup>
</xref> Artificial intelligence (AI) methods are also being extensively applied to large
molecule databases to find existing drugs that could be repurposed based on previously
reported antiviral activities.<xref rid="B103" ref-type="bibr">
<sup>103</sup>
</xref>
<sup>,</sup>
<xref rid="B161" ref-type="bibr">
<sup>161</sup>
</xref>
<sup>,</sup>
<xref rid="B162" ref-type="bibr">
<sup>162</sup>
</xref>
<sup>,</sup>
<xref rid="B163" ref-type="bibr">
<sup>163</sup>
</xref> AI approaches can even explore hidden connections between drugs, human and viral
targets to find novel bioactivities and even combinations of drugs.<xref rid="B52" ref-type="bibr">
<sup>52</sup>
</xref>
<sup>,</sup>
<xref rid="B161" ref-type="bibr">
<sup>161</sup>
</xref>
<sup>,</sup>
<xref rid="B164" ref-type="bibr">
<sup>164</sup>
</xref> These studies emphasize how important computational methods are in modern drug
discovery to analyse the huge amount of biomedical data available. <xref rid="t1" ref-type="table">Table I</xref> summarises a selection of studies that
suggested potential drugs for repurposing. Below we will describe the main computational
methods and results. Smith and Smith performed a large virtual high-throughput screening
to identify drugs, natural products and metabolites that could disrupt the interaction
between SARS-CoV-2 S protein and human ACE2 receptor. The authors used a supercomputer
called SUMMIT to conduct the simulations, which included structural modeling of the S
protein:ACE2 complex, generation of an ensemble of conformations for the complex and
molecular docking.<xref rid="B160" ref-type="bibr">
<sup>160</sup>
</xref> The ensemble generation was a crucial step in this work, allowing the authors to
explore different conformations of the complex and identify drugs that could interact
with binding sites not easily identified in static conformations.</p><p>
<table-wrap id="t1" orientation="portrait" position="float"><label>TABLE I</label><caption><title>
<italic>In silico</italic> studies of drug repurposing for coronavirus
disease 2019 (COVID-19)</title></caption><table frame="hsides" rules="groups"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td align="left" rowspan="1" colspan="1">Repurposed drug</td><td align="center" rowspan="1" colspan="1">Previous use</td><td align="center" rowspan="1" colspan="1">Predicted targets</td><td align="center" rowspan="1" colspan="1">Discovery origin</td><td align="center" rowspan="1" colspan="1">Experimental evidence</td><td align="center" rowspan="1" colspan="1">Reference</td></tr><tr><td align="left" rowspan="1" colspan="1">Pemirolast (30), nitrofurantoin (31), isoniazid
pyruvate (32), eriodictyol (33), cepharanthine (34), ergoloid (35)
and hypericin (36)</td><td align="center" rowspan="1" colspan="1">Multiple</td><td align="center" rowspan="1" colspan="1">Disrupting spike protein (S-protein) and ACE2
receptor interaction or inhibit S-protein and block ACE2
receptor</td><td align="center" rowspan="1" colspan="1">Ensemble docking</td><td align="center" rowspan="1" colspan="1">Natural products, such as eriodictyol (33),
cepharanthin (34), ergoloid (35) and hypericin (36) have shown
antiviral activity against coronaviruses, including severe acute
respiratory syndrome coronavirus (SARS-CoV).<sup><italic>a</italic></sup>
</td><td align="center" rowspan="1" colspan="1">
<xref rid="B160" ref-type="bibr">
<sup>160</sup>
</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Mefuparib hydrochloride (CVL218) (37)</td><td align="center" rowspan="1" colspan="1">Cancer</td><td align="center" rowspan="1" colspan="1">Nucleocapsid (N protein)</td><td align="center" rowspan="1" colspan="1">Knowledge-graph docking <italic>in vitro</italic> and
<italic>in vivo</italic> assays</td><td align="center" rowspan="1" colspan="1">Mefuparib (37) achieved an EC<sub>50</sub> of 5.12
&#x003bc;M.</td><td align="center" rowspan="1" colspan="1">
<xref rid="B164" ref-type="bibr">
<sup>164</sup>
</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Atazanavir (12) and efavirenz (38)</td><td align="center" rowspan="1" colspan="1">HIV</td><td align="center" rowspan="1" colspan="1">SARS-CoV-2 3C-like protease (M<sup>pro</sup>)</td><td align="center" rowspan="1" colspan="1">Molecule transformer drug-target interaction
(MT-DTI)</td><td align="center" rowspan="1" colspan="1">Atazanavir (12) can been found in lungs after
administration and have shown inhibitory activity against
M<sup>pro</sup>.<sup><italic>b</italic></sup>
</td><td align="center" rowspan="1" colspan="1">
<xref rid="B103" ref-type="bibr">
<sup>103</sup>
</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Baricitinib (39)</td><td align="center" rowspan="1" colspan="1">Rheumatoid arthritis</td><td align="center" rowspan="1" colspan="1">Human AP2-associated protein kinase 1 (AAK1)</td><td align="center" rowspan="1" colspan="1">Knowledge-graph</td><td align="center" rowspan="1" colspan="1">A pilot trial indicated that baricitinib (39)
improved clinical parameters (e.g., cough and dyspnea) in a small
group of patients.<sup><italic>c</italic></sup>
</td><td align="center" rowspan="1" colspan="1">
<xref rid="B161" ref-type="bibr">
<sup>161</sup>
</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Toremifene (40), sirolimus (41), mercaptopurine (42),
irbesartan (43)</td><td align="center" rowspan="1" colspan="1">Multiple</td><td align="center" rowspan="1" colspan="1">Multiple targets in humans and coronaviruses</td><td align="center" rowspan="1" colspan="1">Systems pharmacology-based network and human
protein-protein (PPI) network</td><td align="center" rowspan="1" colspan="1">Antiviral activities against coronaviruses has been
described for selective estrogen modulators toremifene (40),
immunosuppressants sirolimus (41) and mercaptopurine (42) and
angiotensin receptor blockers irbesartan (43).<sup><italic>d</italic></sup>
</td><td align="center" rowspan="1" colspan="1">
<xref rid="B52" ref-type="bibr">
<sup>52</sup>
</xref>
</td></tr></tbody></table><table-wrap-foot><fn id="TFN1"><p>
<italic>a</italic>: Cepharanthin (34) has been shown to decrease the
expression levels of S-protein in MRC-5 cells infected with
<italic>Human coronavirus OC43</italic>
(<italic>HCoV</italic>-<italic>OC43</italic>).<xref rid="B165" ref-type="bibr">
<sup>165</sup>
</xref> Flavonoids have been described as inhibitors of M<sup>pro</sup>
and ligands of the S-protein of SARS-CoV, which could give insights on
possible antiviral activities of eriodictyol (33), hypericin (36) and
other flavonoids on SARS-CoV-2.<xref rid="B166" ref-type="bibr">
<sup>166</sup>
</xref>
<sup>,</sup>
<xref rid="B167" ref-type="bibr">
<sup>167</sup>
</xref>
<italic>b</italic>: a recent study showed that Atazanavir (12) inhibited
M<sup>pro</sup>
<italic>in vitro</italic> with greater potency than lopinavir (1).<xref rid="B168" ref-type="bibr">
<sup>168</sup>
</xref>
<italic>c</italic>: despite the small size (12 patients) and open label,
non-randomised format, baricitinib (39) showed potential safety when
used in combination with lopinavir (1) / ritonavir (2).<xref rid="B169" ref-type="bibr">
<sup>169</sup>
</xref> As of August 3rd 13th, 2020, there are three ongoing clinical
trials with baricitinib (39): NCT04421027 (phase 2, randomised and
double blind), NCT04320277 (phases 2 and 3, non-randomised and
open-label) and NCT04321993 (phase 2, non-randomised and open-label).
<italic>d</italic>: the authors described previous antiviral
activities for the most promising drugs, including against other
coronaviruses (e. g., MERS-CoV and SARS-CoV), showing a correlation
between the original target of each drug and coronaviruses target.</p></fn></table-wrap-foot></table-wrap>
</p><p>Using the GROMACS molecular dynamics simulation suite, six different clusters of
conformations were generated by restrained temperature replica-exchange molecular
dynamics simulation (T-REMD) and submitted to docking with Autodock Vina using the
SWEETLEAD compound collection.<xref rid="B170" ref-type="bibr">
<sup>170</sup>
</xref>
<sup>,</sup>
<xref rid="B171" ref-type="bibr">
<sup>171</sup>
</xref>
<sup>,</sup>
<xref rid="B172" ref-type="bibr">
<sup>172</sup>
</xref> The authors explored two strategies, consisting of disrupting the S protein:
ACE2 complex and preventing its formation by docking on the isolated proteins. From this
analysis, four compounds [pemirolast (30), nitrofurantoin (31), isoniazid pyruvate (32)
and eriodictyol (33)] displayed potential to disrupt the S protein: ACE2 interaction,
and three natural compounds [cepharanthine (34), ergoloid (35) and hypericin (36)]
showed potential to block host recognition.<xref rid="B160" ref-type="bibr">
<sup>160</sup>
</xref> Chemical structures for compounds 30-49 are shown in <xref ref-type="fig" rid="f12">Fig. 12</xref>.</p><p>
<fig id="f12" orientation="portrait" position="float"><label>Fig. 12:</label><caption><title>chemical structures for drug repurposing candidates and compounds 30-49
under investigation against coronavirus disease 2019 (COVID-19).</title></caption><graphic xlink:href="1678-8060-mioc-115-e200254-gf12"/></fig>
</p><p>Ge and coworkers constructed a virus-related knowledge graph (or network) by combining
seven networks with information about target-drug and protein-protein interactions,
molecule similarity and sequence similarity of human and viral sources to predict drugs
targeting SARS-CoV-2.<xref rid="B164" ref-type="bibr">
<sup>164</sup>
</xref> Well known biological and interaction databases were employed, such as DrugBank,
ChEMBL,&#x02060; BindingDB,&#x02060; and UniProt&#x02060;.<xref rid="B173" ref-type="bibr">
<sup>173</sup>
</xref>
<sup>,</sup>
<xref rid="B174" ref-type="bibr">
<sup>174</sup>
</xref>
<sup>,</sup>
<xref rid="B175" ref-type="bibr">
<sup>175</sup>
</xref>
<sup>,</sup>
<xref rid="B176" ref-type="bibr">
<sup>176</sup>
</xref> The final knowledge graph was assembled by merging the nodes and edges of the
seven networks, where each node represent drugs or targets, while the edges between them
are the identified relations, such as similarity (i.e., molecular and sequence
similarities) and drug-target or target-target interactions.<xref rid="B164" ref-type="bibr">
<sup>164</sup>
</xref>&#x02060; A graph convolutional network (GCN) was used to learn and extract the hidden
information on the nodes and edges of the knowledge-graph, allowing the authors to
access novel drug-target and target-target interactions and find molecules that could be
repurposed to SARS-CoV-2.<xref rid="B164" ref-type="bibr">
<sup>164</sup>
</xref> GCN&#x02019;s are powerful neural networks that can access the rich information within
the nodes of a graph and return insights about possible relations (e.g., potential drugs
and targets interactions), representing a valuable tool in the modern drug discovery
scenario, where massive biological data are available in databases such as DrugBank and
ChEMBL.<xref rid="B177" ref-type="bibr">
<sup>177</sup>
</xref>
<sup>,</sup>
<xref rid="B178" ref-type="bibr">
<sup>178</sup>
</xref>
</p><p>The final knowledge-graph was then mined to gather an initial list of drugs, which was
further refined by extracting previous evidence of antiviral activity from PubMed using
a deep learning method called Biomedical Entity Relation Extraction (BERE) and manual
inspection.<xref rid="B179" ref-type="bibr">
<sup>179</sup>
</xref> In a subsequent step, the authors elaborated a final list of drug candidates
using transcriptome analysis of ten SARS-CoV patients. The poly-ADP-ribose polymerase 1
(PARP1) inhibitor, mefuparib hydrochloride (CVL218) (37), currently in Phase I clinical
trials, was identified as a potential drug for repurposing. <italic>In vitro</italic>
and <italic>in vivo</italic> validation showed promising inhibition and safety profiles.
Concretely, compared to arbidol (19), one of the standard treatments for COVID-19 in
China, CVL218 showed higher antiviral efficacy and higher concentration in lungs of
rats.<xref rid="B164" ref-type="bibr">
<sup>164</sup>
</xref> The authors also found that CVL218 significantly inhibited the production of
IL-6 induced by the CpG oligodeoxynucleotide 1826 (CPG-ODN1826) in peripheral blood
mononuclear cells (PMBC) indicating it might be an alternative to treat the inflammation
caused by SARS-CoV-2. Furthermore, CVL218 showed favorable pharmacokinetics and toxicity
profiles in rats and monkey models.<xref rid="B164" ref-type="bibr">
<sup>164</sup>
</xref>&#x02060; This integration of artificial intelligence with wet-lab experiments highlights
the importance of <italic>in silico</italic> methods to mine large amounts of data from
databases and accelerate the discovery of potential drugs for the CoVid-19 pandemic.</p><p>Beck et al. used a natural language processing (NLP)-based approach to estimate the
binding affinity of 3,410 FDA-approved drugs against potential targets of SARS-CoV-2,
including 3CL<sup>pro</sup>, S protein, RdRP, helicase, endoRNAse, 3&#x02019;-to-5&#x02019;- exonuclease
and 2&#x02019;-O-ribose methyltransferase.<xref rid="B103" ref-type="bibr">
<sup>103</sup>
</xref> The premise of their approach is analogous to understanding text in different
languages, for instance by learning the semantic relationships of words to execute a
task, such as predicting the most probable word in a text or the sentiment expressed by
it.<xref rid="B180" ref-type="bibr">
<sup>180</sup>
</xref>
<sup>,</sup>
<xref rid="B181" ref-type="bibr">
<sup>181</sup>
</xref>
<sup>,</sup>
<xref rid="B182" ref-type="bibr">
<sup>182</sup>
</xref>&#x02060; Their model, called molecular transformer-drug target interaction (MT-DTI) was
trained on 1 billion SMILES strings and the FASTA sequence of target proteins, which
bypass the need for 3D structures (e.g., X-ray) of protein-target complexes.<xref rid="B183" ref-type="bibr">
<sup>183</sup>
</xref>&#x02060; The pre-training approach allows the model to be used for other related tasks
without the need to train from scratch, which is especially important when not enough
data is available, which is the case for SARS-CoV-2 inhibitors. In addition, this
approach is able to transfer more general features learned by the model, making it
extremely flexible to deal with related tasks.<xref rid="B184" ref-type="bibr">
<sup>184</sup>
</xref>
<sup>,</sup>
<xref rid="B185" ref-type="bibr">
<sup>185</sup>
</xref>
</p><p>Therefore, the task consisted of training the model to understand the chemical structure
of small compounds and protein targets. The authors found that atazanavir (12),
remdesivir (8) and efavirenz (38) are potential inhibitors of M<sup>pro</sup>, while
atazanavir (12) also yielded nanomolar predicted binding affinity for RdRP, helicase,
endoRNAse, 3&#x02019;-to-5&#x02019;- exonuclease and 2&#x02019;-O-ribose methyltransferase.<xref rid="B103" ref-type="bibr">
<sup>103</sup>
</xref>&#x02060;&#x02060; It is important to highlight that although these drugs were predicted as
nanomolar inhibitors, experimental confirmation is essential to validate the
computational analysis.</p><p>Researchers at the UK-based company BenevolentAI (https://www.benevolent.com/) analysed
medical data from different sources to create a knowledge graph of biomedical
information, showing possible drug-target interactions on its nodes and edges (similar
to the previously mentioned approach adopted by Ge et al.) to explore new strategies for
SARS-CoV-2.<xref rid="B161" ref-type="bibr">
<sup>161</sup>
</xref>
<sup>,</sup>
<xref rid="B164" ref-type="bibr">
<sup>164</sup>
</xref> Among the drugs identified by mining the hidden information within the graph,
there were 378 inhibitors of the P2-associated protein kinase 1 (AAK1), a regulator of
viral endocytosis in AT2 alveolar epithelial cells.<xref rid="B161" ref-type="bibr">
<sup>161</sup>
</xref> Inhibitors of AAK1 could then potentially block viral entry into alveolar cells.
However, the authors argued that only one of these drugs, baricitinib (39), a janus
kinase inhibitor, has an acceptable safety profile. In addition, the low therapeutic
dosing of baricitinib (39) (2mg or 4mg daily) makes it a promising drug for
repurposing.<xref rid="B161" ref-type="bibr">
<sup>161</sup>
</xref> Baricitinib (39) will be further discussed below.</p><p>Zhou et al. developed a network-based approach to identify potential repurposable drugs
based on the interactions between their human targets and coronavirus-associated
proteins.<xref rid="B52" ref-type="bibr">
<sup>52</sup>
</xref> The premise is that protein targets that are associated with viral infections
are part of a subnetwork of the human protein-protein interaction network. The targets
of a repurposable drug should be in or close in proximity to this subnetwork. The
authors identified many potential targets, such as Poly [ADP-ribose] polymerase 1
(PARP-1), Glycogen synthase kinase 3 (GSK-3), and also biological pathways that could be
explored, such as NF-kappa B signaling.<xref rid="B52" ref-type="bibr">
<sup>52</sup>
</xref>&#x02060; The most interesting drugs selected by the authors are from a diverse set,
including toremifene (40) (selective estrogen receptor modulator), sirolimus (41)
(immunosuppressant), mercaptopurine (42) (antineoplastic) and irbesartan (43)
(antihypertensive). An interesting finding was that the selected molecules and targets
have reported links to viral infection and some have been used for treatment of
Coronavirus-related disease, such as emodin (44) in SARS-CoV, and mercaptopurine (42)
and toremifene (40) in SARS-CoV and MERS-CoV.<xref rid="B52" ref-type="bibr">
<sup>52</sup>
</xref> In addition to identifying repurposable drugs, possible synergistic combinations
between them were also suggested by the network, such as sirolimus (41) and dactinomycin
(45), and mercaptopurine (42) and melatonin (46).<xref rid="B52" ref-type="bibr">
<sup>52</sup>
</xref>
</p><p>
<italic>In vitro and in vivo studies</italic> - Genome and replication kinetics of
SARS-CoV, MERS-CoV and SARS-CoV-2 viruses are very similar, suggesting that these
diseases could be treated by a single drug that modulates the activity of a common
target or mechanism among them.<xref rid="B52" ref-type="bibr">
<sup>52</sup>
</xref>
<sup>,</sup>
<xref rid="B186" ref-type="bibr">
<sup>186</sup>
</xref> So far, no clinically available antiviral drugs have been developed for any of
these three viruses.<xref rid="B187" ref-type="bibr">
<sup>187</sup>
</xref> This fact demonstrates that we did not learn a suitable strategy for treatment
from these two prior diseases, and we are not yet prepared to deal with this new
coronavirus epidemic, regarding therapeutic options.<xref rid="B188" ref-type="bibr">
<sup>188</sup>
</xref>
</p><p>Experimental target validation (e.g., by genetic and proteomic approaches), cellular
<italic>in vitro</italic> and <italic>in vivo</italic> animal models of SARS-CoV-2
infection, are pivotal for the discovery of molecular pathways involved in pathogenesis,
supporting the discovery of new drugs.<xref rid="B189" ref-type="bibr">
<sup>189</sup>
</xref>
<sup>,</sup>
<xref rid="B190" ref-type="bibr">
<sup>190</sup>
</xref> SARS-CoV-2 genome encodes less than 30 proteins that can be explored for
generating new avenues for further research. Heterologous viral protein expression could
be used in a myriad of structural and functional target-based biochemical studies.<xref rid="B191" ref-type="bibr">
<sup>191</sup>
</xref> These assays do not need to be performed in biosafety level 3 laboratory,
democratising the early research on searching for a new drug candidate for COVID-19
treatment.<xref rid="B192" ref-type="bibr">
<sup>192</sup>
</xref> Genome-wide expression studies, nucleotide sequences, protein structures and
associated sequences are available online providing a foundation for preclinical drug
discovery and development research against SARS-CoV-2 (Available from:
https://www.ncbi.nlm.nih.gov/genbank/sars-cov-2-seqs/). It is good to point out that
many drugs show <italic>in vitro</italic> effect (e.g., target and/or cellular assays)
that may not last <italic>in vivo</italic>, in animal models, including humans. An ideal
animal model of COVID-19 should reflect the clinical signs, viral replication and
pathology reported in humans.<xref rid="B193" ref-type="bibr">
<sup>193</sup>
</xref>
<italic>In vivo</italic> animal infection experiments with SARS-CoV-2 require
infrastructure of a biosafety level 3 laboratory, restricting scientific research to
well-equipped research groups. Animal models are indispensable, because they could
identify toxic hits or molecules that could enhance COVID-19 pathogenicity. <xref rid="t2" ref-type="table">Table II</xref> lists some compounds that have the
potential to be clinically tested and that will be discussed in more details below in
this topic.</p><p>
<table-wrap id="t2" orientation="portrait" position="float"><label>TABLE II</label><caption><title>
<italic>In vitro</italic> and <italic>in vivo</italic> studies of drug
repurposing for coronavirus disease 2019 (COVID-19)</title></caption><table frame="hsides" rules="groups"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td align="left" rowspan="1" colspan="1">Repurposed drug</td><td align="center" rowspan="1" colspan="1">Previous use</td><td align="center" rowspan="1" colspan="1">Targets</td><td align="center" rowspan="1" colspan="1">
<italic>In vitro</italic> potency (EC<sub>50</sub>)</td><td align="center" rowspan="1" colspan="1">Selectivity index</td><td align="center" rowspan="1" colspan="1">Reference</td></tr><tr><td align="left" rowspan="1" colspan="1">Remdesivir (8)</td><td align="center" rowspan="1" colspan="1">Ebola</td><td align="center" rowspan="1" colspan="1">RNA polymerase</td><td align="center" rowspan="1" colspan="1">0.77 &#x003bc;M</td><td align="center" rowspan="1" colspan="1">129.9</td><td align="center" rowspan="1" colspan="1">
<xref rid="B194" ref-type="bibr">
<sup>194</sup>
</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Chloroquine (20) / Hydroxychloroquine (26)</td><td align="center" rowspan="1" colspan="1">Malaria / Lupus and rheumatoid arthritis</td><td align="center" rowspan="1" colspan="1">Acidification in endosomes and lysosomes,
glycosylation of cellular virus receptors and modulation host immune
response</td><td align="center" rowspan="1" colspan="1">1.13 &#x003bc;M / 0.72 &#x003bc;M</td><td align="center" rowspan="1" colspan="1">37.1 to 100.8 / 14.4 to 61.5 depending on
multiplicities of infection</td><td align="center" rowspan="1" colspan="1">
<xref rid="B194" ref-type="bibr">
<sup>194</sup>
</xref>
<sup>,</sup>
<xref rid="B195" ref-type="bibr">
<sup>195</sup>
</xref>
<sup>,</sup>
<xref rid="B196" ref-type="bibr">
<sup>196</sup>
</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Ritonavir (2) + lopinavir (1)</td><td align="center" rowspan="1" colspan="1">HIV</td><td align="center" rowspan="1" colspan="1">3-chymotrypsin-like protease (3CL<sup>pro</sup>) and
papain-like protease (PL<sup>pro</sup>)</td><td align="center" rowspan="1" colspan="1">6.6 to 17.1 &#x003bc;M for Lopinavir (1)</td><td align="center" rowspan="1" colspan="1">ND</td><td align="center" rowspan="1" colspan="1">
<xref rid="B197" ref-type="bibr">
<sup>197</sup>
</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Nitazoxanide (47)</td><td align="center" rowspan="1" colspan="1">Broad-spectrum antiparasitic and antiviral</td><td align="center" rowspan="1" colspan="1">Still needs confirmation</td><td align="center" rowspan="1" colspan="1">2.1 &#x003bc;M</td><td align="center" rowspan="1" colspan="1">16.8</td><td align="center" rowspan="1" colspan="1">
<xref rid="B194" ref-type="bibr">
<sup>194</sup>
</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Ivermectin (48)</td><td align="center" rowspan="1" colspan="1">Broad-spectrum antiparasitic</td><td align="center" rowspan="1" colspan="1">Still needs confirmation</td><td align="center" rowspan="1" colspan="1">2 &#x003bc;M</td><td align="center" rowspan="1" colspan="1">ND</td><td align="center" rowspan="1" colspan="1">
<xref rid="B198" ref-type="bibr">
<sup>198</sup>
</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Teicoplanin (27)</td><td align="center" rowspan="1" colspan="1">Antibiotic for gram-positive bacteria</td><td align="center" rowspan="1" colspan="1">Still needs confirmation</td><td align="center" rowspan="1" colspan="1">1.7 &#x003bc;M</td><td align="center" rowspan="1" colspan="1">ND</td><td align="center" rowspan="1" colspan="1">
<xref rid="B199" ref-type="bibr">
<sup>199</sup>
</xref>
</td></tr></tbody></table></table-wrap>
</p><p>Remdesivir (8), a nucleotide analog pro-drug developed by Gilead Sciences Inc. to fight
Ebola, acts on viral replication by inhibiting RNA polymerase.<xref rid="B96" ref-type="bibr">
<sup>96</sup>
</xref> This molecule was also active against SARS and MERS viruses.<xref rid="B200" ref-type="bibr">
<sup>200</sup>
</xref>
<sup>,</sup>
<xref rid="B201" ref-type="bibr">
<sup>201</sup>
</xref>
<sup>,</sup>
<xref rid="B202" ref-type="bibr">
<sup>202</sup>
</xref> Wang et al. demonstrated reduced viral copy numbers in cell culture supernatant
of Vero E6 cells infected with nCoV- 2019BetaCoV/Wuhan/WIV04/20192, in the presence of
varying concentrations of Remdesivir (8).<xref rid="B194" ref-type="bibr">
<sup>194</sup>
</xref> This compound blocked virus infection at low-micromolar concentration
(EC<sub>50</sub> = 0.77 &#x003bc;M) and showed a high selectivity index (&#x0003e; 100). The
authors also disclosed that remdesivir (8) inhibited virus infection efficiently in
human liver cancer Huh-7 cells.</p><p>Chloroquine (CQ; 20) and its less toxic derivative, hydroxychloroquine (HCQ; 26), are
used to treat malaria and lupus/rheumatoid arthritis, respectively. Both drugs have
already been described as possible antivirals.<xref rid="B195" ref-type="bibr">
<sup>195</sup>
</xref>
<sup>,</sup>
<xref rid="B203" ref-type="bibr">
<sup>203</sup>
</xref>
<sup>,</sup>
<xref rid="B204" ref-type="bibr">
<sup>204</sup>
</xref> CQ (20) and derivatives probably act by decreasing acidity in endosomes and
lysosomes, intervening on glycosylation of cellular virus receptors and modulating host
immunological activity.<xref rid="B118" ref-type="bibr">
<sup>118</sup>
</xref>
<sup>,</sup>
<xref rid="B205" ref-type="bibr">
<sup>205</sup>
</xref> Studies in cultures of Vero E6 cells have suggested that HCQ (26) can affect the
virus SARS-CoV-2 in both entry and post entry stages at host cells.<xref rid="B194" ref-type="bibr">
<sup>194</sup>
</xref> This molecule presented an EC<sub>50</sub> value of 1.13 &#x003bc;M and selectivity
index of 88.5. HCQ (26) is also being studied <italic>in vitro</italic> as a SARS-CoV-2
infection inhibitor acting on both virus entry, as well as post-entry steps on host
cells.<xref rid="B206" ref-type="bibr">
<sup>206</sup>
</xref> Comparing dose-response curves of the two compounds against an <italic>in
vitro</italic> model of SARS-CoV-2 infection on Vero E6 cells, demonstrated that CQ
(20) is slightly more potent than HCQ (26) at four different multiplicities of infection
(0.01, 0.02, 0.2 and 0.8): EC<sub>50</sub> 2.71, 3.81, 7.14 and 7.36 &#x003bc;M for CQ versus
4.51, 4.06, 17.31, and 12.96 &#x003bc;M for HCQ, respectively. RNA copy numbers in the cell
supernatant at 48 h post infection were measured. The authors also measured the
cytotoxicity of both compounds at the same <italic>in vitro</italic> model and
demonstrated that the 50% cytotoxic concentration (CC<sub>50</sub>) values of CQ (20)
and its derivative were remarkably similar ~ 250 &#x003bc;M. In another study Yao et al.
demonstrated that HCQ (26) was more potent than CQ (20) to inhibit <italic>in
vitro</italic> SARS-CoV-2 infection (EC<sub>50</sub> 0.72 vs 5.47 &#x003bc;M).<xref rid="B196" ref-type="bibr">
<sup>196</sup>
</xref> The authors also performed <italic>in vitro</italic> physiologically based
pharmacokinetic models for both drugs, separately. Interestingly, when comparing
toxicity in five animal models, McChesney et al. demonstrated that HCQ (26) is two to
three times less toxic than CQ (20) itself.<xref rid="B207" ref-type="bibr">
<sup>207</sup>
</xref> It is also good to point out that chloroquine (20) has shown <italic>in
vitro</italic> activity against many different viruses, but no significant
beneficial effect on animal models.<xref rid="B208" ref-type="bibr">
<sup>208</sup>
</xref>
</p><p>The association ritonavir (2)/lopinavir (1) is used together with other antiretrovirals
for the treatment of human immunodeficiency virus since the beginning of the
century.<xref rid="B209" ref-type="bibr">
<sup>209</sup>
</xref> Ritonavir (2) is a potent CYP3A inhibitor therefore inhibiting the metabolism of
lopinavir (1), increasing its plasma levels. Both are reported as peptidomimetic
molecules that inhibit HIV-1 protease activity in a competitive manner.<xref rid="B210" ref-type="bibr">
<sup>210</sup>
</xref> The M<sup>pro</sup> plays a major role in homeostasis of viral polyproteins
essential for viral function and replication, being considered a validated drug
target.<xref rid="B211" ref-type="bibr">
<sup>211</sup>
</xref> This combination may be useful against SARS-CoV-2 virus by acting on its main
protease, an enzyme essential in processing polyproteins translated from viral RNA.<xref rid="B212" ref-type="bibr">
<sup>212</sup>
</xref> Choy et al. demonstrated that it inhibits SARS-CoV-2 replication in Vero E6
cells with EC<sub>50</sub> value of 26.6 &#x003bc;M.<xref rid="B197" ref-type="bibr">
<sup>197</sup>
</xref> These results corroborate with the study of de Wilde et al. that demonstrated
antiviral <italic>in vitro</italic> effect of lopinavir (1), but not ritonavir (2),
against SARS-CoV, MERS-CoV, and hCoV-229E, with mean EC<sub>50</sub> varying from 6.6 to
17.1 &#x003bc;M.<xref rid="B213" ref-type="bibr">
<sup>213</sup>
</xref>
</p><p>Other compounds were also tested against SARS-CoV-2 <italic>in vitro</italic>.
Nitazoxanide (47), a broad-spectrum antiparasitic and antiviral, inhibits a
low-micromolar range with an EC<sub>50</sub> of 2.1 &#x003bc;M but has a selective index of only
16.8.<xref rid="B194" ref-type="bibr">
<sup>194</sup>
</xref> Ivermectin (48), another broad spectrum antiparasitic agent also demonstrated
<italic>in vitro</italic> anti-SARS-CoV-2 activity. Its EC<sub>50</sub> was
determined to be 2 &#x003bc;M when added to Vero-hSLAM cells 2 h post-infection and measuring
viral RNA at 48h post-infection.<xref rid="B198" ref-type="bibr">
<sup>198</sup>
</xref> Teicoplanin (27), an antibiotic used against gram-positive bacterial infections,
was found to be active <italic>in vitro</italic> against SARS-CoV-2 with an
EC<sub>50</sub> value of 1.7 &#x003bc;M, but <italic>in vivo</italic> efficacy still needs
to be determined.<xref rid="B199" ref-type="bibr">
<sup>199</sup>
</xref> A robust preclinical drug discovery pipeline comprising <italic>in
vitro,</italic> and <italic>in vivo</italic> models of SARS-CoV-2 infection is
particularly important to identify new antivirals for human COVID-19 treatment. This
pipeline can munition clinical studies with molecules that have a higher chance to
become a drug, decreasing attrition rates.</p><p>
<italic>Clinical studies</italic> - Over 1452 clinical trials have been unveiled, until
the publication of this manuscript, focusing on COVID-19 treatment interventions
(Available from: https://clinicaltrials.gov/ct2/results?cond=COVID-19). With a growing
number of patients suffering from acute severe respiratory symptoms and hospital
capacities reaching its limit, therapeutic options are urgently essential to avoid human
mass deaths. Drug repurposing approaches of approved (with safe and effectiveness
proven) and unapproved molecules, that were promising in pre-clinical and early stages
of clinical studies of SARS and MERS, are in vogue. With this premise, World Health
Organization (WHO) organised a simplified dynamic platform comparing the effectiveness
of treatment strategies around the globe. This clinical trial design, called SOLIDARITY,
can shrink by 80% the time of clinical studies, compared with the &#x0201c;gold standard&#x0201d;
double-blind, placebo-controlled trials. This strategy could overcome the uncertainty of
multiple small trials that do not produce a solid base necessary to establish the
relative success of arising probable treatments. On the other hand, this shorter time
required reflects the compassionate characteristic of the studies, that cannot rule out
placebo effects and patient severe adverse effects, including death.<xref rid="B214" ref-type="bibr">
<sup>214</sup>
</xref> Currently, WHO is focusing on four most promising therapies: remdesivir (8); CQ
(20) or HCQ (26); ritonavir (2)/lopinavir (1); ritonavir (2) /lopinavir (1) plus
interferon-beta, an immune response modulator.<xref rid="B44" ref-type="bibr">
<sup>44</sup>
</xref> A selection of studies with these drugs, alone or in combination, are summarised
in <xref rid="t3" ref-type="table">Table III</xref>. For other studies, the reader can
refer to Kupferschmidt and Cohen, which summarised several clinical studies on drug
repurposing for Covid-19 reported so far.<xref rid="B44" ref-type="bibr">
<sup>44</sup>
</xref> It is worth noting that many clinical studies are beginning to be carried out in
different parts of the world and their number is increasing rapidly day by day.</p><p>
<table-wrap id="t3" orientation="portrait" position="float"><label>TABLE III</label><caption><title>Clinical studies of drug repurposing for coronavirus disease 2019
(COVID-19)</title></caption><table frame="hsides" rules="groups"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td align="left" rowspan="1" colspan="1">Repurposed drug</td><td align="center" rowspan="1" colspan="1">Study characteristics</td><td align="center" rowspan="1" colspan="1">Estimated enrolment</td><td align="center" rowspan="1" colspan="1">Dosage</td><td align="center" rowspan="1" colspan="1">Characteristics of the study and conclusion</td><td align="center" rowspan="1" colspan="1">Clinical trial and recruitment status</td></tr><tr><td align="left" rowspan="3" colspan="1">Remdesivir (8)</td><td align="center" rowspan="3" colspan="1">Phase III, double-blind, randomised,
placebo-controlled, multicentre</td><td align="center" rowspan="1" colspan="1">308 patients</td><td align="center" rowspan="3" colspan="1">200 mg Intravenously on the first day
plus 100 mg once daily, for more nine consecutive days</td><td align="center" rowspan="1" colspan="1">Adult patients with mild and moderate COVID-19, no
published results</td><td align="center" rowspan="1" colspan="1">NCT04252664 (suspended by epidemic control in China
with no eligible patients)</td></tr><tr><td align="center" rowspan="1" colspan="1">237 patients</td><td align="center" rowspan="1" colspan="1">Adult patients with severe COVID-19, remdesivir (8)
was not associated with clinical benefits in severe forms. However,
an observed numerical reduction in time to clinical improvement in
patients treated earlier, but still requires confirmation</td><td align="center" rowspan="1" colspan="1">
<xref rid="B215" ref-type="bibr">
<sup>215</sup>
</xref>; NCT04257656 (terminated by epidemic control in China with
no eligible patients)</td></tr><tr><td align="center" rowspan="1" colspan="1">1063 patients</td><td align="center" rowspan="1" colspan="1">Remdesivir (8) treated patients with lower
respiratory tract infection have a shorter time to recovery compared
to placebo group (11 vs 15 days)</td><td align="center" rowspan="1" colspan="1">
<xref rid="B216" ref-type="bibr">
<sup>216</sup>
</xref>; NCT04280705</td></tr><tr><td align="left" rowspan="2" colspan="1">Chloroquine (20)</td><td align="center" rowspan="1" colspan="1">Multicentre</td><td align="center" rowspan="1" colspan="1">&#x0003e; 100 patients</td><td align="center" rowspan="1" colspan="1">500 mg per day, for 10 days</td><td align="center" rowspan="1" colspan="1">Compilation of various clinical studies that are in
course, authors conclude that the dosage used could be
sufficient</td><td align="center" rowspan="1" colspan="1">
<xref rid="B217" ref-type="bibr">
<sup>217</sup>
</xref>
</td></tr><tr><td align="center" rowspan="1" colspan="1">Phase IIb Double-blind, randomised</td><td align="center" rowspan="1" colspan="1">81 patients</td><td align="center" rowspan="1" colspan="1">600 mg twice daily for 10 days and 450 mg twice on
the first day, once daily for more 4 days</td><td align="center" rowspan="1" colspan="1">Higher dosage of chloroquine (20) has toxic effects
and increased lethality, with any clinical benefit</td><td align="center" rowspan="1" colspan="1">
<xref rid="B218" ref-type="bibr">
<sup>218</sup>
</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Hydroxychloroquine (26)</td><td align="center" rowspan="1" colspan="1">non-randomised, non-double-blind,
non-placebo-controlled</td><td align="center" rowspan="1" colspan="1">36 patients</td><td align="center" rowspan="1" colspan="1">600 mg of hydroxychloroquine (26) daily for 10
days</td><td align="center" rowspan="1" colspan="1">Hydroxychloroquine (26) significantly reduces viral
load despite small sample size</td><td align="center" rowspan="1" colspan="1">
<xref rid="B219" ref-type="bibr">
<sup>219</sup>
</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Ritonavir (2)/lopinavir (1)</td><td align="center" rowspan="1" colspan="1">Randomised, controlled, open-label</td><td align="center" rowspan="1" colspan="1">199 patients</td><td align="center" rowspan="1" colspan="1">400 mg/100 mg twice a day for 14 days</td><td align="center" rowspan="1" colspan="1">No benefit was observed with lopinavir (1)-ritonavir
(2) treatment compared to standard care in severe Covid-19
patients</td><td align="center" rowspan="1" colspan="1">
<xref rid="B220" ref-type="bibr">
<sup>220</sup>
</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Ritonavir (2)/lopinavir (1) plus interferon</td><td align="center" rowspan="1" colspan="1">Phase II, randomised, controlled, open-label</td><td align="center" rowspan="1" colspan="1">127 participants</td><td align="center" rowspan="1" colspan="1">400 mg/100 mg twice a day for 14 days; Interferon
Beta-1B plus 0.25 mg subcutaneous injection alternate day for three
days</td><td align="center" rowspan="1" colspan="1">Completed with no published results until this
moment</td><td align="center" rowspan="1" colspan="1">NCT04276688</td></tr></tbody></table></table-wrap>
</p><p>Remdesivir (8), a nucleoside analogue that acts by inhibiting RNA synthesis, is already
in clinical studies for treatment of COVID-19.<xref rid="B96" ref-type="bibr">
<sup>96</sup>
</xref> This prodrug was already investigated in clinical trial testing for Ebola virus
with no effect but showed efficiency against different types of coronaviruses in cell
culture and animal models.<xref rid="B200" ref-type="bibr">
<sup>200</sup>
</xref>
<sup>,</sup>
<xref rid="B221" ref-type="bibr">
<sup>221</sup>
</xref> From the drugs in the SOLIDARITY trial, remdesivir (8) has the best potential to
be used in clinics, having a low toxicity profile to humans.<xref rid="B44" ref-type="bibr">
<sup>44</sup>
</xref> This molecule was used compassionately in the first COVID-19 patient diagnosed
in the United States by intravenous treatment and improved patient clinical
condition.<xref rid="B222" ref-type="bibr">
<sup>222</sup>
</xref> Grein et al. reported a study in a cohort of patients hospitalised for severe
COVID-19 who were treated with compassionate-use remdesivir (8), clinical improvement
was observed in 68% of the patients (36 of 53).<xref rid="B223" ref-type="bibr">
<sup>223</sup>
</xref> There are two clinical trials at phase III, being designed to evaluate the
efficacy and safety of parenteral remdesivir (8) in mild/moderate (NCT04252664) and
severe (NCT04257656) hospitalised adults with COVID-19.<xref rid="B224" ref-type="bibr">
<sup>224</sup>
</xref> These trials are evaluating intravenous remdesivir (8) at a dose of 200 mg on
the first day plus 100 mg once daily, for an additional 9 consecutive days. The
randomised, double-blind, placebo-controlled, multicentre trials were recently suspended
(NCT04252664) or terminated (NCT04257656) because no eligible patients for enrollment
were found, due pandemic control in China.<xref rid="B215" ref-type="bibr">
<sup>215</sup>
</xref> The study NCT04257656 showed that remdesivir (8) was not associated with
statistically significant clinical benefits in severe forms of COVID-19. However, the
authors observed a numerical reduction in time to clinical improvement in those treated
earlier, but still requires confirmation. Another study, performed by Beigel et al.
(with the same dosage and treatment period than the previous works cited above) enrolled
1063 patients with lower respiratory tract infection, demonstrated that individuals that
were treated with remdesivir (8) had a shorter time to recovery than placebo group (11
days compared with 15 days).<xref rid="B216" ref-type="bibr">
<sup>216</sup>
</xref> Even with a small scientific ballast, due to limited information about safety
and effectiveness of using remdesivir (8), U.S. Food and Drug Administration (FDA)
approved its emergency use on severe COVID-19.<xref rid="B225" ref-type="bibr">
<sup>225</sup>
</xref> The approval was based on review of the topline data on two studies that are
recruiting patients, (NCT04280705) and (NCT04292899). Other clinical studies are being
conducted to address the effect of remdesivir (8) on COVID-19 treatment (Available from:
https://clinicaltrials.gov/ct2/results?cond=COVID-19&#x00026;term=remdesivir&#x00026;cntry=&#x00026;state=&#x00026;city=&#x00026;dist=).</p><p>Other Phase III clinical trials evaluated for COVID-19 treatment included CQ (20)/HCQ
(26). These studies were endorsed by promising <italic>in vitro</italic> data that
suggested an impairment of viral replication by acting on endosome-mediated viral entry
or later phases of viral replication.<xref rid="B194" ref-type="bibr">
<sup>194</sup>
</xref>
<sup>,</sup>
<xref rid="B226" ref-type="bibr">
<sup>226</sup>
</xref> Both molecules have a well-studied toxicity profile being used for more than
half-century as antimalarials, but in some cases can induce heart side effects.<xref rid="B227" ref-type="bibr">
<sup>227</sup>
</xref> These drugs have already been examined against at least five other viruses with
good initial <italic>in vitro</italic> results, but without significant effects in
animal models and humans.<xref rid="B205" ref-type="bibr">
<sup>205</sup>
</xref>
</p><p>Clinical trials to measure the effectiveness of CQ (20) at 500 mg of chloroquine
diphosphate (corresponding to 300 mg of chloroquine (20) base) per day, for ten
consecutive days on the treatment of COVID-19 were performed.<xref rid="B217" ref-type="bibr">
<sup>217</sup>
</xref> Based on results for a very limited number of patients (100), it was concluded
that CQ (20) presented apparent efficacy and acceptable safety against COVID-19
associated pneumonia. Borba et al. performed a double-blind, randomised clinical trial
designed to assess the safety of CQ (20) in two dosages: 600 mg twice daily for 10 days
with an initial dose of 450 mg twice daily on the first day, decreasing to once daily
for four more days.<xref rid="B218" ref-type="bibr">
<sup>218</sup>
</xref> The study suggests that the higher dosage should not be recommended for
critically ill patients with COVID-19 because of its potential side effects. It is
important to note that both doses studied were above the Brazilian recommended dose.</p><p>A controversial study performed by Gautret et al. with a small sample size demonstrated
that HCQ (26) treatment daily at 600 mg significantly decreases viral load in COVID-19
patients and its effect is reinforced by azithromycin (AZ; 49) combination.<xref rid="B219" ref-type="bibr">
<sup>219</sup>
</xref> Until this moment there is clinical robustness to support AZ (49) therapy in
COVID-19.<xref rid="B228" ref-type="bibr">
<sup>228</sup>
</xref>
</p><p>Mehra et al. performed a registry analysis of 96,032 hospitalised patients regarding the
use of CQ (20) or HCQ (26, combined or not with a macrolide) for treatment of
COVID-19.<xref rid="B229" ref-type="bibr">
<sup>229</sup>
</xref> The observational study verified that with COVID-19 requiring hospitalisation a
regimen containing CQ (20) or HCQ (26) had no evidence of benefit, but instead was
associated with an increase in the risk of ventricular arrhythmias and a greater hazard
for in-hospital death with COVID-19. These findings suggest that these drug regimens
should not be used outside of clinical trials and urgent confirmation from randomised
clinical trials is needed. After the publication, the paper was retracted, which
influenced WHO to return the studies on CQ (20) and HCQ (26).<xref rid="B230" ref-type="bibr">
<sup>230</sup>
</xref> Recently, on 17 June 2020, WHO stopped the HCQ (26) arm of the Solidarity trials
again based on the RECOVERY trials (Available from: https://www.recoverytrial.net/). In
this study 1542 patients were randomised to HCQ (26) and compared with 3132 patients
randomised to usual care alone. There was no significant difference in any of the
parameters evaluated: the primary endpoint of 28-day mortality, hazard ratio and
hospital stay duration or other issues. Other study reported that HCQ (26) did not
prevent COVID-19 when used as postexposure prophylaxis within 4 days after moderate or
high-risk exposure.<xref rid="B231" ref-type="bibr">
<sup>231</sup>
</xref> Robust data from well-designed control randomised clinical trials with large
number of patients is still expected for concluding on the efficacy of
hydroxychloroquine (26).</p><p>Ritonavir (2) and lopinavir (1) were developed to target HIV-1 protease and postulated to
inhibit the 3-chymotrypsin-like protease of SARS and MERS, being associated with
improved clinical outcomes.<xref rid="B232" ref-type="bibr">
<sup>232</sup>
</xref> The combination has beneficial effects in marmoset monkeys infected with the
MERS-CoV virus.<xref rid="B233" ref-type="bibr">
<sup>233</sup>
</xref> (1)/(2) may have clinical efficacy against SARS-CoV-2, as seen in the response
against SARS-CoV.<xref rid="B234" ref-type="bibr">
<sup>234</sup>
</xref>
<italic>In vitro</italic> sensitivity and satisfactory response in a preliminary
non-randomised clinical trial of SARS-CoV to (1)/(2) have already been reported,
encouraging its testing in SARS-CoV-2.<xref rid="B235" ref-type="bibr">
<sup>235</sup>
</xref> A total of 199 patients confirmed severe SARS-CoV-2 infection were randomly
designated to be given either (1)/(2) (400 mg/100 mg) twice a day for 14 consecutive
days plus standard care or standard care alone.<xref rid="B220" ref-type="bibr">
<sup>220</sup>
</xref> This first trial was not promising, no benefit was observed on clinical
improvement, mortality and viral loads on severe COVID-19 patients. Other clinical
trials are being carried out and should decide whether these drugs are useful for
COVID-19 treatment or not.</p><p>Ritonavir (2)/lopinavir (1) plus interferon-beta, a cytokine involved in inflammatory
modulation, is the last bet of the SOLIDARITY megatrial. Sheahan et al. demonstrated
that this combination improves pulmonary function but does not reduce virus replication
or severe lung pathology in mice model of MERS-CoV.<xref rid="B236" ref-type="bibr">
<sup>236</sup>
</xref> This combination also showed promising results in MERS-CoV Infection in a
Nonhuman Primate Model.<xref rid="B233" ref-type="bibr">
<sup>233</sup>
</xref> The study (NCT04276688) administered ritonavir (2)/lopinavir (1) 400 mg + 100
mg/ml twice daily for 14 days and Interferon beta-1b 0.25 mg subcutaneous, every
alternate day for 14 days. Another study (NCT04343768) will perform a randomised trial
to verify the effects of interferon beta 1a, compared to interferon beta 1b and the base
therapeutic treatment in Moderate to Severe COVID-19.</p><p>Currently, there is a lot of research around the world examining drugs that can be used
for the treatment of COVID-19. Unfortunately, until this moment no therapeutic options
are promptly effectively available. Most of the studies have a small number of patients
with variable dose and/or duration, fact that hinders a comparison. To successfully
undertake the COVID-19 pandemic with new medicines, synchronised clinical trials with
randomised, double-blind, placebo-controlled are still needed. Infection prevention by
social distancing and supportive medical care, are the only strategies to deal with this
disease until this moment.</p><p>Patent protection and synthesis of repositionable drugs</p><p>The goal of this session is to consider potential obstacles for effective adoption of a
repurposed drug to widespread treatment of COVID-19. Both patent protection and
scalability of manufacturing processes are key aspects to consider while choosing the
best therapeutic option to adopt when dealing with a pandemic.</p><p>A patent can be defined as a government license that confers the owner the exclusivity
over a new invention or medication. With the patent, the inventor is able to exclude
others from making and selling the invention for a determined period of time. When it
comes to medication, the market exclusivity granted by the patent generates enormous
economic profit for the patent holder, once the company will have the monopoly over the
product for around 20 years. Once the patent term finishes, generic companies can start
producing and selling the drug, increasing the market competition over the product. A
strategy adopted by some companies is to maximise the term of patent of successful
products, extending market exclusivity, for instance, increasing economic rewards with
the invention. In order to extend patent terms, the companies can apply for new
formulations, new routes of administration, new uses of the drug among other
strategies.<xref rid="B237" ref-type="bibr">
<sup>237</sup>
</xref>
<sup>,</sup>
<xref rid="B238" ref-type="bibr">
<sup>238</sup>
</xref> This is very important when considering drug repurposing, once those strategies
can make it harder to patent a new method of use for the drug, compromising the legal
rights of the new repurposed indication. As a consequence, the expected profit
associated with repurposing can be severely affected.<xref rid="B39" ref-type="bibr">
<sup>39</sup>
</xref>
</p><p>Remdesivir (8) a good example of maximising the term of patent is the drug remdesivir
(8), which was developed by the American pharmaceutical company Gilead Sciences, Inc. in
2011. Nowadays, (8) has shown promising results as a suitable repurposed drug in the
treatment of the COVID-19 disease. Indeed, there are many ongoing clinical trials with
this drug in COVID-19 patients.<xref rid="B239" ref-type="bibr">
<sup>239</sup>
</xref>
<sup>,</sup>
<xref rid="B240" ref-type="bibr">
<sup>240</sup>
</xref> Due to the good results concerning remdesivir (8), in January 2020, the Wuhan
Institute of Virology applied for a patent on Gilead&#x02019;s remdesivir (8) for the treatment
of coronavirus, in an attempt to protect China&#x02019;s economic and medical interests.
However, remdesivir (8) has already 133 patents related to the coronavirus filed by
Gilead Science in 43 countries around the globe since 2011. In fact, the company has a
robust patent portfolio that includes structures of remdesivir-related compounds (Family
1), the manufacturing method of the drug (Family 2), the use of remdesivir (8) in
treating Coronaviridae infection (Family 3), among other patents that claims the use of
(8) for the treatment of a series of viral infections (Families 3 and 4) (<xref ref-type="fig" rid="f13">Fig. 13</xref>).<xref rid="B241" ref-type="bibr">
<sup>241</sup>
</xref> Practically, this means that if the (8) is proved to be efficient for the
treatment of COVID-19, Gilead Science is the only pharmaceutical company owing the
market exclusivity of the drug, at least until 2031. In fact, the company has already
started to produce larger amounts of the drug and they already made improvements to
optimise the drug manufacturing timeline. Now, the company can produce the drug in 6
months, half the time that they used to need to get the final product. In addition, the
company has been donating remdesivir (8) to ongoing clinical trials, a gesture that will
not only help the trial patients, but Gilead itself.<xref rid="B242" ref-type="bibr">
<sup>242</sup>
</xref>
</p><p>
<fig id="f13" orientation="portrait" position="float"><label>Fig. 13:</label><caption><title>patent families of Gilead Science related to remdesivir (8). Adapted from
www.inquartik.com.<xref rid="B241" ref-type="bibr">
<sup>241</sup>
</xref>
</title></caption><graphic xlink:href="1678-8060-mioc-115-e200254-gf13"/></fig>
</p><p>
<italic>Baricitinib (39)</italic> - In 2009, a patent assigned to Incyte Corporation
disclosed the preparation of several active compounds as JAK inhibitors, including
Baricitinib (39). In the same year, Lilly and Incyte made an agreement allowing Lilly
Co. to manufacture and commercialise the medicine worldwide, making it Lilly Co. the
only supplier around the globe.<xref rid="B243" ref-type="bibr">
<sup>243</sup>
</xref> There are two patents that protect the drug, one concerning its synthetic
pathway and another disclosing the use of (39) in the treatment of Rheumatoid Arthritis.
Both of them will expire in nine years, which could open opportunities for generic drug
companies to produce baricitinib (39). Nowadays, (39) has been investigated as a drug
that could be used in the treatment of COVID 19 patients, since its anti-inflammatory
activity could minimise inflammatory complications in COVID 19 patients. According to
the platform ClinicalTrials.gov, there are 14 ongoing clinical trials to evaluate the
efficacy and safety of Baricitinib (39) in the treatment of COVID 19.<xref rid="B244" ref-type="bibr">
<sup>244</sup>
</xref> If the drug succeeds, there will be a need for larger and faster production and
distribution of the medicine worldwide. There are two patents disclosing a synthetic
method for the preparation of (39). The first one is from 2009 and owned by Incyte Co.
and the latest is from 2016, by Lilly Co.<xref rid="B245" ref-type="bibr">
<sup>245</sup>
</xref>
<sup>,</sup>
<xref rid="B246" ref-type="bibr">
<sup>246</sup>
</xref> The main difference between them is how the central pyrazole ring is installed
in the molecule.</p><p>In the patent from 2009, baricitinib (39) is obtained by a convergent synthesis. The
synthetic pathway starts with the protection in position 7 of 4-chloro-7H-
pyrrolo[2,3-d]pyrimidine (50) using 2-(trimethylsilyl)ethoxymethyl chloride (51),
affording intermediate (52). Next step is a Suzuki-Miyaura reaction, coupling the fused
ring system to a 4-pyrazoleboronic acid pinacol ester (53), giving key intermediate
(54). Parallelly, a couple of steps starting from 2-(chloromethyl)oxirane (55) lead to
1-Boc-3-azetidinone (58) that reacts with diethyl cyanomethylphosphonate (59), affording
key intermediate (60). Next, the key intermediates (54) and (60) react in the presence
of DBU, giving (61). Then, steps involving hydrolysis of the Boc, sulfonation and
pyrrolopyrimidine deprotection afford (39) with an overall yield of 21 % (<xref ref-type="fig" rid="f14">Fig. 14</xref>).<xref rid="B246" ref-type="bibr">
<sup>246</sup>
</xref>
</p><p>
<fig id="f14" orientation="portrait" position="float"><label>Fig. 14:</label><caption><title>synthesis of Baricitinib (39) via the key intermediates (54) and
(60).</title></caption><graphic xlink:href="1678-8060-mioc-115-e200254-gf14"/></fig>
</p><p>The synthetic pathway described in the patent from 2016 has only six steps in a linear
approach, as a consequence, the product is obtained in a higher overall yield when
compared to the synthetic pathway discussed above. Intermediate (67) is obtained from
azetidine-3-ol (64) in a couple of steps, including a sulfonation, an oxidation and the
installment of the cyanomethylene moiety (<xref ref-type="fig" rid="f15">Fig.
15</xref>). Furthermore, it is not necessary to protect any position in this sequence.
Additionally, the oxidation step can be performed under flow conditions. Then,
intermediate (67) is reacted with ester (53), affording (68). A Suzuki-Miyaura reaction
involving 7-Boc-4-chloro-7H-pyrrolo[2,3-d]pyrimidine (69) is applied, allowing the
formation of the bound between the azetidinylpyrazole group and the
pyrrolo[2,3-d]pyrimidine system. Last step is a hydrolysis of the Boc, affording
Baricitinib (39) with an overall yield of 50 % (<xref ref-type="fig" rid="f15">Fig.
15</xref>).<xref rid="B245" ref-type="bibr">
<sup>245</sup>
</xref>
</p><p>
<fig id="f15" orientation="portrait" position="float"><label>Fig. 15:</label><caption><title>optimised synthesis of Baricitinib (39).</title></caption><graphic xlink:href="1678-8060-mioc-115-e200254-gf15"/></fig>
</p><p>
<italic>Off-patent drugs</italic> - Fortunately, a number of drugs that have been tested
as possible agents in the COVID-19 treatment are off-patent, meaning that generic drug
companies already manufacture and commercialise the medicine, making it easier for drug
repurposing.<xref rid="B39" ref-type="bibr">
<sup>39</sup>
</xref> The off-patent drugs that have been tested in COVID-19 clinical trials include
CQ (20), HCQ (26), Ritonavir (2) and Lopinavir (1).<xref rid="B239" ref-type="bibr">
<sup>239</sup>
</xref>
<sup>,</sup>
<xref rid="B240" ref-type="bibr">
<sup>240</sup>
</xref> A recent research article published by Hill and collaborators estimated the
minimum cost of production associated with these drugs, showing that all the treatments
under evaluation in current clinical trials are cheap to manufacture. However, list
prices can be over 100 times higher than the costs to produce the drug.<xref rid="B247" ref-type="bibr">
<sup>247</sup>
</xref> If any of those drugs become approved for the treatment of COVID-19, its demand
will increase dramatically. Therefore, it is important to consider the challenges
associated with scaling up the production to meet the demand. For instance, there are
few regulatory approved production facilities, and drug manufacturers rely on low-cost
suppliers of raw materials in India and China, which might be scarce during a pandemic.
Consequently, it would be difficult to ensure short term global availability of the
treatment, since the production depends on different countries.<xref rid="B248" ref-type="bibr">
<sup>248</sup>
</xref> Those conclusions are very helpful in showing the importance of optimising the
way of manufacturing the candidate drugs presented above. For this reason, recent and
optimised synthetic pathways found in patents and articles for some Ritonavir (2) and
Lopinavir (1) are discussed below, as CQ (20) and HCQ (26) have now been abandoned.
Finally, we will briefly discuss the ease of manufacturing in large scale each of the
drugs we had the synthesis reviewed here.</p><p>
<italic>Ritonavir (2)</italic> - The first disclosure of ritonavir (2) is presented in a
patent from 1994, assigned to Abbott Laboratories. Even though the patent consists of a
range of Markush structures, among which is found (2), its synthesis is not
presented.<xref rid="B249" ref-type="bibr">
<sup>249</sup>
</xref> The synthetic pathway to obtain (2) was disclosed for the first time in a
second-generation patent in 1995, by the same company.<xref rid="B250" ref-type="bibr">
<sup>250</sup>
</xref>
<sup>,</sup>
<xref rid="B251" ref-type="bibr">
<sup>251</sup>
</xref> Some drawbacks related to the synthesis presented by Abbott include the
employment of expensive condensing agents, as 1-Ethyl-3-(3-dimethylaminopropyl)
carbodiimide (EDC) and poor reaction yields on the first steps of the synthetic pathway,
making this strategy too expensive and not suitable for scale-up production. Considering
the above deficiencies, a recent Chinese patent concerning the synthesis of ritonavir
(2) has been released.</p><p>The synthetic pathway described in the patent starts with a nucleophilic
addition-elimination reaction between the starting material (2-isopropylthiazol-4-yl)-
nitro-methylamine (71) and N-[(2,2,2-trichloroethoxy)carbonyl]-L-valine (72), generating
intermediate (73). The intermediate is mixed with <italic>p</italic>-toluenesulfonyl
chloride and triethylamine to activate the acid function, followed by the addition of
reagent (74) in a one-pot procedure. The condensation allows the formation of
intermediate (75), which is submitted to acidic conditions for a Boc deprotection,
followed by another nucleophilic addition-elimination reaction with reagent (76), thus
obtaining the final product ritonavir (2) (<xref ref-type="fig" rid="f16">Fig.
16</xref>).<xref rid="B252" ref-type="bibr">
<sup>252</sup>
</xref> When comparing both patents, it is possible to highlight important advantages
present in the latest one, including the use of cheap and easily available reagents, for
instance, the use of p-toluenesulfonyl chloride as an amide condensing agent, the
synthetic pathway has a high yield (79% overall), low cost and it is ease to scale-up
the production.</p><p>
<fig id="f16" orientation="portrait" position="float"><label>Fig. 16:</label><caption><title>synthesis of Ritonavir (2) via a cost-effective and easy synthetic
pathway.</title></caption><graphic xlink:href="1678-8060-mioc-115-e200254-gf16"/></fig>
</p><p>
<italic>Lopinavir (1)</italic> - The first synthetic methods related to the synthesis of
lopinavir (1) are present in a patent from 1996 owned by Abbott Laboratories.<xref rid="B249" ref-type="bibr">
<sup>249</sup>
</xref> (1) has 4 chiral centres, and the synthetic strategies reported by Abbott are
similar, involving the synthesis of a key intermediate amino alcohol unit, that is then
connected to the appropriated side chains. Some drawbacks that can be pointed out in the
synthesis include the use of 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) as a
condensing agent and the weak base 1-hydroxybenzotriazole, both expensive reagents,
making the synthesis not suitable from the viewpoint of cost and industrial application.
In addition, one of the methods described by Abbott includes the synthesis of an acid
chloride as an intermediate, which is very unstable, and it can be easily decomposed by
humidity, making the synthesis not suitable for industrial production.</p><p>The most recent patent related to the synthesis of lopinavir (1) is dated 2018 and it is
from the Chinese company Shanghai Desano Pharmaceuticals Co. Ltd.<xref rid="B253" ref-type="bibr">
<sup>253</sup>
</xref> The patent is described as technical, with the aim of improving the synthesis of
(1) presented in the patent from 1996, by Abbott Laboratories. The patent describes the
synthesis of lopinavir (1) by a one-pot procedure starting with the formation of an acid
chloride from (2S)-(1-tetrahydropyramid-2-one)-3-methylbutanoic acid (77) followed by
addition of a weak base and the reactant (78) to the reaction system. The amine function
of (78) allows a nucleophilic addition-elimination reaction to occur, affording (1)
after treatment with NaHCO<sub>3</sub> (<xref ref-type="fig" rid="f17">Fig. 17</xref>).
Therefore, it is possible to synthesise lopinavir (1) in high yield (90%) in an
optimised method, which involves a few reagents, mild conditions and is performed in a
one-pot procedure.</p><p>
<fig id="f17" orientation="portrait" position="float"><label>Fig. 17:</label><caption><title>synthesis of Lopinavir (1) via a one-pot procedure.</title></caption><graphic xlink:href="1678-8060-mioc-115-e200254-gf17"/></fig>
</p><p>
<italic>Synthetic scalability and cost-effectiveness</italic> - The synthetic pathways
described above show how much improvement has been done concerning the preparation of
these drugs in a more cost-effective way. Furthermore, when comparing the drugs
discussed above, it is worth pointing out which one could be the easiest one to produce
when analysing the factors that influence the final cost of a synthetic pathway, such as
chiral centres, cost of starting materials, number of steps and overall yield. Regarding
chiral centres, ritonavir (2) and lopinavir (1) have four chiral centres each, and they
are not sold as racemate mixtures. Moreover, to synthesise those compounds the chiral
centres do not come from natural molecules, but have to be synthetically installed,
which makes the chiral starting materials more expensive and enantiomeric excess has to
be accessed more carefully at the end of the synthetic pathway. As a consequence, it can
take longer and more expensive to obtain the final product. On the other hand,
baricitinib (39) does not have any chiral centres, making the synthetic pathway easier
and cheaper to perform. Concerning the number of steps and overall yield, baricitinib
(39) has the highest number of steps and lower overall yield when compared to ritonavir
(2) and lopinavir (1). However, one of the steps in the synthesis of baricitinib (39)
can be performed under flow conditions, which is very interesting from the industrial
point of view. Therefore, when taking into account the most recent synthetic pathways
proposed for these drugs, the synthesis of baricitinib (39) is the most cost-effective
of the three of them.</p><p>
<italic>In conclusion</italic> - SARS-CoV-2 infection is a life-threatening disease with
such a high transmission rate that can surpass even the most well-structured health
systems in developed high-income countries. While vaccines are the ideal solution for
preventing the spread of infectious diseases like COVID-19 their development cycle have
intrinsic challenges and safety checking steps that require several months or years to
complete their development. A similar situation is found for developing new drugs for
COVID-19 (as with any other disease), because of the long process involving discovery,
validation and safety evaluation of new chemical entities for use in human health. In
this scenario, repositioning drugs already in clinical use for treatment of COVID-19 is
an important shortcut, as we have discussed.</p><p>Data are accumulating about the molecular pathology of COVID-19 as well as structural
information on the viral and host proteins involved in the infection mechanism. This
knowledge is essential for allowing researchers to have new insights on approved or
investigational drugs that can be repurposed to treat SARS-CoV-2 infection. As reviewed
here, over 10 targets distributed amongst distinct steps of the SARS-CoV-2 replication
cycle or host cell mediators are currently being investigated. Here, we highlighted
several up-to-date examples of potential repurposable drug candidates proposed from
either computational approaches or experimental trials (or their combination) at
different levels of validation and stages of development. Noteworthy, AI methods hold a
great promise in finding occult links between drugs, human and viral targets to find
novel bioactivities and even combinations of drugs.</p><p>Remdesivir (8), CQ (20)/HCQ (26) (alone or in association with other drugs) and the
association lopinavir (1)/ritonavir (2) have been the focus of most clinical studies. So
far, results have been mostly disappointing with these trials, stressing the importance
of carefully performed studies in patients to attest that biological activities observed
<italic>in vitro</italic> actually be translated into clinical efficacy and safety.
At the moment, even with limited information about safety and effectiveness, remdesivir
is the only drug approved by the FDA for emergency use on severe COVID-19. As discussed
here, a major concern with drugs for effectively fighting the pandemic is the drug&#x02019;s
industrial production cost and its impact on final treatment cost. Gilead, remdesivir&#x02019;s
owner company, has recently signed non-exclusive voluntary licensing agreements with
five generic pharmaceutical manufacturers to produce remdesivir for distribution in 127
countries, nearly all low-income and lower-middle income countries. Hopefully, based on
the constantly growing scientific knowledge summarised in this review, other treatment
options will be revealed soon enough to help stop the havoc caused by the COVID-19
pandemic.</p></body><back><fn-group><fn fn-type="financial-disclosure" id="fn1"><p>Financial support: CNPq, FAPERJ, CAPES, FIOCRUZ. FPSJ and SBF are CNPq
scholarship recipients (CNPq research productivity); LRSN and TCSE are supported
by CAPES (Finance code 001).</p></fn></fn-group><ref-list><title>REFERENCES</title><ref id="B1"><label>1</label><element-citation publication-type="webpage"><person-group person-group-type="author"><collab>WHO</collab></person-group><article-title>Coronavirus disease (COVID-2019) situation report 198;
2020</article-title><ext-link ext-link-type="uri" xlink:href="https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports">https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports</ext-link></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kampf</surname><given-names>G</given-names></name><name><surname>Todt</surname><given-names>D</given-names></name><name><surname>Pfaender</surname><given-names>S</given-names></name><name><surname>Steinmann</surname><given-names>E</given-names></name></person-group><article-title>Persistence of coronaviruses on inanimate surfaces and their
inactivation with biocidal agents</article-title><source>J Hosp Infect</source><year>2020</year><volume>104</volume><issue>3</issue><fpage>246</fpage><lpage>251</lpage><pub-id pub-id-type="pmid">32035997</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bourouiba</surname><given-names>L</given-names></name></person-group><article-title>Turbulent gas clouds and respiratory pathogen emissions potential
implications for reducing transmission of COVID-19</article-title><source>JAMA</source><year>2020</year><volume>323</volume><issue>18</issue><fpage>1837</fpage><lpage>1838</lpage><pub-id pub-id-type="pmid">32215590</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Ning</surname><given-names>Z</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Guo</surname><given-names>M</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Gali</surname><given-names>NK</given-names></name></person-group><article-title>Aerodynamic analysis of SARS-CoV-2 in two Wuhan
hospitals</article-title><source>Nature</source><year>2020</year><volume>582</volume><issue>7813</issue><fpage>557</fpage><lpage>560</lpage><pub-id pub-id-type="pmid">32340022</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lodder</surname><given-names>W</given-names></name><name><surname>Husman</surname><given-names>AMR</given-names></name></person-group><article-title>SARS-CoV-2 in wastewater potential health risk, but also data
source</article-title><source>Lancet Gastroenterol Hepatol</source><year>2020</year><volume>5</volume><issue>6</issue><fpage>533</fpage><lpage>534</lpage><pub-id pub-id-type="pmid">32246939</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahmed</surname><given-names>W</given-names></name><name><surname>Angel</surname><given-names>N</given-names></name><name><surname>Edson</surname><given-names>J</given-names></name><name><surname>Bibby</surname><given-names>K</given-names></name><name><surname>Bivins</surname><given-names>A</given-names></name></person-group><person-group person-group-type="author"><collab>O'Brien JW</collab></person-group><article-title>First confirmed detection of SARS-CoV-2 in untreated wastewater
in Australia a proof of concept for the wastewater surveillance of COVID-19
in the community</article-title><source>Sci Total Environ</source><year>2020</year><volume>728</volume><fpage>138764</fpage><lpage>138764</lpage><pub-id pub-id-type="pmid">32387778</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="webpage"><person-group person-group-type="author"><collab>FIOCRUZ</collab></person-group><article-title>Fiocruz divulga estudo sobre a presen&#x000e7;a do novo coronav&#x000ed;rus em
esgotos sanit&#x000e1;rios; 2020</article-title><ext-link ext-link-type="uri" xlink:href="https://portal.fiocruz.br/noticia/fiocruz-divulga-resultados-de-estudo-sobre-presenca-do-novo-coronavirus-em-esgotos.">https://portal.fiocruz.br/noticia/fiocruz-divulga-resultados-de-estudo-sobre-presenca-do-novo-coronavirus-em-esgotos.</ext-link></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kraemer</surname><given-names>MUG</given-names></name><name><surname>Yang C-H</surname><given-names/></name><name><surname>Gutierrez</surname><given-names>B</given-names></name><name><surname>Wu C-H</surname><given-names/></name><name><surname>Klein</surname><given-names>B</given-names></name><name><surname>Pigott</surname><given-names>DM</given-names></name></person-group><article-title>The effect of human mobility and control measures on the COVID-19
epidemic in China</article-title><source>Science</source><year>2020</year><volume>368</volume><issue>6490</issue><fpage>493</fpage><lpage>497</lpage><pub-id pub-id-type="pmid">32213647</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kissler</surname><given-names>SM</given-names></name><name><surname>Tedijanto</surname><given-names>C</given-names></name><name><surname>Goldstein</surname><given-names>E</given-names></name><name><surname>Grad</surname><given-names>YH</given-names></name><name><surname>Lipsitch</surname><given-names>M</given-names></name></person-group><article-title>Projecting the transmission dynamics of SARS-CoV-2 through the
postpandemic period</article-title><source>Science</source><year>2020</year><volume>368</volume><issue>6493</issue><fpage>860</fpage><lpage>868</lpage><pub-id pub-id-type="pmid">32291278</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>R</given-names></name><name><surname>Zhao</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Niu</surname><given-names>P</given-names></name><name><surname>Yang</surname><given-names>B</given-names></name><name><surname>Wu</surname><given-names>H</given-names></name></person-group><article-title>Genomic characterisation and epidemiology of 2019 novel
coronavirus implications for virus origins and receptor
binding</article-title><source>Lancet</source><year>2020</year><volume>395</volume><issue>10224</issue><fpage>565</fpage><lpage>574</lpage><pub-id pub-id-type="pmid">32007145</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Almaz&#x000e1;n</surname><given-names>F</given-names></name><name><surname>Sola</surname><given-names>I</given-names></name><name><surname>Zu&#x000f1;iga</surname><given-names>S</given-names></name><name><surname>Marquez-Jurado</surname><given-names>S</given-names></name><name><surname>Morales</surname><given-names>L</given-names></name><name><surname>Becares</surname><given-names>M</given-names></name></person-group><article-title>Coronavirus reverse genetic systems infectious clones and
replicons</article-title><source>Virus Res</source><year>2014</year><volume>189</volume><fpage>262</fpage><lpage>270</lpage><pub-id pub-id-type="pmid">24930446</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Woo</surname><given-names>PCY</given-names></name><name><surname>Lau</surname><given-names>SKP</given-names></name><name><surname>Lam</surname><given-names>CSF</given-names></name><name><surname>Lau</surname><given-names>CCY</given-names></name><name><surname>Tsang</surname><given-names>AKL</given-names></name><name><surname>Lau</surname><given-names>JHN</given-names></name></person-group><article-title>Discovery of seven novel mammalian and avian coronaviruses in the
genus deltacoronavirus supports bat coronaviruses as the gene source of
alphacoronavirus and betacoronavirus and avian coronaviruses as the gene
source of gammacoronavirus and deltacoronavirus</article-title><source>J Virol</source><year>2012</year><volume>86</volume><issue>7</issue><fpage>3995</fpage><lpage>4008</lpage><pub-id pub-id-type="pmid">22278237</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kandeil</surname><given-names>A</given-names></name><name><surname>Gomaa</surname><given-names>M</given-names></name><name><surname>Shehata</surname><given-names>M</given-names></name><name><surname>El-Taweel</surname><given-names>A</given-names></name><name><surname>Kayed</surname><given-names>AE</given-names></name><name><surname>Abiadh</surname><given-names>A</given-names></name></person-group><article-title>Middle East Respiratory Syndrome coronavirus infection in
non-camelid domestic mammals</article-title><source>Emerg Microbes Infect</source><year>2019</year><volume>8</volume><issue>1</issue><fpage>103</fpage><lpage>108</lpage><pub-id pub-id-type="pmid">30866764</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tyrrell</surname><given-names>DA</given-names></name><name><surname>Bynoe</surname><given-names>M</given-names></name></person-group><article-title>Cultivation of viruses from a high proportion of patients with
colds</article-title><source>Lancet</source><year>1966</year><volume>287</volume><issue>7428</issue><fpage>76</fpage><lpage>77</lpage></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guan</surname><given-names>Y</given-names></name></person-group><article-title>Isolation and characterization of viruses related to the SARS
coronavirus from animals in Southern China</article-title><source>Science</source><year>2003</year><volume>302</volume><issue>5643</issue><fpage>276</fpage><lpage>278</lpage><pub-id pub-id-type="pmid">12958366</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cui</surname><given-names>J</given-names></name><name><surname>Eden J-S</surname><given-names/></name><name><surname>Holmes</surname><given-names>EC</given-names></name><name><surname>Wang L-F</surname><given-names/></name></person-group><article-title>Adaptive evolution of bat dipeptidyl peptidase 4 (dpp4)
implications for the origin and emergence of Middle East Respiratory
Syndrome coronavirus</article-title><source>Virol J</source><year>2013</year><volume>10</volume><issue>1</issue><fpage>304</fpage><lpage>304</lpage><pub-id pub-id-type="pmid">24107353</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Wilde</surname><given-names>AH</given-names></name><name><surname>Snijder</surname><given-names>EJ</given-names></name><name><surname>Kikkert</surname><given-names>M</given-names></name><name><surname>van Hemert</surname><given-names>MJ.</given-names></name></person-group><article-title>Host factors in coronavirus replication. In: Tripp RA, Tompkins
SM, editors. Roles of host gene and non-coding RNA expression in virus
infection</article-title><source>Springer International Publishing</source><year>2017</year></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>F</given-names></name></person-group><article-title>Structure, function, and evolution of coronavirus spike
proteins</article-title><source>Annu Rev Virol</source><year>2016</year><volume>3</volume><issue>1</issue><fpage>237</fpage><lpage>261</lpage><pub-id pub-id-type="pmid">27578435</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Yang</surname><given-names>L</given-names></name><name><surname>Lian</surname><given-names>X</given-names></name><name><surname>Xie</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>S</given-names></name></person-group><article-title>The MERS-CoV receptor DPP4 as a candidate binding target of
the</article-title><source>SARS-CoV-2 spike. iScience</source><year>2020</year><volume>23</volume><issue>6</issue><fpage>101160</fpage><lpage>101160</lpage><pub-id pub-id-type="pmid">32405622</pub-id></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>F</given-names></name></person-group><article-title>Receptor recognition mechanisms of coronaviruses a decade of
structural studies</article-title><source>J Virol</source><year>2015</year><volume>89</volume><issue>4</issue><fpage>1954</fpage><lpage>1964</lpage><pub-id pub-id-type="pmid">25428871</pub-id></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schoeman</surname><given-names>D</given-names></name><name><surname>Fielding</surname><given-names>BC</given-names></name></person-group><article-title>Coronavirus envelope protein current knowledge</article-title><source>Virol J</source><year>2019</year><volume>16</volume><issue>1</issue><fpage>69</fpage><lpage>69</lpage><pub-id pub-id-type="pmid">31133031</pub-id></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuo</surname><given-names>L</given-names></name><name><surname>Hurst-Hess</surname><given-names>KR</given-names></name><name><surname>Koetzner</surname><given-names>CA</given-names></name><name><surname>Masters</surname><given-names>PS</given-names></name></person-group><article-title>Analyses of coronavirus assembly interactions with interspecies
membrane and nucleocapsid protein chimeras</article-title><source>J Virol</source><year>2016</year><volume>90</volume><issue>9</issue><fpage>4357</fpage><lpage>4368</lpage><pub-id pub-id-type="pmid">26889024</pub-id></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andersen</surname><given-names>KG</given-names></name><name><surname>Rambaut</surname><given-names>A</given-names></name><name><surname>Lipkin</surname><given-names>WI</given-names></name><name><surname>Holmes</surname><given-names>EC</given-names></name><name><surname>Garry</surname><given-names>RF</given-names></name></person-group><article-title>The proximal origin of SARS-CoV-2</article-title><source>Nat Med</source><year>2020</year><volume>26</volume><issue>4</issue><fpage>450</fpage><lpage>452</lpage><pub-id pub-id-type="pmid">32284615</pub-id></element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Forster</surname><given-names>P</given-names></name><name><surname>Forster</surname><given-names>L</given-names></name><name><surname>Renfrew</surname><given-names>C</given-names></name><name><surname>Forster</surname><given-names>M</given-names></name></person-group><article-title>Phylogenetic network analysis of SARS-CoV-2
genomes</article-title><source>Proc Natl Acad Sci USA</source><year>2020</year><volume>117</volume><issue>17</issue><fpage>9241</fpage><lpage>9243</lpage><pub-id pub-id-type="pmid">32269081</pub-id></element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>P</given-names></name><name><surname>Yang X-L</surname><given-names/></name><name><surname>Wang X-G</surname><given-names/></name><name><surname>Hu</surname><given-names>B</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name></person-group><article-title>A pneumonia outbreak associated with a new coronavirus of
probable bat origin</article-title><source>Nature</source><year>2020</year><volume>579</volume><issue>7798</issue><fpage>270</fpage><lpage>273</lpage><pub-id pub-id-type="pmid">32015507</pub-id></element-citation></ref><ref id="B26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>F</given-names></name><name><surname>Zhao</surname><given-names>S</given-names></name><name><surname>Yu</surname><given-names>B</given-names></name><name><surname>Chen Y-M</surname><given-names/></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Song Z-G</surname><given-names/></name></person-group><article-title>A new coronavirus associated with human respiratory disease in
China</article-title><source>Nature</source><year>2020</year><volume>579</volume><issue>7798</issue><fpage>265</fpage><lpage>269</lpage><pub-id pub-id-type="pmid">32015508</pub-id></element-citation></ref><ref id="B27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Menni</surname><given-names>C</given-names></name><name><surname>Valdes</surname><given-names>AM</given-names></name><name><surname>Freidin</surname><given-names>MB</given-names></name><name><surname>Sudre</surname><given-names>CH</given-names></name><name><surname>Nguyen</surname><given-names>LH</given-names></name><name><surname>Drew</surname><given-names>DA</given-names></name></person-group><article-title>Real-time tracking of self-reported symptoms to predict potential
COVID-19</article-title><source>Nat Med</source><year>2020</year><volume>26</volume><issue>7</issue><fpage>1037</fpage><lpage>1040</lpage><pub-id pub-id-type="pmid">32393804</pub-id></element-citation></ref><ref id="B28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rodriguez-Morales</surname><given-names>AJ</given-names></name><name><surname>Cardona-Ospina</surname><given-names>JA</given-names></name><name><surname>Guti&#x000e9;rrez-Ocampo</surname><given-names>E</given-names></name><name><surname>Villamizar-Pe&#x000f1;a</surname><given-names>R</given-names></name><name><surname>Holguin-Rivera</surname><given-names>Y</given-names></name><name><surname>Escalera-Antezana</surname><given-names>JP</given-names></name></person-group><article-title>Clinical, laboratory and imaging features of COVID-19 a
systematic review and meta-analysis</article-title><source>Travel Med Infect Dis</source><year>2020</year><volume>34</volume><fpage>101623</fpage><lpage>101623</lpage><pub-id pub-id-type="pmid">32179124</pub-id></element-citation></ref><ref id="B29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>G</given-names></name><name><surname>Fan</surname><given-names>Y</given-names></name><name><surname>Lai</surname><given-names>Y</given-names></name><name><surname>Han</surname><given-names>T</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Zhou</surname><given-names>P</given-names></name></person-group><article-title>Coronavirus infections and immune responses</article-title><source>J Med Virol</source><year>2020</year><volume>92</volume><issue>4</issue><fpage>424</fpage><lpage>432</lpage><pub-id pub-id-type="pmid">31981224</pub-id></element-citation></ref><ref id="B30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barnes</surname><given-names>BJ</given-names></name><name><surname>Adrover</surname><given-names>JM</given-names></name><name><surname>Baxter-Stoltzfus</surname><given-names>A</given-names></name><name><surname>Borczuk</surname><given-names>A</given-names></name><name><surname>Cools-Lartigue</surname><given-names>J</given-names></name><name><surname>Crawford</surname><given-names>JM</given-names></name></person-group><article-title>Targeting potential drivers of COVID-19 neutrophil extracellular
traps</article-title><source>J Exp Med</source><year>2020</year><volume>217</volume><issue>6</issue><elocation-id>e20200652</elocation-id><pub-id pub-id-type="pmid">32302401</pub-id></element-citation></ref><ref id="B31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Porcheddu</surname><given-names>R</given-names></name><name><surname>Serra</surname><given-names>C</given-names></name><name><surname>Kelvin</surname><given-names>D</given-names></name><name><surname>Kelvin</surname><given-names>N</given-names></name><name><surname>Rubino</surname><given-names>S</given-names></name></person-group><article-title>Similarity in case fatality rates (CFR) of COVID-19/SARS-COV-2 in
Italy and China</article-title><source>J Infect Dev Ctries</source><year>2020</year><volume>14</volume><issue>02</issue><fpage>125</fpage><lpage>128</lpage><pub-id pub-id-type="pmid">32146445</pub-id></element-citation></ref><ref id="B32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cook</surname><given-names>TM</given-names></name></person-group><article-title>The importance of hypertension as a risk factor for severe
illness and mortality in COVID-19</article-title><source>Anaesthesia</source><year>2020</year><volume>75</volume><issue>7</issue><fpage>976</fpage><lpage>977</lpage><pub-id pub-id-type="pmid">32339251</pub-id></element-citation></ref><ref id="B33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deng</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>W</given-names></name><name><surname>Liu</surname><given-names>K</given-names></name><name><surname>Fang Y-Y</surname><given-names/></name><name><surname>Shang</surname><given-names>J</given-names></name><name><surname>Zhou</surname><given-names>L</given-names></name></person-group><article-title>Clinical characteristics of fatal and recovered cases of
coronavirus disease 2019 in Wuhan, China a retrospective
study</article-title><source>Chin Med J (Engl)</source><year>2020</year><volume>133</volume><issue>11</issue><fpage>1261</fpage><lpage>1267</lpage><pub-id pub-id-type="pmid">32209890</pub-id></element-citation></ref><ref id="B34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>W</given-names></name><name><surname>Li</surname><given-names>M</given-names></name><name><surname>Dong</surname><given-names>Y</given-names></name><name><surname>Zhou</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Tian</surname><given-names>C</given-names></name></person-group><article-title>Diabetes is a risk factor for the progression and prognosis of
COVID-19</article-title><source>Diabetes Metab Res Rev</source><year>2020</year><elocation-id>e3319</elocation-id><pub-id pub-id-type="pmid">32233013</pub-id></element-citation></ref><ref id="B35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brooke</surname><given-names>J</given-names></name><name><surname>Jackson</surname><given-names>D</given-names></name></person-group><article-title>Older people and COVID-19 isolation, risk and
ageism</article-title><source>J Clin Nurs</source><year>2020</year><volume>29</volume><issue>13-14</issue><fpage>2044</fpage><lpage>2046</lpage><pub-id pub-id-type="pmid">32239784</pub-id></element-citation></ref><ref id="B36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Wu</surname><given-names>S</given-names></name><name><surname>Xu</surname><given-names>L</given-names></name></person-group><article-title>Asymptomatic carriers of COVID-19 as a concern for disease
prevention and control more testing, more follow-up</article-title><source>Biosci Trends</source><year>2020</year><volume>14</volume><issue>3</issue><fpage>206</fpage><lpage>208</lpage><pub-id pub-id-type="pmid">32321904</pub-id></element-citation></ref><ref id="B37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ashburn</surname><given-names>TT</given-names></name><name><surname>Thor</surname><given-names>KB</given-names></name></person-group><article-title>Drug repositioning identifying and developing new uses for
existing drugs</article-title><source>Nat Rev Drug Discov</source><year>2004</year><volume>3</volume><issue>8</issue><fpage>673</fpage><lpage>683</lpage><pub-id pub-id-type="pmid">15286734</pub-id></element-citation></ref><ref id="B38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cha</surname><given-names>Y</given-names></name><name><surname>Erez</surname><given-names>T</given-names></name><name><surname>Reynolds</surname><given-names>IJ</given-names></name><name><surname>Kumar</surname><given-names>D</given-names></name><name><surname>Ross</surname><given-names>J</given-names></name><name><surname>Koytiger</surname><given-names>G</given-names></name></person-group><article-title>Drug repurposing from the perspective of pharmaceutical
companies</article-title><source>Br J Pharmacol</source><year>2018</year><volume>175</volume><issue>2</issue><fpage>168</fpage><lpage>180</lpage><pub-id pub-id-type="pmid">28369768</pub-id></element-citation></ref><ref id="B39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pushpakom</surname><given-names>S</given-names></name><name><surname>Iorio</surname><given-names>F</given-names></name><name><surname>Eyers</surname><given-names>PA</given-names></name><name><surname>Escott</surname><given-names>KJ</given-names></name><name><surname>Hopper</surname><given-names>S</given-names></name><name><surname>Wells</surname><given-names>A</given-names></name></person-group><article-title>Drug repurposing progress, challenges and
recommendations</article-title><source>Nat Rev Drug Discov</source><year>2019</year><volume>18</volume><issue>1</issue><fpage>41</fpage><lpage>58</lpage><pub-id pub-id-type="pmid">30310233</pub-id></element-citation></ref><ref id="B40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Howard</surname><given-names>CR</given-names></name><name><surname>Fletcher</surname><given-names>NF</given-names></name></person-group><article-title>Emerging virus diseases can we ever expect the
unexpected?</article-title><source>Emerg Microbes Infect</source><year>2012</year><volume>1</volume><issue>1</issue><fpage>1</fpage><lpage>9</lpage></element-citation></ref><ref id="B41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garc&#x000ed;a-Serradilla</surname><given-names>M</given-names></name><name><surname>Risco</surname><given-names>C</given-names></name><name><surname>Pacheco</surname><given-names>B</given-names></name></person-group><article-title>Drug repurposing for new, efficient, broad spectrum
antivirals</article-title><source>Virus Res</source><year>2019</year><volume>264</volume><fpage>22</fpage><lpage>31</lpage><pub-id pub-id-type="pmid">30794895</pub-id></element-citation></ref><ref id="B42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bloch</surname><given-names>EM</given-names></name><name><surname>Shoham</surname><given-names>S</given-names></name><name><surname>Casadevall</surname><given-names>A</given-names></name><name><surname>Sachais</surname><given-names>BS</given-names></name><name><surname>Shaz</surname><given-names>B</given-names></name><name><surname>Winters</surname><given-names>JL</given-names></name></person-group><article-title>Deployment of convalescent plasma for the prevention and
treatment of COVID-19</article-title><source>J Clin Invest</source><year>2020</year><volume>130</volume><issue>6</issue><fpage>2757</fpage><lpage>2765</lpage><pub-id pub-id-type="pmid">32254064</pub-id></element-citation></ref><ref id="B43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>G</given-names></name><name><surname>De Clercq</surname><given-names>E</given-names></name></person-group><article-title>Therapeutic options for the 2019 novel coronavirus
(2019-nCoV)</article-title><source>Nat Rev Drug Discov</source><year>2020</year><volume>19</volume><issue>3</issue><fpage>149</fpage><lpage>150</lpage><pub-id pub-id-type="pmid">32127666</pub-id></element-citation></ref><ref id="B44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kupferschmidt</surname><given-names>K</given-names></name><name><surname>Cohen</surname><given-names>J</given-names></name></person-group><article-title>Race to find COVID-19 treatments accelerates</article-title><source>Science</source><year>2020</year><volume>367</volume><issue>6485</issue><fpage>1412</fpage><lpage>1413</lpage><pub-id pub-id-type="pmid">32217705</pub-id></element-citation></ref><ref id="B45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chhikara</surname><given-names>BS</given-names></name><name><surname>Rathi</surname><given-names>B</given-names></name><name><surname>Singh</surname><given-names>J</given-names></name><name><surname>FNU</surname><given-names>P</given-names></name></person-group><article-title>Coronavirus SARS-CoV-2 disease COVID-19 infection, prevention and
clinical advances of the prospective chemical drug therapeutics: a Review on
Coronavirus disease COVID-19, epidemiology, prevention, and anticipated
therapeutic advances</article-title><source>Chem Biol Lett</source><year>2020</year><volume>7</volume><issue>1</issue><fpage>63</fpage><lpage>72</lpage></element-citation></ref><ref id="B46"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>N</given-names></name><name><surname>Zhang</surname><given-names>D</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Yang</surname><given-names>B</given-names></name><name><surname>Song</surname><given-names>J</given-names></name></person-group><article-title>A novel coronavirus from patients with pneumonia in China,
2019</article-title><source>N Engl J Med</source><year>2020</year><volume>382</volume><issue>8</issue><fpage>727</fpage><lpage>733</lpage><pub-id pub-id-type="pmid">31978945</pub-id></element-citation></ref><ref id="B47"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Caly</surname><given-names>L</given-names></name><name><surname>Druce</surname><given-names>J</given-names></name><name><surname>Roberts</surname><given-names>J</given-names></name><name><surname>Bond</surname><given-names>K</given-names></name><name><surname>Tran</surname><given-names>T</given-names></name><name><surname>Kostecki</surname><given-names>R</given-names></name></person-group><article-title>Isolation and rapid sharing of the 2019 novel coronavirus
(SARS-CoV-2) from the first patient diagnosed with COVID-19 in
Australia</article-title><source>Med J Aust</source><year>2020</year><volume>212</volume><issue>10</issue><fpage>459</fpage><lpage>462</lpage><pub-id pub-id-type="pmid">32237278</pub-id></element-citation></ref><ref id="B48"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shereen</surname><given-names>MA</given-names></name><name><surname>Khan</surname><given-names>S</given-names></name><name><surname>Kazmi</surname><given-names>A</given-names></name><name><surname>Bashir</surname><given-names>N</given-names></name><name><surname>Siddique</surname><given-names>R</given-names></name></person-group><article-title>COVID-19 infection origin, transmission, and characteristics of
human coronaviruses</article-title><source>J Adv Res</source><year>2020</year><volume>24</volume><fpage>91</fpage><lpage>98</lpage><pub-id pub-id-type="pmid">32257431</pub-id></element-citation></ref><ref id="B49"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>N</given-names></name><name><surname>Shen H-M</surname><given-names/></name></person-group><article-title>Targeting the endocytic pathway and autophagy process as a novel
therapeutic strategy in COVID-19</article-title><source>Int J Biol Sci</source><year>2020</year><volume>16</volume><issue>10</issue><fpage>1724</fpage><lpage>1731</lpage><pub-id pub-id-type="pmid">32226290</pub-id></element-citation></ref><ref id="B50"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>Q</given-names></name><name><surname>Guo</surname><given-names>D</given-names></name></person-group><article-title>Emerging coronaviruses genome structure, replication, and
pathogenesis</article-title><source>J Med Virol</source><year>2020</year><volume>92</volume><issue>4</issue><fpage>418</fpage><lpage>423</lpage><pub-id pub-id-type="pmid">31967327</pub-id></element-citation></ref><ref id="B51"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chan JF-W</surname><given-names/></name><name><surname>Kok K-H</surname><given-names/></name><name><surname>Zhu</surname><given-names>Z</given-names></name><name><surname>Chu</surname><given-names>H</given-names></name><name><surname>To KK-W</surname><given-names/></name><name><surname>Yuan</surname><given-names>S</given-names></name></person-group><article-title>Genomic characterization of the 2019 novel human-pathogenic
coronavirus isolated from a patient with atypical pneumonia after visiting
Wuhan</article-title><source>Emerg Microbes Infect</source><year>2020</year><volume>9</volume><issue>1</issue><fpage>221</fpage><lpage>236</lpage><pub-id pub-id-type="pmid">31987001</pub-id></element-citation></ref><ref id="B52"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Hou</surname><given-names>Y</given-names></name><name><surname>Shen</surname><given-names>J</given-names></name><name><surname>Huang</surname><given-names>Y</given-names></name><name><surname>Martin</surname><given-names>W</given-names></name><name><surname>Cheng</surname><given-names>F</given-names></name></person-group><article-title>Network-based drug repurposing for novel coronavirus
2019-nCoV/SARS-CoV-2</article-title><source>Cell Discov</source><year>2020</year><volume>6</volume><issue>1</issue><fpage>14</fpage><lpage>14</lpage><pub-id pub-id-type="pmid">32194980</pub-id></element-citation></ref><ref id="B53"><label>53</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>D</given-names></name><name><surname>Lee</surname><given-names>J-Y</given-names></name><name><surname>Yang</surname><given-names>J-S</given-names></name><name><surname>Kim</surname><given-names>JW</given-names></name><name><surname>Kim</surname><given-names>VN</given-names></name><name><surname>Chang</surname><given-names>H</given-names></name></person-group><article-title>The architecture of SARS-CoV-2 transcriptome</article-title><source>Cell</source><year>2020</year><volume>181</volume><issue>4</issue></element-citation></ref><ref id="B54"><label>54</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gordon</surname><given-names>DE</given-names></name><name><surname>Jang</surname><given-names>GM</given-names></name><name><surname>Bouhaddou</surname><given-names>M</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Obernier</surname><given-names>K</given-names></name><name><surname>White</surname><given-names>KM</given-names></name></person-group><article-title>A SARS-CoV-2 protein interaction map reveals targets for drug
repurposing</article-title><source>Nature</source><year>2020</year><volume>583</volume><issue>7816</issue><fpage>459</fpage><lpage>468</lpage><pub-id pub-id-type="pmid">32353859</pub-id></element-citation></ref><ref id="B55"><label>55</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khailany</surname><given-names>RA</given-names></name><name><surname>Safdar</surname><given-names>M</given-names></name><name><surname>Ozaslan</surname><given-names>M</given-names></name></person-group><article-title>Genomic characterization of a novel SARS-CoV-2</article-title><source>Gene Rep</source><year>2020</year><volume>19</volume><fpage>100682</fpage><lpage>100682</lpage><pub-id pub-id-type="pmid">32300673</pub-id></element-citation></ref><ref id="B56"><label>56</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Astuti</surname><given-names>I</given-names></name><name><surname>Ysrafil</surname><given-names/></name></person-group><article-title>Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) an
overview of viral structure and host response</article-title><source>Diabetes Metab Syndr</source><year>2020</year><volume>14</volume><issue>4</issue><fpage>407</fpage><lpage>412</lpage><pub-id pub-id-type="pmid">32335367</pub-id></element-citation></ref><ref id="B57"><label>57</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qiu</surname><given-names>Y</given-names></name><name><surname>Xu</surname><given-names>K</given-names></name></person-group><article-title>Functional studies of the coronavirus nonstructural
proteins</article-title><source>STEMedicine</source><year>2020</year><volume>1</volume><issue>2</issue><elocation-id>e39</elocation-id></element-citation></ref><ref id="B58"><label>58</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Peng</surname><given-names>H</given-names></name><name><surname>Mackey</surname><given-names>V</given-names></name><name><surname>Sun</surname><given-names>L</given-names></name></person-group><article-title>Coronaviruses and the associated potential therapeutics for the
viral infections</article-title><source>J Infect Dis Ther</source><year>2020</year><volume>8</volume><issue>2</issue><fpage>1</fpage><lpage>8</lpage></element-citation></ref><ref id="B59"><label>59</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>T</given-names></name><name><surname>Bidon</surname><given-names>M</given-names></name><name><surname>Jaimes</surname><given-names>JA</given-names></name><name><surname>Whittaker</surname><given-names>GR</given-names></name><name><surname>Daniel</surname><given-names>S</given-names></name></person-group><article-title>Coronavirus membrane fusion mechanism offers a potential target
for antiviral development</article-title><source>Antiviral Res</source><year>2020</year><volume>178</volume><fpage>104792</fpage><lpage>104792</lpage><pub-id pub-id-type="pmid">32272173</pub-id></element-citation></ref><ref id="B60"><label>60</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coutard</surname><given-names>B</given-names></name><name><surname>Valle</surname><given-names>C</given-names></name><name><surname>de Lamballerie</surname><given-names>X</given-names></name><name><surname>Canard</surname><given-names>B</given-names></name><name><surname>Seidah</surname><given-names>NG</given-names></name><name><surname>Decroly</surname><given-names>E</given-names></name></person-group><article-title>The spike glycoprotein of the new coronavirus 2019-nCoV contains
a furin-like cleavage site absent in CoV of the same clade</article-title><source>Antiviral Res</source><year>2020</year><volume>176</volume><fpage>104742</fpage><lpage>104742</lpage><pub-id pub-id-type="pmid">32057769</pub-id></element-citation></ref><ref id="B61"><label>61</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ruch</surname><given-names>TR</given-names></name><name><surname>Machamer</surname><given-names>CE</given-names></name></person-group><article-title>The coronavirus E protein assembly and beyond</article-title><source>Viruses</source><year>2012</year><volume>4</volume><issue>3</issue><fpage>363</fpage><lpage>382</lpage><pub-id pub-id-type="pmid">22590676</pub-id></element-citation></ref><ref id="B62"><label>62</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kandeel</surname><given-names>M</given-names></name><name><surname>Ibrahim</surname><given-names>A</given-names></name><name><surname>Fayez</surname><given-names>M</given-names></name><name><surname>Al-Nazawi</surname><given-names>M</given-names></name></person-group><article-title>From SARS and MERS CoVs to SARS-CoV-2 moving toward more biased
codon usage in viral structural and nonstructural genes</article-title><source>J Med Virol</source><year>2020</year><volume>92</volume><issue>6</issue><fpage>660</fpage><lpage>666</lpage><pub-id pub-id-type="pmid">32159237</pub-id></element-citation></ref><ref id="B63"><label>63</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>J</given-names></name><name><surname>Song</surname><given-names>W</given-names></name><name><surname>Huang</surname><given-names>H</given-names></name><name><surname>Sun</surname><given-names>Q</given-names></name></person-group><article-title>Pharmacological therapeutics targeting RNA-dependent RNA
polymerase, proteinase and spike protein from mechanistic studies to
clinical trials for COVID-19</article-title><source>J Clin Med</source><year>2020</year><volume>9</volume><issue>4</issue><fpage>1131</fpage><lpage>1131</lpage></element-citation></ref><ref id="B64"><label>64</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ou</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Lei</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>P</given-names></name><name><surname>Mi</surname><given-names>D</given-names></name><name><surname>Ren</surname><given-names>L</given-names></name></person-group><article-title>Characterization of spike glycoprotein of SARS-CoV-2 on virus
entry and its immune cross-reactivity with SARS-CoV</article-title><source>Nat Commun</source><year>2020</year><volume>11</volume><issue>1</issue><fpage>1620</fpage><lpage>1620</lpage><pub-id pub-id-type="pmid">32221306</pub-id></element-citation></ref><ref id="B65"><label>65</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoffmann</surname><given-names>M</given-names></name><name><surname>Kleine-Weber</surname><given-names>H</given-names></name><name><surname>Schroeder</surname><given-names>S</given-names></name><name><surname>Kr&#x000fc;ger</surname><given-names>N</given-names></name><name><surname>Herrler</surname><given-names>T</given-names></name><name><surname>Erichsen</surname><given-names>S</given-names></name><etal/></person-group><article-title>SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked
by a clinically proven protease inhibitor</article-title><source>Cell</source><year>2020</year><volume>181</volume><issue>2</issue></element-citation></ref><ref id="B66"><label>66</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sanders</surname><given-names>JM</given-names></name><name><surname>Monogue</surname><given-names>ML</given-names></name><name><surname>Jodlowski</surname><given-names>TZ</given-names></name><name><surname>Cutrell</surname><given-names>JB</given-names></name></person-group><article-title>Pharmacologic treatments for Coronavirus disease 2019
(COVID-19)</article-title><source>JAMA</source><year>2020</year><volume>323</volume><issue>18</issue><fpage>1824</fpage><lpage>1836</lpage><pub-id pub-id-type="pmid">32282022</pub-id></element-citation></ref><ref id="B67"><label>67</label><element-citation publication-type="webpage"><person-group person-group-type="author"><name><surname>Boopathi</surname><given-names>S</given-names></name><name><surname>Poma</surname><given-names>AB</given-names></name><name><surname>Kolandaivel</surname><given-names>P.</given-names></name></person-group><article-title>Novel 2019 coronavirus structure, mechanism of action, antiviral
drug promises and rule out against its treatment.</article-title><source>J Biomol Struct Dyn</source><year>2020</year><pub-id pub-id-type="doi">10.1080/07391102.2020.1758788</pub-id></element-citation></ref><ref id="B68"><label>68</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jin</surname><given-names>Z</given-names></name><name><surname>Du</surname><given-names>X</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Deng</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>M</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name></person-group><article-title>Structure of Mpro from SARS-CoV-2 and discovery of its
inhibitors</article-title><source>Nature</source><year>2020</year><volume>582</volume><issue>7811</issue><fpage>289</fpage><lpage>293</lpage><pub-id pub-id-type="pmid">32272481</pub-id></element-citation></ref><ref id="B69"><label>69</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rawlings</surname><given-names>ND</given-names></name><name><surname>Waller</surname><given-names>M</given-names></name><name><surname>Barrett</surname><given-names>AJ</given-names></name><name><surname>Bateman</surname><given-names>A</given-names></name></person-group><article-title>MEROPS : the database of proteolytic enzymes, their substrates
and inhibitors</article-title><source>Nucleic Acids Res</source><year>2014</year><volume>42</volume><issue>D1</issue><fpage>D503</fpage><lpage>D509</lpage><pub-id pub-id-type="pmid">24157837</pub-id></element-citation></ref><ref id="B70"><label>70</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Lin</surname><given-names>D</given-names></name><name><surname>Sun</surname><given-names>X</given-names></name><name><surname>Curth</surname><given-names>U</given-names></name><name><surname>Drosten</surname><given-names>C</given-names></name><name><surname>Sauerhering</surname><given-names>L</given-names></name></person-group><article-title>Crystal structure of SARS-CoV-2 main protease provides a basis
for design of improved a-ketoamide inhibitors</article-title><source>Science</source><year>2020</year><volume>368</volume><issue>6489</issue><fpage>409</fpage><lpage>412</lpage><pub-id pub-id-type="pmid">32198291</pub-id></element-citation></ref><ref id="B71"><label>71</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jeske</surname><given-names>L</given-names></name><name><surname>Placzek</surname><given-names>S</given-names></name><name><surname>Schomburg</surname><given-names>I</given-names></name><name><surname>Chang</surname><given-names>A</given-names></name><name><surname>Schomburg</surname><given-names>D</given-names></name></person-group><article-title>BRENDA in 2019: a European ELIXIR core data
resource</article-title><source>Nucleic Acids Res</source><year>2019</year><volume>47</volume><issue>D1</issue></element-citation></ref><ref id="B72"><label>72</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang H-M</surname><given-names/></name><name><surname>Liang P-H</surname><given-names/></name></person-group><article-title>Pharmacophores and biological activities of severe acute
respiratory syndrome viral protease inhibitors</article-title><source>Expert Opin Ther Pat</source><year>2007</year><volume>17</volume><issue>5</issue><fpage>533</fpage><lpage>546</lpage></element-citation></ref><ref id="B73"><label>73</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jin</surname><given-names>Z</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name><name><surname>Sun</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>B</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Wu</surname><given-names>Y</given-names></name></person-group><article-title>Structural basis for the inhibition of SARS-CoV-2 main protease
by antineoplastic drug carmofur</article-title><source>Nat Struct Mol Biol</source><year>2020</year><volume>27</volume><issue>6</issue><fpage>529</fpage><lpage>532</lpage><pub-id pub-id-type="pmid">32382072</pub-id></element-citation></ref><ref id="B74"><label>74</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mirza</surname><given-names>MU</given-names></name><name><surname>Froeyen</surname><given-names>M</given-names></name></person-group><article-title>Structural elucidation of SARS-CoV-2 vital proteins computational
methods reveal potential drug candidates against main protease, Nsp12
polymerase and Nsp13 helicase</article-title><source>J Pharm Anal</source><year>2020</year><volume>10</volume><issue>4</issue><fpage>320</fpage><lpage>328</lpage><pub-id pub-id-type="pmid">32346490</pub-id></element-citation></ref><ref id="B75"><label>75</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ton A-T</surname><given-names/></name><name><surname>Gentile</surname><given-names>F</given-names></name><name><surname>Hsing</surname><given-names>M</given-names></name><name><surname>Ban</surname><given-names>F</given-names></name><name><surname>Cherkasov</surname><given-names>A</given-names></name></person-group><article-title>Rapid identification of potential inhibitors of SARS-CoV-2 main
protease by deep docking of 1 3 billion compounds</article-title><source>Mol Inform</source><year>2020</year><volume>39</volume><issue>8</issue><elocation-id>e2000028</elocation-id><pub-id pub-id-type="pmid">32162456</pub-id></element-citation></ref><ref id="B76"><label>76</label><element-citation publication-type="webpage"><person-group person-group-type="author"><name><surname>Rasool</surname><given-names>N</given-names></name><name><surname>Akhtar</surname><given-names>A</given-names></name><name><surname>Hussain</surname><given-names>W</given-names></name></person-group><article-title>Insights into the inhibitory potential of selective
phytochemicals against Mpro of 2019-nCoV: a computer-aided
study</article-title><source>Struct Chem</source><year>2020</year><pub-id pub-id-type="doi">10.1007/s11224-020-01536-6</pub-id></element-citation></ref><ref id="B77"><label>77</label><element-citation publication-type="webpage"><person-group person-group-type="author"><name><surname>Joshi</surname><given-names>RS</given-names></name><name><surname>Jagdale</surname><given-names>SS</given-names></name><name><surname>Bansode</surname><given-names>SB</given-names></name><name><surname>Shankar</surname><given-names>SS</given-names></name><name><surname>Tellis</surname><given-names>MB</given-names></name><name><surname>Pandya</surname><given-names>VK</given-names></name><etal/></person-group><article-title>Discovery of potential multi-target-directed ligands by targeting
host-specific SARS-CoV-2 structurally conserved main
protease</article-title><source>J Biomol Struct Dyn</source><year>2020</year><pub-id pub-id-type="doi">10.1080/07391102.2020.1760137</pub-id></element-citation></ref><ref id="B78"><label>78</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Wang X-J</surname><given-names/></name></person-group><article-title>Potential inhibitors against 2019-nCoV coronavirus M protease
from clinically approved medicines</article-title><source>J Genet Genomics</source><year>2020</year><volume>47</volume><issue>2</issue><fpage>119</fpage><lpage>121</lpage><pub-id pub-id-type="pmid">32173287</pub-id></element-citation></ref><ref id="B79"><label>79</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>C</given-names></name><name><surname>Sacco</surname><given-names>MD</given-names></name><name><surname>Hurst</surname><given-names>B</given-names></name><name><surname>Townsend</surname><given-names>JA</given-names></name><name><surname>Hu</surname><given-names>Y</given-names></name><name><surname>Szeto</surname><given-names>T</given-names></name></person-group><article-title>Boceprevir, GC-376, and calpain inhibitors II, XII inhibit
SARS-CoV-2 viral replication by targeting the viral main
protease</article-title><source>Cell Res</source><year>2020</year><volume>30</volume><issue>8</issue><fpage>678</fpage><lpage>692</lpage><pub-id pub-id-type="pmid">32541865</pub-id></element-citation></ref><ref id="B80"><label>80</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shamsi</surname><given-names>A</given-names></name><name><surname>Mohammad</surname><given-names>T</given-names></name><name><surname>Anwar</surname><given-names>S</given-names></name><name><surname>AlAjmi</surname><given-names>MF</given-names></name><name><surname>Hussain</surname><given-names>A</given-names></name><name><surname>Rehman</surname><given-names>MT</given-names></name></person-group><article-title>Glecaprevir and Maraviroc are high-affinity inhibitors of
SARS-CoV-2 main protease possible implication in COVID-19
therapy</article-title><source>Biosci Rep</source><year>2020</year><volume>40</volume><issue>6</issue><fpage>1</fpage><lpage>8</lpage></element-citation></ref><ref id="B81"><label>81</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>J</given-names></name></person-group><article-title>Fast identification of possible drug treatment of Coronavirus
disease-19 (COVID-19) through computational drug repurposing
study</article-title><source>J Chem Inf Model</source><year>2020</year><volume>60</volume><issue>6</issue><fpage>3277</fpage><lpage>3286</lpage><pub-id pub-id-type="pmid">32315171</pub-id></element-citation></ref><ref id="B82"><label>82</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bharadwaj</surname><given-names>S</given-names></name><name><surname>Lee</surname><given-names>KE</given-names></name><name><surname>Dwivedi</surname><given-names>VD</given-names></name><name><surname>Kang</surname><given-names>SG</given-names></name></person-group><article-title>Computational insights into tetracyclines as inhibitors against
SARS-CoV-2 Mpro via combinatorial molecular simulation
calculations</article-title><source>Life Sci</source><year>2020</year><volume>257</volume><fpage>118080</fpage><lpage>118080</lpage><pub-id pub-id-type="pmid">32653520</pub-id></element-citation></ref><ref id="B83"><label>83</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lei</surname><given-names>J</given-names></name><name><surname>Kusov</surname><given-names>Y</given-names></name><name><surname>Hilgenfeld</surname><given-names>R</given-names></name></person-group><article-title>Nsp3 of coronaviruses structures and functions of a large
multi-domain protein</article-title><source>Antiviral Res</source><year>2018</year><volume>149</volume><fpage>58</fpage><lpage>74</lpage><pub-id pub-id-type="pmid">29128390</pub-id></element-citation></ref><ref id="B84"><label>84</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>B&#x000e1;ez-Santos</surname><given-names>YM</given-names></name><name><surname>St</surname><given-names/></name></person-group><article-title>John SE, Mesecar AD The SARS-coronavirus papain-like protease:
structure, function and inhibition by designed antiviral
compounds</article-title><source>Antiviral Res</source><year>2015</year><volume>115</volume><fpage>21</fpage><lpage>38</lpage><pub-id pub-id-type="pmid">25554382</pub-id></element-citation></ref><ref id="B85"><label>85</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ratia</surname><given-names>K</given-names></name><name><surname>Kilianski</surname><given-names>A</given-names></name><name><surname>Baez-Santos</surname><given-names>YM</given-names></name><name><surname>Baker</surname><given-names>SC</given-names></name><name><surname>Mesecar</surname><given-names>A</given-names></name></person-group><article-title>Structural basis for the ubiquitin-linkage specificity and
deISGylating activity of SARS-CoV papain-like protease</article-title><source>PLoS Pathog</source><year>2014</year><volume>10</volume><issue>5</issue><elocation-id>e1004113</elocation-id><pub-id pub-id-type="pmid">24854014</pub-id></element-citation></ref><ref id="B86"><label>86</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park J-Y</surname><given-names/></name><name><surname>Yuk</surname><given-names>HJ</given-names></name><name><surname>Ryu</surname><given-names>HW</given-names></name><name><surname>Lim</surname><given-names>SH</given-names></name><name><surname>Kim</surname><given-names>KS</given-names></name><name><surname>Park</surname><given-names>KH</given-names></name></person-group><article-title>Evaluation of polyphenols from Broussonetia papyrifera as
coronavirus protease inhibitors</article-title><source>J Enzyme Inhib Med Chem</source><year>2017</year><volume>32</volume><issue>1</issue><fpage>504</fpage><lpage>515</lpage><pub-id pub-id-type="pmid">28112000</pub-id></element-citation></ref><ref id="B87"><label>87</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park J-Y</surname><given-names/></name><name><surname>Jeong</surname><given-names>HJ</given-names></name><name><surname>Kim</surname><given-names>JH</given-names></name><name><surname>Kim</surname><given-names>YM</given-names></name><name><surname>Park S-J</surname><given-names/></name><name><surname>Kim</surname><given-names>D</given-names></name></person-group><article-title>Diarylheptanoids from Alnus japonica inhibit papain-like protease
of severe acute respiratory Syndrome coronavirus</article-title><source>Biol Pharm Bull</source><year>2012</year><volume>35</volume><issue>11</issue><fpage>2036</fpage><lpage>2042</lpage><pub-id pub-id-type="pmid">22971649</pub-id></element-citation></ref><ref id="B88"><label>88</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin M-H</surname><given-names/></name><name><surname>Moses</surname><given-names>DC</given-names></name><name><surname>Hsieh C-H</surname><given-names/></name><name><surname>Cheng S-C</surname><given-names/></name><name><surname>Chen Y-H</surname><given-names/></name><name><surname>Sun C-Y</surname><given-names/></name></person-group><article-title>Disulfiram can inhibit MERS and SARS coronavirus papain-like
proteases via different modes</article-title><source>Antiviral Res</source><year>2018</year><volume>150</volume><fpage>155</fpage><lpage>163</lpage><pub-id pub-id-type="pmid">29289665</pub-id></element-citation></ref><ref id="B89"><label>89</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>C</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>P</given-names></name><name><surname>Zhong</surname><given-names>W</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name></person-group><article-title>Analysis of therapeutic targets for SARS-CoV-2 and discovery of
potential drugs by computational methods</article-title><source>Acta Pharm Sin B</source><year>2020</year><volume>10</volume><issue>5</issue><fpage>766</fpage><lpage>788</lpage><pub-id pub-id-type="pmid">32292689</pub-id></element-citation></ref><ref id="B90"><label>90</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rismanbaf</surname><given-names>A</given-names></name></person-group><article-title>Potential treatments for COVID-19; a narrative literature
review</article-title><source>Arch Acad Emerg Med</source><year>2020</year><volume>8</volume><issue>1</issue><elocation-id>e29</elocation-id><pub-id pub-id-type="pmid">32232214</pub-id></element-citation></ref><ref id="B91"><label>91</label><element-citation publication-type="webpage"><person-group person-group-type="author"><name><surname>Kandeel</surname><given-names>M</given-names></name><name><surname>Abdelrahman</surname><given-names>AHM</given-names></name><name><surname>Oh-Hashi</surname><given-names>K</given-names></name><name><surname>Ibrahim</surname><given-names>A</given-names></name><name><surname>Venugopala</surname><given-names>KN</given-names></name><name><surname>Morsy</surname><given-names>MA</given-names></name><etal/></person-group><article-title>Repurposing of FDA-approved antivirals, antibiotics,
anthelmintics, antioxidants, and cell protectives against SARS-CoV-2
papain-like protease</article-title><source>J Biomol Struct Dyn</source><year>2020</year><pub-id pub-id-type="doi">10.1080/07391102.2020.1784291</pub-id></element-citation></ref><ref id="B92"><label>92</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yin</surname><given-names>W</given-names></name><name><surname>Mao</surname><given-names>C</given-names></name><name><surname>Luan</surname><given-names>X</given-names></name><name><surname>Shen D-D</surname><given-names/></name><name><surname>Shen</surname><given-names>Q</given-names></name><name><surname>Su</surname><given-names>H</given-names></name></person-group><article-title>Structural basis for inhibition of the RNA-dependent RNA
polymerase from SARS-CoV-2 by remdesivir</article-title><source>Science</source><year>2020</year><volume>368</volume><issue>6498</issue><fpage>1499</fpage><lpage>1504</lpage><pub-id pub-id-type="pmid">32358203</pub-id></element-citation></ref><ref id="B93"><label>93</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shannon</surname><given-names>A</given-names></name><name><surname>Le NT-T</surname><given-names/></name><name><surname>Selisko</surname><given-names>B</given-names></name><name><surname>Eydoux</surname><given-names>C</given-names></name><name><surname>Alvarez</surname><given-names>K</given-names></name><name><surname>Guillemot J-C</surname><given-names/></name></person-group><article-title>Remdesivir and SARS-CoV-2 structural requirements at both nsp12
RdRp and nsp14 exonuclease active-sites</article-title><source>Antiviral Res</source><year>2020</year><volume>178</volume><fpage>104793</fpage><lpage>104793</lpage><pub-id pub-id-type="pmid">32283108</pub-id></element-citation></ref><ref id="B94"><label>94</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>Y</given-names></name><name><surname>Yan</surname><given-names>L</given-names></name><name><surname>Huang</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>F</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name><name><surname>Cao</surname><given-names>L</given-names></name></person-group><article-title>Structure of the RNA-dependent RNA polymerase from COVID-19
virus</article-title><source>Science</source><year>2020</year><volume>368</volume><issue>6492</issue><fpage>779</fpage><lpage>782</lpage><pub-id pub-id-type="pmid">32277040</pub-id></element-citation></ref><ref id="B95"><label>95</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kirchdoerfer</surname><given-names>RN</given-names></name><name><surname>Ward</surname><given-names>AB</given-names></name></person-group><article-title>Structure of the SARS-CoV nsp12 polymerase bound to nsp7 and nsp8
co-factors</article-title><source>Nat Commun</source><year>2019</year><volume>10</volume><issue>1</issue><fpage>2342</fpage><lpage>2342</lpage><pub-id pub-id-type="pmid">31138817</pub-id></element-citation></ref><ref id="B96"><label>96</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gordon</surname><given-names>CJ</given-names></name><name><surname>Tchesnokov</surname><given-names>EP</given-names></name><name><surname>Woolner</surname><given-names>E</given-names></name><name><surname>Perry</surname><given-names>JK</given-names></name><name><surname>Feng</surname><given-names>JY</given-names></name><name><surname>Porter</surname><given-names>DP</given-names></name></person-group><article-title>Remdesivir is a direct-acting antiviral that inhibits
RNA-dependent RNA polymerase from severe acute respiratory syndrome
coronavirus 2 with high potency</article-title><source>J Biol Chem</source><year>2020</year><volume>295</volume><issue>20</issue><fpage>6785</fpage><lpage>6797</lpage><pub-id pub-id-type="pmid">32284326</pub-id></element-citation></ref><ref id="B97"><label>97</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Du</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name></person-group><article-title>Favipiravir pharmacokinetics and concerns about clinical trials
for 2019-nCoV infection</article-title><source>Clin Pharmacol Ther</source><year>2020</year><volume>108</volume><issue>2</issue><fpage>242</fpage><lpage>247</lpage><pub-id pub-id-type="pmid">32246834</pub-id></element-citation></ref><ref id="B98"><label>98</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elfiky</surname><given-names>AA</given-names></name></person-group><article-title>Anti-HCV, nucleotide inhibitors, repurposing against
COVID-19</article-title><source>Life Sci</source><year>2020</year><volume>248</volume><fpage>117477</fpage><lpage>117477</lpage><pub-id pub-id-type="pmid">32119961</pub-id></element-citation></ref><ref id="B99"><label>99</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shum</surname><given-names>KT</given-names></name><name><surname>Tanner</surname><given-names>JA</given-names></name></person-group><article-title>Differential inhibitory activities and stabilisation of dna
aptamers against the SARS coronavirus helicase</article-title><source>Chembiochem</source><year>2008</year><volume>9</volume><issue>18</issue><fpage>3037</fpage><lpage>3045</lpage><pub-id pub-id-type="pmid">19031435</pub-id></element-citation></ref><ref id="B100"><label>100</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keum Y-S</surname><given-names/></name><name><surname>Jeong Y-J</surname><given-names/></name></person-group><article-title>Development of chemical inhibitors of the SARS coronavirus viral
helicase as a potential target</article-title><source>Biochem Pharmacol</source><year>2012</year><volume>84</volume><issue>10</issue><fpage>1351</fpage><lpage>1358</lpage><pub-id pub-id-type="pmid">22935448</pub-id></element-citation></ref><ref id="B101"><label>101</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jia</surname><given-names>Z</given-names></name><name><surname>Yan</surname><given-names>L</given-names></name><name><surname>Ren</surname><given-names>Z</given-names></name><name><surname>Wu</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Guo</surname><given-names>J</given-names></name></person-group><article-title>Delicate structural coordination of the severe acute respiratory
syndrome coronavirus Nsp13 upon ATP hydrolysis</article-title><source>Nucleic Acids Res</source><year>2019</year><volume>47</volume><issue>12</issue><fpage>6538</fpage><lpage>6550</lpage><pub-id pub-id-type="pmid">31131400</pub-id></element-citation></ref><ref id="B102"><label>102</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu M-S</surname><given-names/></name><name><surname>Lee</surname><given-names>J</given-names></name><name><surname>Lee</surname><given-names>JM</given-names></name><name><surname>Kim</surname><given-names>Y</given-names></name><name><surname>Chin Y-W</surname><given-names/></name><name><surname>Jee J-G</surname><given-names/></name></person-group><article-title>Identification of myricetin and scutellarein as novel chemical
inhibitors of the SARS coronavirus helicase, nsP13</article-title><source>Bioorg Med Chem Lett</source><year>2012</year><volume>22</volume><issue>12</issue><fpage>4049</fpage><lpage>4054</lpage><pub-id pub-id-type="pmid">22578462</pub-id></element-citation></ref><ref id="B103"><label>103</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beck</surname><given-names>BR</given-names></name><name><surname>Shin</surname><given-names>B</given-names></name><name><surname>Choi</surname><given-names>Y</given-names></name><name><surname>Park</surname><given-names>S</given-names></name><name><surname>Kang</surname><given-names>K</given-names></name></person-group><article-title>Predicting commercially available antiviral drugs that may act on
the novel coronavirus (SARS-CoV-2) through a drug-target interaction deep
learning model</article-title><source>Comput Struct Biotechnol J</source><year>2020</year><volume>18</volume><fpage>784</fpage><lpage>790</lpage><pub-id pub-id-type="pmid">32280433</pub-id></element-citation></ref><ref id="B104"><label>104</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Borgio</surname><given-names>JF</given-names></name><name><surname>Alsuwat</surname><given-names>HS</given-names></name><name><surname>Al Otaibi</surname><given-names>WM</given-names></name><name><surname>Ibrahim</surname><given-names>AM</given-names></name><name><surname>Almandil</surname><given-names>N</given-names></name><name><surname>Al Asoom</surname><given-names>LI</given-names></name></person-group><article-title>State-of-the-art tools unveil potent drug targets amongst
clinically approved drugs to inhibit helicase in SARS-CoV-2</article-title><source>Arch Med Sci</source><year>2020</year><volume>16</volume><issue>3</issue><fpage>508</fpage><lpage>518</lpage><pub-id pub-id-type="pmid">32399096</pub-id></element-citation></ref><ref id="B105"><label>105</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iftikhar</surname><given-names>H</given-names></name><name><surname>Ali</surname><given-names>HN</given-names></name><name><surname>Farooq</surname><given-names>S</given-names></name><name><surname>Naveed</surname><given-names>H</given-names></name><name><surname>Shahzad-ul-Hussan</surname><given-names>S</given-names></name></person-group><article-title>Identification of potential inhibitors of three key enzymes of
SARS-CoV2 using computational approach</article-title><source>Comput Biol Med</source><year>2020</year><volume>122</volume><fpage>103848</fpage><lpage>103848</lpage><pub-id pub-id-type="pmid">32658735</pub-id></element-citation></ref><ref id="B106"><label>106</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shu</surname><given-names>T</given-names></name><name><surname>Huang</surname><given-names>M</given-names></name><name><surname>Wu</surname><given-names>D</given-names></name><name><surname>Ren</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Han</surname><given-names>Y</given-names></name></person-group><article-title>SARS-Coronavirus-2 Nsp13 possesses NTPase and RNA helicase
activities that can be inhibited by bismuth salts</article-title><source>Virol Sin</source><year>2020</year><volume>35</volume><issue>3</issue><fpage>321</fpage><lpage>329</lpage><pub-id pub-id-type="pmid">32500504</pub-id></element-citation></ref><ref id="B107"><label>107</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Decroly</surname><given-names>E</given-names></name><name><surname>Debarnot</surname><given-names>C</given-names></name><name><surname>Ferron</surname><given-names>F</given-names></name><name><surname>Bouvet</surname><given-names>M</given-names></name><name><surname>Coutard</surname><given-names>B</given-names></name><name><surname>Imbert</surname><given-names>I</given-names></name></person-group><article-title>Crystal structure and functional analysis of the SARS-Coronavirus
RNA Cap 2&#x00026;apos;-O-methyltransferase nsp10/nsp16 complex</article-title><source>PLoS Pathog</source><year>2011</year><volume>7</volume><issue>5</issue><elocation-id>e1002059</elocation-id><pub-id pub-id-type="pmid">21637813</pub-id></element-citation></ref><ref id="B108"><label>108</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Cai</surname><given-names>H</given-names></name><name><surname>Pan</surname><given-names>J</given-names></name><name><surname>Xiang</surname><given-names>N</given-names></name><name><surname>Tien</surname><given-names>P</given-names></name><name><surname>Ahola</surname><given-names>T</given-names></name></person-group><article-title>Functional screen reveals SARS coronavirus nonstructural protein
nsp14 as a novel cap N7 methyltransferase</article-title><source>Proc Natl Acad Sci USA</source><year>2009</year><volume>106</volume><issue>9</issue><fpage>3484</fpage><lpage>3489</lpage><pub-id pub-id-type="pmid">19208801</pub-id></element-citation></ref><ref id="B109"><label>109</label><element-citation publication-type="webpage"><person-group person-group-type="author"><name><surname>Khan</surname><given-names>RJ</given-names></name><name><surname>Jha</surname><given-names>RK</given-names></name><name><surname>Amera</surname><given-names>GM</given-names></name><name><surname>Jain</surname><given-names>M</given-names></name><name><surname>Singh</surname><given-names>E</given-names></name><name><surname>Pathak</surname><given-names>A</given-names></name><etal/></person-group><article-title>Targeting SARS-CoV-2: a systematic drug repurposing approach to
identify promising inhibitors against 3C-like proteinase and 2'-O-ribose
methyltransferase</article-title><source>J Biomol Struct Dyn</source><year>2020</year><pub-id pub-id-type="doi">10.1080/07391102.2020.1753577</pub-id></element-citation></ref><ref id="B110"><label>110</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bouvet</surname><given-names>M</given-names></name><name><surname>Lugari</surname><given-names>A</given-names></name><name><surname>Posthuma</surname><given-names>CC</given-names></name><name><surname>Zevenhoven</surname><given-names>JC</given-names></name><name><surname>Bernard</surname><given-names>S</given-names></name><name><surname>Betzi</surname><given-names>S</given-names></name></person-group><article-title>Coronavirus Nsp10, a critical co-factor for activation of
multiple replicative enzymes</article-title><source>J Biol Chem</source><year>2014</year><volume>289</volume><issue>37</issue><fpage>25783</fpage><lpage>25796</lpage><pub-id pub-id-type="pmid">25074927</pub-id></element-citation></ref><ref id="B111"><label>111</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Tao</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Wu</surname><given-names>A</given-names></name><name><surname>Yang</surname><given-names>Z</given-names></name></person-group><article-title>Yeast-based assays for the high-throughput screening of
inhibitors of coronavirus RNA cap
guanine-N7-methyltransferase</article-title><source>Antiviral Res</source><year>2014</year><volume>104</volume><fpage>156</fpage><lpage>164</lpage><pub-id pub-id-type="pmid">24530452</pub-id></element-citation></ref><ref id="B112"><label>112</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahmed-Belkacem</surname><given-names>R</given-names></name><name><surname>Sutto-Ortiz</surname><given-names>P</given-names></name><name><surname>Guiraud</surname><given-names>M</given-names></name><name><surname>Canard</surname><given-names>B</given-names></name><name><surname>Vasseur J-J</surname><given-names/></name><name><surname>Decroly</surname><given-names>E</given-names></name></person-group><article-title>Synthesis of adenine dinucleosides SAM analogs as specific
inhibitors of SARS-CoV nsp14 RNA cap
guanine-N7-methyltransferase</article-title><source>Eur J Med Chem</source><year>2020</year><volume>201</volume><fpage>112557</fpage><lpage>112557</lpage><pub-id pub-id-type="pmid">32563813</pub-id></element-citation></ref><ref id="B113"><label>113</label><element-citation publication-type="webpage"><person-group person-group-type="author"><name><surname>Selvaraj</surname><given-names>C</given-names></name><name><surname>Dinesh</surname><given-names>DC</given-names></name><name><surname>Panwar</surname><given-names>U</given-names></name><name><surname>Abhirami</surname><given-names>R</given-names></name><name><surname>Boura</surname><given-names>E</given-names></name><name><surname>Singh</surname><given-names>SK</given-names></name></person-group><article-title>Structure-based virtual screening and molecular dynamics
simulation of SARS-CoV-2 Guanine-N7 methyltransferase (nsp14) for
identifying antiviral inhibitors against COVID-19</article-title><source>J Biomol Struct Dyn</source><year>2020</year><pub-id pub-id-type="doi">10.1080/07391102.2020.1778535</pub-id></element-citation></ref><ref id="B114"><label>114</label><element-citation publication-type="webpage"><person-group person-group-type="author"><name><surname>Maurya</surname><given-names>SK</given-names></name><name><surname>Maurya</surname><given-names>AK</given-names></name><name><surname>Mishra</surname><given-names>N</given-names></name><name><surname>Siddique</surname><given-names>HR</given-names></name></person-group><article-title>Virtual screening, ADME/T, and binding free energy analysis of
anti-viral, anti-protease, and anti-infectious compounds against NSP10/NSP16
methyltransferase and main protease of SARS CoV-2.</article-title><source>J Recept Signal Transduct Res</source><year>2020</year><pub-id pub-id-type="doi">10.1080/10799893.2020.1772298</pub-id></element-citation></ref><ref id="B115"><label>115</label><element-citation publication-type="webpage"><person-group person-group-type="author"><name><surname>Tazikeh-Lemeski</surname><given-names>E</given-names></name><name><surname>Moradi</surname><given-names>S</given-names></name><name><surname>Raoufi</surname><given-names>R</given-names></name><name><surname>Shahlaei</surname><given-names>M</given-names></name><name><surname>Janlou</surname><given-names>MAM</given-names></name><name><surname>Zolghadri</surname><given-names>S.</given-names></name></person-group><article-title>Targeting SARS-COV-2 non-structural protein 16: a virtual drug
repurposing study</article-title><source>J Biomol Struct Dyn</source><year>2020</year><pub-id pub-id-type="doi">10.1080/07391102.2020.1779133</pub-id></element-citation></ref><ref id="B116"><label>116</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heald-Sargent</surname><given-names>T</given-names></name><name><surname>Gallagher</surname><given-names>T</given-names></name></person-group><article-title>Ready, set, fuse The coronavirus spike protein and acquisition of
fusion competence</article-title><source>Viruses</source><year>2012</year><volume>4</volume><issue>4</issue><fpage>557</fpage><lpage>580</lpage><pub-id pub-id-type="pmid">22590686</pub-id></element-citation></ref><ref id="B117"><label>117</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Qiu</surname><given-names>Y</given-names></name><name><surname>Li J-Y</surname><given-names/></name><name><surname>Zhou Z-J</surname><given-names/></name><name><surname>Liao C-H</surname><given-names/></name><name><surname>Ge X-Y</surname><given-names/></name></person-group><article-title>A unique protease cleavage site predicted in the spike protein of
the novel pneumonia coronavirus (2019-nCoV) potentially related to viral
transmissibility</article-title><source>Virol Sin</source><year>2020</year><volume>35</volume><issue>3</issue><fpage>337</fpage><lpage>339</lpage><pub-id pub-id-type="pmid">32198713</pub-id></element-citation></ref><ref id="B118"><label>118</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fantini</surname><given-names>J</given-names></name><name><surname>Di Scala</surname><given-names>C</given-names></name><name><surname>Chahinian</surname><given-names>H</given-names></name><name><surname>Yahi</surname><given-names>N</given-names></name></person-group><article-title>Structural and molecular modelling studies reveal a new mechanism
of action of chloroquine and hydroxychloroquine against SARS-CoV-2
infection</article-title><source>Int J Antimicrob Agents</source><year>2020</year><volume>55</volume><issue>5</issue><fpage>105960</fpage><lpage>105960</lpage><pub-id pub-id-type="pmid">32251731</pub-id></element-citation></ref><ref id="B119"><label>119</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stopsack</surname><given-names>KH</given-names></name><name><surname>Mucci</surname><given-names>LA</given-names></name><name><surname>Antonarakis</surname><given-names>ES</given-names></name><name><surname>Nelson</surname><given-names>PS</given-names></name><name><surname>Kantoff</surname><given-names>PW</given-names></name></person-group><article-title>TMPRSS2 and COVID-19 serendipity or opportunity for
intervention?</article-title><source>Cancer Discov</source><year>2020</year><volume>10</volume><issue>6</issue><fpage>779</fpage><lpage>782</lpage><pub-id pub-id-type="pmid">32276929</pub-id></element-citation></ref><ref id="B120"><label>120</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Torres</surname><given-names>J</given-names></name><name><surname>Surya</surname><given-names>W</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>D</given-names></name></person-group><article-title>Protein-protein interactions of viroporins in coronaviruses and
paramyxoviruses new targets for antivirals?</article-title><source>Viruses</source><year>2015</year><volume>7</volume><issue>6</issue><fpage>2858</fpage><lpage>2883</lpage><pub-id pub-id-type="pmid">26053927</pub-id></element-citation></ref><ref id="B121"><label>121</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jimenez-Guarde&#x000f1;o</surname><given-names>JM</given-names></name><name><surname>Nieto-Torres</surname><given-names>JL</given-names></name><name><surname>DeDiego</surname><given-names>ML</given-names></name><name><surname>Regla-Nava</surname><given-names>JA</given-names></name><name><surname>Fernandez-Delgado</surname><given-names>R</given-names></name><name><surname>Casta&#x000f1;o-Rodriguez</surname><given-names>C</given-names></name></person-group><article-title>The PDZ-binding motif of severe acute respiratory syndrome
coronavirus envelope protein is a determinant of viral
pathogenesis</article-title><source>PLoS Pathog</source><year>2014</year><volume>10</volume><issue>8</issue><elocation-id>e1004320</elocation-id><pub-id pub-id-type="pmid">25122212</pub-id></element-citation></ref><ref id="B122"><label>122</label><element-citation publication-type="webpage"><person-group person-group-type="author"><name><surname>Gupta</surname><given-names>MK</given-names></name><name><surname>Vemula</surname><given-names>S</given-names></name><name><surname>Donde</surname><given-names>R</given-names></name><name><surname>Gouda</surname><given-names>G</given-names></name><name><surname>Behera</surname><given-names>L</given-names></name><name><surname>Vadde</surname><given-names>R</given-names></name></person-group><article-title>In-silico approaches to detect inhibitors of the human severe
acute respiratory syndrome coronavirus envelope protein ion
channel.</article-title><source>J Biomol Struct Dyn</source><year>2020</year><pub-id pub-id-type="doi">10.1080/07391102.2020.1751300</pub-id></element-citation></ref><ref id="B123"><label>123</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pervushin</surname><given-names>K</given-names></name><name><surname>Tan</surname><given-names>E</given-names></name><name><surname>Parthasarathy</surname><given-names>K</given-names></name><name><surname>Lin</surname><given-names>X</given-names></name><name><surname>Jiang</surname><given-names>FL</given-names></name><name><surname>Yu</surname><given-names>D</given-names></name></person-group><article-title>Structure and inhibition of the SARS coronavirus envelope protein
ion channel Baric RS</article-title><source>PLoS Pathog</source><year>2009</year><volume>5</volume><issue>7</issue><elocation-id>e1000511</elocation-id><pub-id pub-id-type="pmid">19593379</pub-id></element-citation></ref><ref id="B124"><label>124</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nieto-Torres</surname><given-names>JL</given-names></name><name><surname>DeDiego</surname><given-names>ML</given-names></name><name><surname>Verdi&#x000e1;-B&#x000e1;guena</surname><given-names>C</given-names></name><name><surname>Jimenez-Guarde&#x000f1;o</surname><given-names>JM</given-names></name><name><surname>Regla-Nava</surname><given-names>JA</given-names></name><name><surname>Fernandez-Delgado</surname><given-names>R</given-names></name></person-group><article-title>Severe acute respiratory syndrome coronavirus envelope protein
ion channel activity promotes virus fitness and pathogenesis</article-title><source>PLoS Pathog</source><year>2014</year><volume>10</volume><issue>5</issue><elocation-id>e1004077</elocation-id><pub-id pub-id-type="pmid">24788150</pub-id></element-citation></ref><ref id="B125"><label>125</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khan</surname><given-names>S</given-names></name><name><surname>Siddique</surname><given-names>R</given-names></name><name><surname>Shereen</surname><given-names>MA</given-names></name><name><surname>Ali</surname><given-names>A</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Bai</surname><given-names>Q</given-names></name></person-group><article-title>Emergence of a novel coronavirus, severe acute respiratory
syndrome coronavirus 2 biology and therapeutic options</article-title><source>J Clin Microbiol</source><year>2020</year><volume>58</volume><issue>5</issue><fpage>1</fpage><lpage>22</lpage></element-citation></ref><ref id="B126"><label>126</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singh Tomar</surname><given-names>PP</given-names></name><name><surname>Arkin</surname><given-names>IT</given-names></name></person-group><article-title>SARS-CoV-2 E protein is a potential ion channel that can be
inhibited by Gliclazide and Memantine</article-title><source>Biochem Biophys Res Commun</source><year>2020</year><volume>530</volume><issue>1</issue><fpage>10</fpage><lpage>14</lpage><pub-id pub-id-type="pmid">32828269</pub-id></element-citation></ref><ref id="B127"><label>127</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McKinney</surname><given-names>CA</given-names></name><name><surname>Fattah</surname><given-names>C</given-names></name><name><surname>Loughrey</surname><given-names>CM</given-names></name><name><surname>Milligan</surname><given-names>G</given-names></name><name><surname>Nicklin</surname><given-names>SA</given-names></name></person-group><article-title>Angiotensin-(1-7) and angiotensin-(1-9) function in cardiac and
vascular remodelling</article-title><source>Clin Sci (Lond)</source><year>2014</year><volume>126</volume><issue>12</issue><fpage>815</fpage><lpage>827</lpage><pub-id pub-id-type="pmid">24593683</pub-id></element-citation></ref><ref id="B128"><label>128</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Muniyappa</surname><given-names>R</given-names></name><name><surname>Gubbi</surname><given-names>S</given-names></name></person-group><article-title>COVID-19 pandemic, coronaviruses, and diabetes
mellitus</article-title><source>Am J Physiol Endocrinol Metab</source><year>2020</year><volume>318</volume><issue>5</issue><fpage>E736</fpage><lpage>E741</lpage><pub-id pub-id-type="pmid">32228322</pub-id></element-citation></ref><ref id="B129"><label>129</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Penninger</surname><given-names>JM</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Zhong</surname><given-names>N</given-names></name><name><surname>Slutsky</surname><given-names>AS</given-names></name></person-group><article-title>Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor
molecular mechanisms and potential therapeutic target</article-title><source>Intensive Care Med</source><year>2020</year><volume>46</volume><issue>4</issue><fpage>586</fpage><lpage>590</lpage><pub-id pub-id-type="pmid">32125455</pub-id></element-citation></ref><ref id="B130"><label>130</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>Sorrento Therapeutics [homepage on the Internet]</collab></person-group><source>STI-1499, a potent anti-SARS-CoV-2</source><year>2020</year><publisher-loc>antibody</publisher-loc><publisher-name>demonstrates ability to completely inhibit in vitro virus
infection in preclinical studies</publisher-name></element-citation></ref><ref id="B131"><label>131</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Devaux</surname><given-names>CA</given-names></name><name><surname>Rolain J-M</surname><given-names/></name><name><surname>Colson</surname><given-names>P</given-names></name><name><surname>Raoult</surname><given-names>D</given-names></name></person-group><article-title>New insights on the antiviral effects of chloroquine against
coronavirus what to expect for COVID-19?</article-title><source>Int J Antimicrob Agents</source><year>2020</year><volume>55</volume><issue>5</issue><fpage>105938</fpage><lpage>105938</lpage><pub-id pub-id-type="pmid">32171740</pub-id></element-citation></ref><ref id="B132"><label>132</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Azushima</surname><given-names>K</given-names></name><name><surname>Morisawa</surname><given-names>N</given-names></name><name><surname>Tamura</surname><given-names>K</given-names></name><name><surname>Nishiyama</surname><given-names>A</given-names></name></person-group><article-title>Recent research advances in renin-angiotensin-aldosterone system
receptors</article-title><source>Curr Hypertens Rep</source><year>2020</year><volume>22</volume><issue>3</issue><fpage>22</fpage><lpage>22</lpage><pub-id pub-id-type="pmid">32114685</pub-id></element-citation></ref><ref id="B133"><label>133</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zheng Y-Y</surname><given-names/></name><name><surname>Ma Y-T</surname><given-names/></name><name><surname>Zhang J-Y</surname><given-names/></name><name><surname>Xie</surname><given-names>X</given-names></name></person-group><article-title>COVID-19 and the cardiovascular system</article-title><source>Nat Rev Cardiol</source><year>2020</year><volume>17</volume><issue>5</issue><fpage>259</fpage><lpage>260</lpage><pub-id pub-id-type="pmid">32139904</pub-id></element-citation></ref><ref id="B134"><label>134</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zheng Y-Y</surname><given-names/></name><name><surname>Ma Y-T</surname><given-names/></name><name><surname>Zhang J-Y</surname><given-names/></name><name><surname>Xie</surname><given-names>X</given-names></name></person-group><article-title>Reply to 'interaction between RAAS inhibitors and ACE2 in the
context of COVID-19'. Nat Rev</article-title><source>Cardiol</source><year>2020</year><volume>17</volume><issue>5</issue><fpage>313</fpage><lpage>314</lpage></element-citation></ref><ref id="B135"><label>135</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gurwitz</surname><given-names>D</given-names></name></person-group><article-title>Angiotensin receptor blockers as tentative SARS-CoV-2
therapeutics</article-title><source>Drug Dev Res</source><year>2020</year><volume>81</volume><issue>5</issue><fpage>537</fpage><lpage>540</lpage><pub-id pub-id-type="pmid">32129518</pub-id></element-citation></ref><ref id="B136"><label>136</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vaduganathan</surname><given-names>M</given-names></name><name><surname>Vardeny</surname><given-names>O</given-names></name><name><surname>Michel</surname><given-names>T</given-names></name><name><surname>McMurray</surname><given-names>JJV</given-names></name><name><surname>Pfeffer</surname><given-names>MA</given-names></name><name><surname>Solomon</surname><given-names>SD</given-names></name></person-group><article-title>Renin-angiotensin-aldosterone system inhibitors in patients with
Covid-19</article-title><source>N Engl J Med</source><year>2020</year><volume>382</volume><issue>17</issue><fpage>1653</fpage><lpage>1659</lpage><pub-id pub-id-type="pmid">32227760</pub-id></element-citation></ref><ref id="B137"><label>137</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuster</surname><given-names>GM</given-names></name><name><surname>Pfister</surname><given-names>O</given-names></name><name><surname>Burkard</surname><given-names>T</given-names></name><name><surname>Zhou</surname><given-names>Q</given-names></name><name><surname>Twerenbold</surname><given-names>R</given-names></name><name><surname>Haaf</surname><given-names>P</given-names></name></person-group><article-title>SARS-CoV2 should inhibitors of the renin-angiotensin system be
withdrawn in patients with COVID-19?</article-title><source>Eur Heart J</source><year>2020</year><volume>41</volume><issue>19</issue><fpage>1801</fpage><lpage>1803</lpage><pub-id pub-id-type="pmid">32196087</pub-id></element-citation></ref><ref id="B138"><label>138</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>LW</given-names></name><name><surname>Mao</surname><given-names>HJ</given-names></name><name><surname>Wu</surname><given-names>YL</given-names></name><name><surname>Tanaka</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name></person-group><article-title>TMPRSS2 a potential target for treatment of influenza virus and
coronavirus infections</article-title><source>Biochimie</source><year>2017</year><volume>142</volume><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="pmid">28778717</pub-id></element-citation></ref><ref id="B139"><label>139</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoffmann</surname><given-names>M</given-names></name><name><surname>Schroeder</surname><given-names>S</given-names></name><name><surname>Kleine-Weber</surname><given-names>H</given-names></name><name><surname>M&#x000fc;ller</surname><given-names>MA</given-names></name><name><surname>Drosten</surname><given-names>C</given-names></name><name><surname>P&#x000f6;hlmann</surname><given-names>S</given-names></name></person-group><article-title>Nafamostat mesylate blocks activation of SARS-CoV-2 new treatment
option for COVID-19</article-title><source>Antimicrob Agents Chemother</source><year>2020</year><volume>64</volume><issue>6</issue><fpage>1</fpage><lpage>7</lpage></element-citation></ref><ref id="B140"><label>140</label><element-citation publication-type="webpage"><person-group person-group-type="author"><name><surname>Idris</surname><given-names>MO</given-names></name><name><surname>Yekeen</surname><given-names>AA</given-names></name><name><surname>Alakanse</surname><given-names>OS</given-names></name><name><surname>Durojaye</surname><given-names>OA</given-names></name></person-group><article-title>Computer-aided screening for potential TMPRSS2 inhibitors: a
combination of pharmacophore modeling, molecular docking and molecular
dynamics simulation approaches</article-title><source>J Biomol Struct Dyn</source><year>2020</year><pub-id pub-id-type="doi">10.1080/07391102.2020.1792346</pub-id></element-citation></ref><ref id="B141"><label>141</label><element-citation publication-type="webpage"><person-group person-group-type="author"><name><surname>Kumar</surname><given-names>V</given-names></name><name><surname>Dhanjal</surname><given-names>JK</given-names></name><name><surname>Bhargava</surname><given-names>P</given-names></name><name><surname>Kaul</surname><given-names>A</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><etal/></person-group><article-title>Withanone and Withaferin-A are predicted to interact with
transmembrane protease serine 2 (TMPRSS2) and block entry of SARS-CoV-2 into
cells</article-title><source>J Biomol Struct Dyn</source><year>2020</year><pub-id pub-id-type="doi">10.1080/07391102.2020.1775704</pub-id></element-citation></ref><ref id="B142"><label>142</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaksonen</surname><given-names>M</given-names></name><name><surname>Roux</surname><given-names>A</given-names></name></person-group><article-title>Mechanisms of clathrin-mediated endocytosis</article-title><source>Nat Rev Mol Cell Biol</source><year>2018</year><volume>19</volume><issue>5</issue><fpage>313</fpage><lpage>326</lpage><pub-id pub-id-type="pmid">29410531</pub-id></element-citation></ref><ref id="B143"><label>143</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu Y-B</surname><given-names/></name><name><surname>Dammer</surname><given-names>EB</given-names></name><name><surname>Ren R-J</surname><given-names/></name><name><surname>Wang</surname><given-names>G</given-names></name></person-group><article-title>The endosomal-lysosomal system from acidification and cargo
sorting to neurodegeneration</article-title><source>Transl Neurodegener</source><year>2015</year><volume>4</volume><issue>1</issue><fpage>18</fpage><lpage>18</lpage><pub-id pub-id-type="pmid">26448863</pub-id></element-citation></ref><ref id="B144"><label>144</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>T</given-names></name><name><surname>Luo</surname><given-names>S</given-names></name><name><surname>Libby</surname><given-names>P</given-names></name><name><surname>Shi G-P</surname><given-names/></name></person-group><article-title>Cathepsin L-selective inhibitors a potentially promising
treatment for COVID-19 patients</article-title><source>Pharmacol Ther</source><year>2020</year><volume>213</volume><fpage>107587</fpage><lpage>107587</lpage><pub-id pub-id-type="pmid">32470470</pub-id></element-citation></ref><ref id="B145"><label>145</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rose-John</surname><given-names>S</given-names></name></person-group><article-title>Interleukin-6 family cytokines</article-title><source>Cold Spring Harb Perspect Biol</source><year>2018</year><volume>10</volume><issue>2</issue><fpage>a028415</fpage><lpage>a028415</lpage><pub-id pub-id-type="pmid">28620096</pub-id></element-citation></ref><ref id="B146"><label>146</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O'Shea</surname><given-names>JJ</given-names></name><name><surname>Gadina</surname><given-names>M</given-names></name><name><surname>Siegel</surname><given-names>RM</given-names></name></person-group><article-title>Cytokines and cytokine receptors</article-title><source>Elsevier</source><year>2019</year></element-citation></ref><ref id="B147"><label>147</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mehta</surname><given-names>P</given-names></name><name><surname>McAuley</surname><given-names>DF</given-names></name><name><surname>Brown</surname><given-names>M</given-names></name><name><surname>Sanchez</surname><given-names>E</given-names></name><name><surname>Tattersall</surname><given-names>RS</given-names></name><name><surname>Manson</surname><given-names>JJ</given-names></name></person-group><article-title>COVID-19 consider cytokine storm syndromes and
immunosuppression</article-title><source>Lancet</source><year>2020</year><volume>395</volume><issue>10229</issue><fpage>1033</fpage><lpage>1034</lpage><pub-id pub-id-type="pmid">32192578</pub-id></element-citation></ref><ref id="B148"><label>148</label><element-citation publication-type="webpage"><person-group person-group-type="author"><name><surname>Chakraborty</surname><given-names>C</given-names></name><name><surname>Sharma</surname><given-names>AR</given-names></name><name><surname>Bhattacharya</surname><given-names>M</given-names></name><name><surname>Sharma</surname><given-names>G</given-names></name><name><surname>Lee</surname><given-names>S</given-names></name><name><surname>Agoramoorthy</surname><given-names>G</given-names></name></person-group><article-title>COVID-19: consider IL-6 receptor antagonist for the therapy of
cytokine storm syndrome in SARS-CoV-2 infected patients.</article-title><source>J Med Virol</source><year>2020</year><pub-id pub-id-type="doi">10.1002/jmv.26078</pub-id></element-citation></ref><ref id="B149"><label>149</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lombard</surname><given-names>V</given-names></name><name><surname>Ramulu</surname><given-names>HG</given-names></name><name><surname>Drula</surname><given-names>E</given-names></name><name><surname>Coutinho</surname><given-names>PM</given-names></name><name><surname>Henrissat</surname><given-names>B</given-names></name></person-group><article-title>The carbohydrate-active enzymes database (CAZy) in
2013</article-title><source>Nucleic Acids Res</source><year>2014</year><volume>42</volume><issue>D1</issue><fpage>D490</fpage><lpage>D495</lpage><pub-id pub-id-type="pmid">24270786</pub-id></element-citation></ref><ref id="B150"><label>150</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McAuley</surname><given-names>JL</given-names></name><name><surname>Gilbertson</surname><given-names>BP</given-names></name><name><surname>Trifkovic</surname><given-names>S</given-names></name><name><surname>Brown</surname><given-names>LE</given-names></name><name><surname>McKimm-Breschkin</surname><given-names>JL</given-names></name></person-group><article-title>Influenza virus neuraminidase structure and
functions</article-title><source>Front Microbiol</source><year>2019</year><volume>10</volume><issue>2</issue><fpage>39</fpage><lpage>39</lpage><pub-id pub-id-type="pmid">30761095</pub-id></element-citation></ref><ref id="B151"><label>151</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Drucker</surname><given-names>DJ</given-names></name></person-group><article-title>Coronavirus infections and type 2 diabetes - shared pathways with
therapeutic implications</article-title><source>Endocr Rev</source><year>2020</year><volume>41</volume><issue>3</issue><fpage>457</fpage><lpage>470</lpage></element-citation></ref><ref id="B152"><label>152</label><element-citation publication-type="webpage"><person-group person-group-type="author"><name><surname>Strollo</surname><given-names>R</given-names></name><name><surname>Pozzilli</surname><given-names>P</given-names></name></person-group><article-title>DPP4 inhibition: preventing SARS-CoV-2 infection and/or
progression of COVID-19?</article-title><source>Diabetes Metab Res Rev</source><year>2020</year><pub-id pub-id-type="doi">10.1002/dmrr.3330</pub-id></element-citation></ref><ref id="B153"><label>153</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iacobellis</surname><given-names>G</given-names></name></person-group><article-title>COVID-19 and diabetes Can DPP4 inhibition play a
role?</article-title><source>Diabetes Res Clin Pract</source><year>2020</year><volume>162</volume><fpage>108125</fpage><lpage>108125</lpage><pub-id pub-id-type="pmid">32224164</pub-id></element-citation></ref><ref id="B154"><label>154</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vankadari</surname><given-names>N</given-names></name><name><surname>Wilce</surname><given-names>JA</given-names></name></person-group><article-title>Emerging Wuhan (COVID-19) coronavirus glycan shield and structure
prediction of spike glycoprotein and its interaction with human
CD26</article-title><source>Emerg Microbes Infect</source><year>2020</year><volume>9</volume><issue>1</issue><fpage>601</fpage><lpage>604</lpage><pub-id pub-id-type="pmid">32178593</pub-id></element-citation></ref><ref id="B155"><label>155</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Solerte</surname><given-names>SB</given-names></name><name><surname>Di Sabatino</surname><given-names>A</given-names></name><name><surname>Galli</surname><given-names>M</given-names></name><name><surname>Fiorina</surname><given-names>P</given-names></name></person-group><article-title>Dipeptidyl peptidase-4 (DPP4) inhibition in
COVID-19</article-title><source>Acta Diabetol</source><year>2020</year><volume>57</volume><issue>7</issue><fpage>779</fpage><lpage>783</lpage><pub-id pub-id-type="pmid">32506195</pub-id></element-citation></ref><ref id="B156"><label>156</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dalan</surname><given-names>R</given-names></name></person-group><article-title>Is DPP4 inhibition a comrade or adversary in COVID-19
infection</article-title><source>Diabetes Res Clin Pract</source><year>2020</year><volume>164</volume><fpage>108216</fpage><lpage>108216</lpage><pub-id pub-id-type="pmid">32416120</pub-id></element-citation></ref><ref id="B157"><label>157</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ciliberto</surname><given-names>G</given-names></name><name><surname>Cardone</surname><given-names>L</given-names></name></person-group><article-title>Boosting the arsenal against COVID-19 through computational drug
repurposing</article-title><source>Drug Discov Today</source><year>2020</year><volume>25</volume><issue>6</issue><fpage>946</fpage><lpage>948</lpage><pub-id pub-id-type="pmid">32304645</pub-id></element-citation></ref><ref id="B158"><label>158</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ekins</surname><given-names>S</given-names></name><name><surname>Mottin</surname><given-names>M</given-names></name><name><surname>Ramos</surname><given-names>PRPS</given-names></name><name><surname>Sousa</surname><given-names>BKP</given-names></name><name><surname>Neves</surname><given-names>BJ</given-names></name><name><surname>Foil</surname><given-names>DH</given-names></name></person-group><article-title>D&#x000e9;j&#x000e0; vu stimulating open drug discovery for
SARS-CoV-2</article-title><source>Drug Discov Today</source><year>2020</year><volume>25</volume><issue>5</issue><fpage>928</fpage><lpage>941</lpage><pub-id pub-id-type="pmid">32320852</pub-id></element-citation></ref><ref id="B159"><label>159</label><element-citation publication-type="webpage"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>M</given-names></name><name><surname>Smith</surname><given-names>JC</given-names></name></person-group><article-title>Repurposing therapeutics for COVID-19: supercomputer-based
docking to the SARS-CoV-2 viral spike protein and viral spike protein-human
ACE2 interface</article-title><year>2020</year><ext-link ext-link-type="uri" xlink:href="https://chemrxiv.org/articles/Repurposing_Therapeutics_for_the_Wuhan_Coronavirus_nCov-2019_Supercomputer-Based_Docking_to_the_Viral_S_Protein_and_Human_ACE2_Interface/11871402">https://chemrxiv.org/articles/Repurposing_Therapeutics_for_the_Wuhan_Coronavirus_nCov-2019_Supercomputer-Based_Docking_to_the_Viral_S_Protein_and_Human_ACE2_Interface/11871402</ext-link></element-citation></ref><ref id="B160"><label>160</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pant</surname><given-names>S</given-names></name><name><surname>Singh</surname><given-names>M</given-names></name><name><surname>Ravichandiran</surname><given-names>V</given-names></name><name><surname>Murty</surname><given-names>USN</given-names></name><name><surname>Srivastava</surname><given-names>HK</given-names></name></person-group><article-title>Peptide-like and small-molecule inhibitors against
Covid-19</article-title><source>J Biomol Struct Dyn</source><year>2020</year><fpage>1</fpage><lpage>10</lpage></element-citation></ref><ref id="B161"><label>161</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Richardson</surname><given-names>P</given-names></name><name><surname>Griffin</surname><given-names>I</given-names></name><name><surname>Tucker</surname><given-names>C</given-names></name><name><surname>Smith</surname><given-names>D</given-names></name><name><surname>Oechsle</surname><given-names>O</given-names></name><name><surname>Phelan</surname><given-names>A</given-names></name></person-group><article-title>Baricitinib as potential treatment for 2019-nCoV acute
respiratory disease</article-title><source>Lancet</source><year>2020</year><volume>395</volume><issue>10223</issue><fpage>e30</fpage><lpage>e31</lpage><pub-id pub-id-type="pmid">32032529</pub-id></element-citation></ref><ref id="B162"><label>162</label><element-citation publication-type="webpage"><person-group person-group-type="author"><name><surname>Bung</surname><given-names>N</given-names></name><name><surname>Krishnan</surname><given-names>SR</given-names></name><name><surname>Bulusu</surname><given-names>G</given-names></name><name><surname>Roy</surname><given-names>A.</given-names></name></person-group><article-title>De novo design of new chemical entities (NCEs) for SARS-CoV-2
using artificial intelligence</article-title><year>2020</year><ext-link ext-link-type="uri" xlink:href="https://chemrxiv.org/articles/De_Novo_Design_of_New_Chemical_Entities_NCEs_for_SARS-CoV-2_Using_Artificial_Intelligence/11998347/2">https://chemrxiv.org/articles/De_Novo_Design_of_New_Chemical_Entities_NCEs_for_SARS-CoV-2_Using_Artificial_Intelligence/11998347/2</ext-link></element-citation></ref><ref id="B163"><label>163</label><element-citation publication-type="webpage"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>K</given-names></name><name><surname>Fu</surname><given-names>T</given-names></name><name><surname>Glass</surname><given-names>L</given-names></name><name><surname>Zitnik</surname><given-names>M</given-names></name><name><surname>Xiao</surname><given-names>C</given-names></name><name><surname>Sun</surname><given-names>J</given-names></name></person-group><article-title>DeepPurpose: a deep learning library for drug-target interaction
prediction and applications to repurposing and screening</article-title><year>2020</year><ext-link ext-link-type="uri" xlink:href="https://arxiv.org/abs/2004.08919">https://arxiv.org/abs/2004.08919</ext-link></element-citation></ref><ref id="B164"><label>164</label><element-citation publication-type="webpage"><person-group person-group-type="author"><name><surname>Ge</surname><given-names>Y</given-names></name><name><surname>Tian</surname><given-names>T</given-names></name><name><surname>Huang</surname><given-names>S</given-names></name><name><surname>Wan</surname><given-names>F</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><etal/></person-group><article-title>A data-driven drug repositioning framework discovered a potential
therapeutic agent targeting COVID-19</article-title><year>2020</year><ext-link ext-link-type="uri" xlink:href="https://www.biorxiv.org/content/10.1101/2020.03.11.986836v1">https://www.biorxiv.org/content/10.1101/2020.03.11.986836v1</ext-link></element-citation></ref><ref id="B165"><label>165</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>DE</given-names></name><name><surname>Min</surname><given-names>JS</given-names></name><name><surname>Jang</surname><given-names>MS</given-names></name><name><surname>Lee</surname><given-names>JY</given-names></name><name><surname>Shin</surname><given-names>YS</given-names></name><name><surname>Park</surname><given-names>CM</given-names></name></person-group><article-title>Natural bis-benzylisoquinoline alkaloids-tetrandrine,
fangchinoline, and cepharanthine, inhibit human coronavirus OC43 infection
of MRC-5 human lung cells</article-title><source>Biomolecules</source><year>2019</year><volume>9</volume><issue>11</issue><fpage>696</fpage><lpage>696</lpage></element-citation></ref><ref id="B166"><label>166</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jo</surname><given-names>S</given-names></name><name><surname>Kim</surname><given-names>S</given-names></name><name><surname>Shin</surname><given-names>DH</given-names></name><name><surname>Kim M-S</surname><given-names/></name></person-group><article-title>Inhibition of SARS-CoV 3CL protease by flavonoids</article-title><source>J Enzyme Inhib Med Chem</source><year>2020</year><volume>35</volume><issue>1</issue><fpage>145</fpage><lpage>151</lpage><pub-id pub-id-type="pmid">31724441</pub-id></element-citation></ref><ref id="B167"><label>167</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yi</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Yuan</surname><given-names>K</given-names></name><name><surname>Qu</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>G</given-names></name></person-group><article-title>Small molecules blocking the entry of severe acute respiratory
syndrome coronavirus into host cells</article-title><source>J Virol</source><year>2004</year><volume>78</volume><issue>20</issue><fpage>11334</fpage><lpage>11339</lpage><pub-id pub-id-type="pmid">15452254</pub-id></element-citation></ref><ref id="B168"><label>168</label><element-citation publication-type="webpage"><person-group person-group-type="author"><name><surname>Fintelman-Rodrigues</surname><given-names>N</given-names></name><name><surname>Sacramento</surname><given-names>CQ</given-names></name><name><surname>Lima</surname><given-names>CR</given-names></name><name><surname>da Silva</surname><given-names>FS</given-names></name><name><surname>Ferreira</surname><given-names>AC</given-names></name><name><surname>Mattos</surname><given-names>M</given-names></name><etal/></person-group><article-title>Atazanavir inhibits SARS-CoV-2 replication and pro-inflammatory
cytokine production.</article-title><year>2020</year><ext-link ext-link-type="uri" xlink:href="https://www.biorxiv.org/content/10.1101/2020.04.04.020925v2">https://www.biorxiv.org/content/10.1101/2020.04.04.020925v2</ext-link></element-citation></ref><ref id="B169"><label>169</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cantini</surname><given-names>F</given-names></name><name><surname>Niccoli</surname><given-names>L</given-names></name><name><surname>Matarrese</surname><given-names>D</given-names></name><name><surname>Nicastri</surname><given-names>E</given-names></name><name><surname>Stobbione</surname><given-names>P</given-names></name><name><surname>Goletti</surname><given-names>D</given-names></name></person-group><article-title>Baricitinib therapy in COVID-19 a pilot study on safety and
clinical impact</article-title><source>J Infect</source><year>2020</year><volume>81</volume><issue>2</issue><fpage>318</fpage><lpage>356</lpage></element-citation></ref><ref id="B170"><label>170</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abraham</surname><given-names>MJ</given-names></name><name><surname>Murtola</surname><given-names>T</given-names></name><name><surname>Schulz</surname><given-names>R</given-names></name><name><surname>P&#x000e1;ll</surname><given-names>S</given-names></name><name><surname>Smith</surname><given-names>JC</given-names></name><name><surname>Hess</surname><given-names>B</given-names></name><etal/></person-group><article-title>GROMACS: high performance molecular simulations through
multi-level parallelism from laptops to supercomputers</article-title><source>SoftwareX</source><year>2015</year></element-citation></ref><ref id="B171"><label>171</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trott</surname><given-names>O</given-names></name><name><surname>Olson</surname><given-names>AJ</given-names></name></person-group><article-title>AutoDock Vina improving the speed and accuracy of docking with a
new scoring function, efficient optimization, and
multithreading</article-title><source>J Comput Chem</source><year>2010</year><volume>31</volume><issue>2</issue><fpage>455</fpage><lpage>461</lpage><pub-id pub-id-type="pmid">19499576</pub-id></element-citation></ref><ref id="B172"><label>172</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Novick</surname><given-names>PA</given-names></name><name><surname>Ortiz</surname><given-names>OF</given-names></name><name><surname>Poelman</surname><given-names>J</given-names></name><name><surname>Abdulhay</surname><given-names>AY</given-names></name><name><surname>Pande</surname><given-names>VS</given-names></name></person-group><article-title>SWEETLEAD an in silico database of approved drugs, regulated
chemicals, and herbal isolates for computer-aided drug
discovery</article-title><source>PLoS One</source><year>2013</year><volume>8</volume><issue>11</issue><elocation-id>e79568</elocation-id><pub-id pub-id-type="pmid">24223973</pub-id></element-citation></ref><ref id="B173"><label>173</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wishart</surname><given-names>DS</given-names></name><name><surname>Feunang</surname><given-names>YD</given-names></name><name><surname>Guo</surname><given-names>AC</given-names></name><name><surname>Lo</surname><given-names>EJ</given-names></name><name><surname>Marcu</surname><given-names>A</given-names></name><name><surname>Grant</surname><given-names>JR</given-names></name></person-group><article-title>DrugBank 5 0: a major update to the DrugBank database for
2018</article-title><source>Nucleic Acids Res</source><year>2018</year><volume>46</volume><issue>D1</issue><fpage>D1074</fpage><lpage>D1082</lpage><pub-id pub-id-type="pmid">29126136</pub-id></element-citation></ref><ref id="B174"><label>174</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mendez</surname><given-names>D</given-names></name><name><surname>Gaulton</surname><given-names>A</given-names></name><name><surname>Bento</surname><given-names>AP</given-names></name><name><surname>Chambers</surname><given-names>J</given-names></name><name><surname>De Veij</surname><given-names>M</given-names></name><name><surname>F&#x000e9;lix</surname><given-names>E</given-names></name></person-group><article-title>ChEMBL towards direct deposition of bioassay data</article-title><source>Nucleic Acids Res</source><year>2019</year><volume>47</volume><issue>D1</issue><fpage>D930</fpage><lpage>D940</lpage><pub-id pub-id-type="pmid">30398643</pub-id></element-citation></ref><ref id="B175"><label>175</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>T</given-names></name><name><surname>Lin</surname><given-names>Y</given-names></name><name><surname>Wen</surname><given-names>X</given-names></name><name><surname>Jorissen</surname><given-names>RN</given-names></name><name><surname>Gilson</surname><given-names>MK</given-names></name></person-group><article-title>BindingDB a web-accessible database of experimentally determined
protein-ligand binding affinities</article-title><source>Nucleic Acids Res</source><year>2007</year><volume>35</volume><issue>Database</issue><fpage>D198</fpage><lpage>D201</lpage><pub-id pub-id-type="pmid">17145705</pub-id></element-citation></ref><ref id="B176"><label>176</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>UniProt Consortium</surname><given-names>T</given-names></name></person-group><article-title>UniProt the universal protein knowledgebase</article-title><source>Nucleic Acids Res</source><year>2018</year><volume>46</volume><issue>5</issue><fpage>2699</fpage><lpage>2699</lpage><pub-id pub-id-type="pmid">29425356</pub-id></element-citation></ref><ref id="B177"><label>177</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Torng</surname><given-names>W</given-names></name><name><surname>Altman</surname><given-names>RB</given-names></name></person-group><article-title>Graph convolutional neural networks for predicting drug-target
interactions</article-title><source>J Chem Inf Model</source><year>2019</year><volume>59</volume><issue>10</issue><fpage>4131</fpage><lpage>4149</lpage><pub-id pub-id-type="pmid">31580672</pub-id></element-citation></ref><ref id="B178"><label>178</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>S</given-names></name><name><surname>Tong</surname><given-names>H</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Maciejewski</surname><given-names>R</given-names></name></person-group><article-title>Graph convolutional networks a comprehensive
review</article-title><source>Comput Soc Netw</source><year>2019</year><volume>6</volume><issue>1</issue><fpage>11</fpage><lpage>11</lpage></element-citation></ref><ref id="B179"><label>179</label><element-citation publication-type="webpage"><person-group person-group-type="author"><name><surname>Hong</surname><given-names>L</given-names></name><name><surname>Lin</surname><given-names>J</given-names></name><name><surname>Tao</surname><given-names>J</given-names></name><name><surname>Zeng</surname><given-names>J.</given-names></name></person-group><article-title>BERE: an accurate distantly supervised biomedical entity relation
extraction network.</article-title><year>2019</year><ext-link ext-link-type="uri" xlink:href="https://arxiv.org/abs/1906.06916">https://arxiv.org/abs/1906.06916</ext-link></element-citation></ref><ref id="B180"><label>180</label><element-citation publication-type="webpage"><person-group person-group-type="author"><name><surname>Young</surname><given-names>T</given-names></name><name><surname>Hazarika</surname><given-names>D</given-names></name><name><surname>Poria</surname><given-names>S</given-names></name><name><surname>Cambria</surname><given-names>E</given-names></name></person-group><article-title>Recent trends in deep learning based natural language
processing</article-title><year>2018</year><ext-link ext-link-type="uri" xlink:href="https://arxiv.org/abs/1708.02709">https://arxiv.org/abs/1708.02709</ext-link></element-citation></ref><ref id="B181"><label>181</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>X</given-names></name><name><surname>Deng</surname><given-names>L</given-names></name></person-group><article-title>Deep learning in natural language generation from
images</article-title><source>Springer Singapore</source><year>2018</year></element-citation></ref><ref id="B182"><label>182</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>LeCun</surname><given-names>Y</given-names></name><name><surname>Bengio</surname><given-names>Y</given-names></name><name><surname>Hinton</surname><given-names>G</given-names></name></person-group><article-title>Deep learning</article-title><source>Nature</source><year>2015</year><volume>521</volume><issue>7553</issue><fpage>436</fpage><lpage>444</lpage><pub-id pub-id-type="pmid">26017442</pub-id></element-citation></ref><ref id="B183"><label>183</label><element-citation publication-type="webpage"><person-group person-group-type="author"><name><surname>Shin</surname><given-names>B</given-names></name><name><surname>Park</surname><given-names>S</given-names></name><name><surname>Kang</surname><given-names>K</given-names></name><name><surname>Ho</surname><given-names>JC</given-names></name></person-group><article-title>Self-attention based molecule representation for predicting
drug-target interaction</article-title><year>2019</year><ext-link ext-link-type="uri" xlink:href="https://arxiv.org/abs/1908.06760">https://arxiv.org/abs/1908.06760</ext-link></element-citation></ref><ref id="B184"><label>184</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Fourches</surname><given-names>D</given-names></name></person-group><article-title>Inductive transfer learning for molecular activity prediction
Next-Gen QSAR Models with MolPMoFiT</article-title><source>J Cheminform</source><year>2020</year><volume>12</volume><issue>1</issue><fpage>27</fpage><lpage>27</lpage></element-citation></ref><ref id="B185"><label>185</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tan</surname><given-names>C</given-names></name><name><surname>Sun</surname><given-names>F</given-names></name><name><surname>Kong</surname><given-names>T</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Yang</surname><given-names>C</given-names></name><name><surname>Liu</surname><given-names>C.</given-names></name></person-group><article-title>A survey on deep transfer learning</article-title><source>Springer International Publishing</source><year>2018</year></element-citation></ref><ref id="B186"><label>186</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peeri</surname><given-names>NC</given-names></name><name><surname>Shrestha</surname><given-names>N</given-names></name><name><surname>Rahman</surname><given-names>MS</given-names></name><name><surname>Zaki</surname><given-names>R</given-names></name><name><surname>Tan</surname><given-names>Z</given-names></name><name><surname>Bibi</surname><given-names>S</given-names></name></person-group><article-title>The SARS, MERS and novel coronavirus (COVID-19) epidemics, the
newest and biggest global health threats what lessons have we
learned?</article-title><source>Int J Epidemiol</source><year>2020</year><volume>49</volume><issue>3</issue><fpage>717</fpage><lpage>726</lpage><pub-id pub-id-type="pmid">32086938</pub-id></element-citation></ref><ref id="B187"><label>187</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Petrosillo</surname><given-names>N</given-names></name><name><surname>Viceconte</surname><given-names>G</given-names></name><name><surname>Ergonul</surname><given-names>O</given-names></name><name><surname>Ippolito</surname><given-names>G</given-names></name><name><surname>Petersen</surname><given-names>E</given-names></name></person-group><article-title>COVID-19, SARS and MERS are they closely related?</article-title><source>Clin Microbiol Infect</source><year>2020</year><volume>26</volume><issue>6</issue><fpage>729</fpage><lpage>734</lpage><pub-id pub-id-type="pmid">32234451</pub-id></element-citation></ref><ref id="B188"><label>188</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Zheng</surname><given-names>X</given-names></name><name><surname>Tong</surname><given-names>Q</given-names></name><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Wang</surname><given-names>B</given-names></name><name><surname>Sutter</surname><given-names>K</given-names></name></person-group><article-title>Overlapping and discrete aspects of the pathology and
pathogenesis of the emerging human pathogenic coronaviruses SARS-CoV,
MERS-CoV, and 2019-nCoV</article-title><source>J Med Virol</source><year>2020</year><volume>92</volume><issue>5</issue><fpage>491</fpage><lpage>494</lpage><pub-id pub-id-type="pmid">32056249</pub-id></element-citation></ref><ref id="B189"><label>189</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>C</given-names></name></person-group><article-title>Drug target validation hitting the target</article-title><source>Nature</source><year>2003</year><volume>422</volume><issue>6929</issue><fpage>342</fpage><lpage>345</lpage><pub-id pub-id-type="pmid">12646928</pub-id></element-citation></ref><ref id="B190"><label>190</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>Coronaviridae Study Group of the International Committee on Taxonomy
of Viruses</collab></person-group><article-title>The species Severe acute respiratory syndrome-related coronavirus
classifying 2019-nCoV and naming it SARS-CoV-2</article-title><source>Nat Microbiol</source><year>2020</year><volume>5</volume><issue>4</issue><fpage>536</fpage><lpage>544</lpage><pub-id pub-id-type="pmid">32123347</pub-id></element-citation></ref><ref id="B191"><label>191</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Herholt</surname><given-names>A</given-names></name><name><surname>Galinski</surname><given-names>S</given-names></name><name><surname>Geyer</surname><given-names>PE</given-names></name><name><surname>Rossner</surname><given-names>MJ</given-names></name><name><surname>Wehr</surname><given-names>MC</given-names></name></person-group><article-title>Multiparametric assays for accelerating early drug
discovery</article-title><source>Trends Pharmacol Sci</source><year>2020</year><volume>41</volume><issue>5</issue><fpage>318</fpage><lpage>335</lpage><pub-id pub-id-type="pmid">32223968</pub-id></element-citation></ref><ref id="B192"><label>192</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barkham</surname><given-names>TMS</given-names></name></person-group><article-title>Laboratory safety aspects of SARS at Biosafety Level
2</article-title><source>Ann Acad Med Singapore</source><year>2004</year><volume>33</volume><issue>2</issue><fpage>252</fpage><lpage>256</lpage><pub-id pub-id-type="pmid">15098644</pub-id></element-citation></ref><ref id="B193"><label>193</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gretebeck</surname><given-names>LM</given-names></name><name><surname>Subbarao</surname><given-names>K</given-names></name></person-group><article-title>Animal models for SARS and MERS coronaviruses</article-title><source>Curr Opin Virol</source><year>2015</year><volume>13</volume><fpage>123</fpage><lpage>129</lpage><pub-id pub-id-type="pmid">26184451</pub-id></element-citation></ref><ref id="B194"><label>194</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>M</given-names></name><name><surname>Cao</surname><given-names>R</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Yang</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Xu</surname><given-names>M</given-names></name></person-group><article-title>Remdesivir and chloroquine effectively inhibit the recently
emerged novel coronavirus (2019-nCoV) in vitro</article-title><source>Cell Res</source><year>2020</year><volume>30</volume><issue>3</issue><fpage>269</fpage><lpage>271</lpage><pub-id pub-id-type="pmid">32020029</pub-id></element-citation></ref><ref id="B195"><label>195</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cao</surname><given-names>B</given-names></name><name><surname>Sheth</surname><given-names>MN</given-names></name><name><surname>Mysorekar</surname><given-names>IU</given-names></name></person-group><article-title>To Zika and destroy an antimalarial drug protects fetuses from
Zika infection</article-title><source>Future Microbiol</source><year>2018</year><volume>13</volume><issue>2</issue><fpage>137</fpage><lpage>139</lpage><pub-id pub-id-type="pmid">29302996</pub-id></element-citation></ref><ref id="B196"><label>196</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yao</surname><given-names>X</given-names></name><name><surname>Ye</surname><given-names>F</given-names></name><name><surname>Zhang</surname><given-names>M</given-names></name><name><surname>Cui</surname><given-names>C</given-names></name><name><surname>Huang</surname><given-names>B</given-names></name><name><surname>Niu</surname><given-names>P</given-names></name></person-group><article-title>In vitro antiviral activity and projection of optimized dosing
design of hydroxychloroquine for the treatment of severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2)</article-title><source>Clin Infect Dis</source><year>2020</year><volume>71</volume><issue>15</issue><fpage>732</fpage><lpage>739</lpage><pub-id pub-id-type="pmid">32150618</pub-id></element-citation></ref><ref id="B197"><label>197</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choy K-T</surname><given-names/></name><name><surname>Wong AY-L</surname><given-names/></name><name><surname>Kaewpreedee</surname><given-names>P</given-names></name><name><surname>Sia</surname><given-names>SF</given-names></name><name><surname>Chen</surname><given-names>D</given-names></name><name><surname>Hui</surname><given-names>KPY</given-names></name></person-group><article-title>Remdesivir, lopinavir, emetine, and homoharringtonine inhibit
SARS-CoV-2 replication in vitro</article-title><source>Antiviral Res</source><year>2020</year><volume>178</volume><fpage>104786</fpage><lpage>104786</lpage><pub-id pub-id-type="pmid">32251767</pub-id></element-citation></ref><ref id="B198"><label>198</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Caly</surname><given-names>L</given-names></name><name><surname>Druce</surname><given-names>JD</given-names></name><name><surname>Catton</surname><given-names>MG</given-names></name><name><surname>Jans</surname><given-names>DA</given-names></name><name><surname>Wagstaff</surname><given-names>KM</given-names></name></person-group><article-title>The FDA-approved drug ivermectin inhibits the replication of
SARS-CoV-2 in vitro</article-title><source>Antiviral Res</source><year>2020</year><volume>178</volume><fpage>104787</fpage><lpage>104787</lpage><pub-id pub-id-type="pmid">32251768</pub-id></element-citation></ref><ref id="B199"><label>199</label><element-citation publication-type="webpage"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Ma</surname><given-names>X</given-names></name><name><surname>Yu</surname><given-names>F</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Zou</surname><given-names>F</given-names></name><name><surname>Pan</surname><given-names>T</given-names></name><etal/></person-group><article-title>Teicoplanin potently blocks the cell entry of
2019-nCoV</article-title><year>2020</year><ext-link ext-link-type="uri" xlink:href="https://www.biorxiv.org/content/10.1101/2020.02.05.935387v1">https://www.biorxiv.org/content/10.1101/2020.02.05.935387v1</ext-link></element-citation></ref><ref id="B200"><label>200</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sheahan</surname><given-names>TP</given-names></name><name><surname>Sims</surname><given-names>AC</given-names></name><name><surname>Graham</surname><given-names>RL</given-names></name><name><surname>Menachery</surname><given-names>VD</given-names></name><name><surname>Gralinski</surname><given-names>LE</given-names></name><name><surname>Case</surname><given-names>JB</given-names></name></person-group><article-title>Broad-spectrum antiviral GS-5734 inhibits both epidemic and
zoonotic coronaviruses</article-title><source>Sci Transl Med</source><year>2017</year><volume>9</volume><issue>396</issue></element-citation></ref><ref id="B201"><label>201</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sheahan</surname><given-names>TP</given-names></name><name><surname>Sims</surname><given-names>AC</given-names></name><name><surname>Zhou</surname><given-names>S</given-names></name><name><surname>Graham</surname><given-names>RL</given-names></name><name><surname>Pruijssers</surname><given-names>AJ</given-names></name><name><surname>Agostini</surname><given-names>ML</given-names></name></person-group><article-title>An orally bioavailable broad-spectrum antiviral inhibits
SARS-CoV-2 in human airway epithelial cell cultures and multiple
coronaviruses in mice</article-title><source>Sci Transl Med</source><year>2020</year><volume>12</volume><issue>541</issue></element-citation></ref><ref id="B202"><label>202</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Wit</surname><given-names>E</given-names></name><name><surname>Feldmann</surname><given-names>F</given-names></name><name><surname>Cronin</surname><given-names>J</given-names></name><name><surname>Jordan</surname><given-names>R</given-names></name><name><surname>Okumura</surname><given-names>A</given-names></name><name><surname>Thomas</surname><given-names>T</given-names></name></person-group><article-title>Prophylactic and therapeutic remdesivir (GS-5734) treatment in
the rhesus macaque model of MERS-CoV infection</article-title><source>Proc Natl Acad Sci USA</source><year>2020</year><volume>117</volume><issue>12</issue><fpage>6771</fpage><lpage>6776</lpage><pub-id pub-id-type="pmid">32054787</pub-id></element-citation></ref><ref id="B203"><label>203</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Clercq</surname><given-names>E</given-names></name></person-group><article-title>Potential antivirals and antiviral strategies against SARS
coronavirus infections</article-title><source>Expert Rev Anti Infect Ther</source><year>2006</year><volume>4</volume><issue>2</issue><fpage>291</fpage><lpage>302</lpage><pub-id pub-id-type="pmid">16597209</pub-id></element-citation></ref><ref id="B204"><label>204</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferner</surname><given-names>RE</given-names></name><name><surname>Aronson</surname><given-names>JK</given-names></name></person-group><article-title>Chloroquine and hydroxychloroquine in covid-19</article-title><source>BMJ</source><year>2020</year><volume>369</volume><fpage>m1432</fpage><lpage>m1432</lpage><pub-id pub-id-type="pmid">32269046</pub-id></element-citation></ref><ref id="B205"><label>205</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Al-Bari</surname><given-names>MAA</given-names></name></person-group><article-title>Targeting endosomal acidification by chloroquine analogs as a
promising strategy for the treatment of emerging viral
diseases</article-title><source>Pharmacol Res Perspect</source><year>2017</year><volume>5</volume><issue>1</issue><elocation-id>e00293</elocation-id><pub-id pub-id-type="pmid">28596841</pub-id></element-citation></ref><ref id="B206"><label>206</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Cao</surname><given-names>R</given-names></name><name><surname>Xu</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Hu</surname><given-names>H</given-names></name></person-group><article-title>Hydroxychloroquine, a less toxic derivative of chloroquine, is
effective in inhibiting SARS-CoV-2 infection in vitro</article-title><source>Cell Discov</source><year>2020</year><volume>6</volume><issue>1</issue><fpage>16</fpage><lpage>16</lpage><pub-id pub-id-type="pmid">32194981</pub-id></element-citation></ref><ref id="B207"><label>207</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McChesney</surname><given-names>EW</given-names></name></person-group><article-title>Animal toxicity and pharmacokinetics of hydroxychloroquine
sulfate</article-title><source>Am J Med</source><year>1983</year><volume>75</volume><issue>1</issue><fpage>11</fpage><lpage>18</lpage><pub-id pub-id-type="pmid">6408923</pub-id></element-citation></ref><ref id="B208"><label>208</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Touret</surname><given-names>F</given-names></name><name><surname>de Lamballerie</surname><given-names>X</given-names></name></person-group><article-title>Of chloroquine and COVID-19</article-title><source>Antiviral Res</source><year>2020</year><volume>177</volume><fpage>104762</fpage><lpage>104762</lpage><pub-id pub-id-type="pmid">32147496</pub-id></element-citation></ref><ref id="B209"><label>209</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lv</surname><given-names>Z</given-names></name><name><surname>Chu</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name></person-group><article-title>HIV protease inhibitors a review of molecular selectivity and
toxicity</article-title><source>HIV AIDS (Auckl)</source><year>2015</year><volume>7</volume><fpage>95</fpage><lpage>104</lpage><pub-id pub-id-type="pmid">25897264</pub-id></element-citation></ref><ref id="B210"><label>210</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Clercq</surname><given-names>E</given-names></name></person-group><article-title>Anti-HIV drugs 25 compounds approved within 25 years after the
discovery of HIV</article-title><source>Int J Antimicrob Agents</source><year>2009</year><volume>33</volume><issue>4</issue><fpage>307</fpage><lpage>320</lpage><pub-id pub-id-type="pmid">19108994</pub-id></element-citation></ref><ref id="B211"><label>211</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sisay</surname><given-names>M</given-names></name></person-group><article-title>3CLpro inhibitors as a potential therapeutic option for COVID-19
Available evidence and ongoing clinical trials</article-title><source>Pharmacol Res</source><year>2020</year><volume>156</volume><fpage>104779</fpage><lpage>104779</lpage><pub-id pub-id-type="pmid">32247821</pub-id></element-citation></ref><ref id="B212"><label>212</label><element-citation publication-type="webpage"><person-group person-group-type="author"><name><surname>Muralidharan</surname><given-names>N</given-names></name><name><surname>Sakthivel</surname><given-names>R</given-names></name><name><surname>Velmurugan</surname><given-names>D</given-names></name><name><surname>Gromiha</surname><given-names>MM</given-names></name></person-group><article-title>Computational studies of drug repurposing and synergism of
lopinavir, oseltamivir and ritonavir binding with SARS-CoV-2 protease
against COVID-19</article-title><source>J Biomol Struct Dyn</source><year>2020</year><pub-id pub-id-type="doi">10.1080/07391102.2020.1752802</pub-id></element-citation></ref><ref id="B213"><label>213</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Wilde</surname><given-names>AH</given-names></name><name><surname>Jochmans</surname><given-names>D</given-names></name><name><surname>Posthuma</surname><given-names>CC</given-names></name><name><surname>Zevenhoven-Dobbe</surname><given-names>JC</given-names></name><name><surname>van Nieuwkoop</surname><given-names>S</given-names></name><name><surname>Bestebroer</surname><given-names>TM</given-names></name></person-group><article-title>Screening of an FDA-approved compound library identifies four
small-molecule inhibitors of Middle East Respiratory Syndrome coronavirus
replication in cell culture</article-title><source>Antimicrob Agents Chemother</source><year>2014</year><volume>58</volume><issue>8</issue><fpage>4875</fpage><lpage>4884</lpage><pub-id pub-id-type="pmid">24841269</pub-id></element-citation></ref><ref id="B214"><label>214</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kalil</surname><given-names>AC</given-names></name></person-group><article-title>Treating COVID-19 - Off-label drug use, compassionate use, and
randomized clinical trials during pandemics</article-title><source>JAMA</source><year>2020</year><volume>323</volume><issue>19</issue><fpage>1897</fpage><lpage>1897</lpage><pub-id pub-id-type="pmid">32208486</pub-id></element-citation></ref><ref id="B215"><label>215</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>D</given-names></name><name><surname>Du</surname><given-names>G</given-names></name><name><surname>Du</surname><given-names>R</given-names></name><name><surname>Zhao</surname><given-names>J</given-names></name><name><surname>Jin</surname><given-names>Y</given-names></name></person-group><article-title>Remdesivir in adults with severe COVID-19 a randomised,
double-blind, placebo-controlled, multicentre trial</article-title><source>Lancet</source><year>2020</year><volume>395</volume><issue>10236</issue><fpage>1569</fpage><lpage>1578</lpage><pub-id pub-id-type="pmid">32423584</pub-id></element-citation></ref><ref id="B216"><label>216</label><element-citation publication-type="webpage"><person-group person-group-type="author"><name><surname>Beigel</surname><given-names>JH</given-names></name><name><surname>Tomashek</surname><given-names>KM</given-names></name><name><surname>Dodd</surname><given-names>LE</given-names></name><name><surname>Mehta</surname><given-names>AK</given-names></name><name><surname>Zingman</surname><given-names>BS</given-names></name><name><surname>Kalil</surname><given-names>AC</given-names></name><etal/></person-group><article-title>Remdesivir for the treatment of Covid-19 - Preliminary
report</article-title><source>N Engl J Med</source><year>2020</year><pub-id pub-id-type="doi">10.1056/NEJMoa2007764</pub-id></element-citation></ref><ref id="B217"><label>217</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>J</given-names></name><name><surname>Tian</surname><given-names>Z</given-names></name><name><surname>Yang</surname><given-names>X</given-names></name></person-group><article-title>Breakthrough chloroquine phosphate has shown apparent efficacy in
treatment of COVID-19 associated pneumonia in clinical
studies</article-title><source>Biosci Trends</source><year>2020</year><volume>14</volume><issue>1</issue><fpage>72</fpage><lpage>73</lpage><pub-id pub-id-type="pmid">32074550</pub-id></element-citation></ref><ref id="B218"><label>218</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Borba</surname><given-names>MGS</given-names></name><name><surname>Val</surname><given-names>FFA</given-names></name><name><surname>Sampaio</surname><given-names>VS</given-names></name><name><surname>Alexandre</surname><given-names>MAA</given-names></name><name><surname>Melo</surname><given-names>GC</given-names></name><name><surname>Brito</surname><given-names>M</given-names></name></person-group><article-title>Effect of high vs low doses of chloroquine diphosphate as
adjunctive therapy for patients hospitalized with severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) infection</article-title><source>JAMA Netw Open</source><year>2020</year><volume>3</volume><issue>4</issue><elocation-id>e208857</elocation-id><pub-id pub-id-type="pmid">32330277</pub-id></element-citation></ref><ref id="B219"><label>219</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gautret</surname><given-names>P</given-names></name><name><surname>Lagier J-C</surname><given-names/></name><name><surname>Parola</surname><given-names>P</given-names></name><name><surname>Hoang</surname><given-names>VT</given-names></name><name><surname>Meddeb</surname><given-names>L</given-names></name><name><surname>Mailhe</surname><given-names>M</given-names></name></person-group><article-title>Hydroxychloroquine and azithromycin as a treatment of COVID-19
results of an open-label non-randomized clinical trial</article-title><source>Int J Antimicrob Agents</source><year>2020</year><volume>56</volume><issue>1</issue><fpage>105949</fpage><lpage>105949</lpage><pub-id pub-id-type="pmid">32205204</pub-id></element-citation></ref><ref id="B220"><label>220</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cao</surname><given-names>B</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Wen</surname><given-names>D</given-names></name><name><surname>Liu</surname><given-names>W</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Fan</surname><given-names>G</given-names></name></person-group><article-title>A trial of lopinavir-ritonavir in adults hospitalized with severe
Covid-19</article-title><source>N Engl J Med</source><year>2020</year><volume>382</volume><issue>19</issue><fpage>1787</fpage><lpage>1799</lpage><pub-id pub-id-type="pmid">32187464</pub-id></element-citation></ref><ref id="B221"><label>221</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mulangu</surname><given-names>S</given-names></name><name><surname>Dodd</surname><given-names>LE</given-names></name><name><surname>Davey</surname><given-names>RT</given-names></name><name><surname>Tshiani Mbaya</surname><given-names>O</given-names></name><name><surname>Proschan</surname><given-names>M</given-names></name><name><surname>Mukadi</surname><given-names>D</given-names></name></person-group><article-title>A randomized, controlled trial of ebola virus disease
therapeutics</article-title><source>N Engl J Med</source><year>2019</year><volume>381</volume><issue>24</issue><fpage>2293</fpage><lpage>2303</lpage><pub-id pub-id-type="pmid">31774950</pub-id></element-citation></ref><ref id="B222"><label>222</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holshue</surname><given-names>ML</given-names></name><name><surname>DeBolt</surname><given-names>C</given-names></name><name><surname>Lindquist</surname><given-names>S</given-names></name><name><surname>Lofy</surname><given-names>KH</given-names></name><name><surname>Wiesman</surname><given-names>J</given-names></name><name><surname>Bruce</surname><given-names>H</given-names></name></person-group><article-title>First case of 2019 novel coronavirus in the United
States</article-title><source>N Engl J Med</source><year>2020</year><volume>382</volume><issue>10</issue><fpage>929</fpage><lpage>936</lpage><pub-id pub-id-type="pmid">32004427</pub-id></element-citation></ref><ref id="B223"><label>223</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grein</surname><given-names>J</given-names></name><name><surname>Ohmagari</surname><given-names>N</given-names></name><name><surname>Shin</surname><given-names>D</given-names></name><name><surname>Diaz</surname><given-names>G</given-names></name><name><surname>Asperges</surname><given-names>E</given-names></name><name><surname>Castagna</surname><given-names>A</given-names></name></person-group><article-title>Compassionate use of remdesivir for patients with severe
Covid-19</article-title><source>N Engl J Med</source><year>2020</year><volume>382</volume><issue>24</issue><fpage>2327</fpage><lpage>2336</lpage><pub-id pub-id-type="pmid">32275812</pub-id></element-citation></ref><ref id="B224"><label>224</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ko W-C</surname><given-names/></name><name><surname>Rolain J-M</surname><given-names/></name><name><surname>Lee N-Y</surname><given-names/></name><name><surname>Chen P-L</surname><given-names/></name><name><surname>Huang C-T</surname><given-names/></name><name><surname>Lee P-I</surname><given-names/></name></person-group><article-title>Arguments in favour of remdesivir for treating SARS-CoV-2
infections</article-title><source>Int J Antimicrob Agents</source><year>2020</year><volume>55</volume><issue>4</issue><fpage>105933</fpage><lpage>105933</lpage><pub-id pub-id-type="pmid">32147516</pub-id></element-citation></ref><ref id="B225"><label>225</label><element-citation publication-type="webpage"><person-group person-group-type="author"><collab>FDA</collab></person-group><article-title>Remdesivir EUA letter of authorization</article-title><year>2020</year><ext-link ext-link-type="uri" xlink:href="https://www.fda.gov/media/137564/download">https://www.fda.gov/media/137564/download</ext-link></element-citation></ref><ref id="B226"><label>226</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Savarino</surname><given-names>A</given-names></name><name><surname>Boelaert</surname><given-names>JR</given-names></name><name><surname>Cassone</surname><given-names>A</given-names></name><name><surname>Majori</surname><given-names>G</given-names></name><name><surname>Cauda</surname><given-names>R</given-names></name></person-group><article-title>Effects of chloroquine on viral infections an old drug against
today's diseases</article-title><source>Lancet Infect Dis</source><year>2003</year><volume>3</volume><issue>11</issue><fpage>722</fpage><lpage>727</lpage><pub-id pub-id-type="pmid">14592603</pub-id></element-citation></ref><ref id="B227"><label>227</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chatre</surname><given-names>C</given-names></name><name><surname>Roubille</surname><given-names>F</given-names></name><name><surname>Vernhet</surname><given-names>H</given-names></name><name><surname>Jorgensen</surname><given-names>C</given-names></name><name><surname>Pers Y-M</surname><given-names/></name></person-group><article-title>Cardiac complications attributed to chloroquine and
hydroxychloroquine a systematic review of the literature</article-title><source>Drug Saf</source><year>2018</year><volume>41</volume><issue>10</issue><fpage>919</fpage><lpage>931</lpage><pub-id pub-id-type="pmid">29858838</pub-id></element-citation></ref><ref id="B228"><label>228</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Damle</surname><given-names>B</given-names></name><name><surname>Vourvahis</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>E</given-names></name><name><surname>Leaney</surname><given-names>J</given-names></name><name><surname>Corrigan</surname><given-names>B</given-names></name></person-group><article-title>Clinical pharmacology perspectives on the antiviral activity of
azithromycin and use in COVID-19</article-title><source>Clin Pharmacol Ther</source><year>2020</year><volume>108</volume><issue>2</issue><fpage>201</fpage><lpage>211</lpage><pub-id pub-id-type="pmid">32302411</pub-id></element-citation></ref><ref id="B229"><label>229</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mehra</surname><given-names>MR</given-names></name><name><surname>Desai</surname><given-names>SS</given-names></name><name><surname>Kuy</surname><given-names>S</given-names></name><name><surname>Henry</surname><given-names>TD</given-names></name><name><surname>Patel</surname><given-names>AN</given-names></name></person-group><article-title>Retraction cardiovascular disease, drug therapy, and mortality in
Covid-19</article-title><source>N Engl J Med</source><year>2020</year><volume>382</volume><issue>26</issue><fpage>2582</fpage><lpage>2582</lpage></element-citation></ref><ref id="B230"><label>230</label><element-citation publication-type="webpage"><person-group person-group-type="author"><name><surname>Mehra</surname><given-names>MR</given-names></name><name><surname>Desai</surname><given-names>SS</given-names></name><name><surname>Ruschitzka</surname><given-names>F</given-names></name><name><surname>Patel</surname><given-names>AN.</given-names></name></person-group><article-title>RETRACTED: hydroxychloroquine or chloroquine with or without a
macrolide for treatment of COVID-19: a multinational registry
analysis</article-title><source>Lancet</source><year>2020</year><pub-id pub-id-type="doi">10.1016/S0140-6736(20)31180-6</pub-id></element-citation></ref><ref id="B231"><label>231</label><element-citation publication-type="webpage"><person-group person-group-type="author"><name><surname>Boulware</surname><given-names>DR</given-names></name><name><surname>Pullen</surname><given-names>MF</given-names></name><name><surname>Bangdiwala</surname><given-names>AS</given-names></name><name><surname>Pastick</surname><given-names>KA</given-names></name><name><surname>Lofgren</surname><given-names>SM</given-names></name><name><surname>Okafor</surname><given-names>EC</given-names></name><etal/></person-group><article-title>A randomized trial of hydroxychloroquine as postexposure
prophylaxis for Covid-19</article-title><source>N Engl J Med</source><year>2020</year><pub-id pub-id-type="doi">10.1056/NEJMoa2016638</pub-id></element-citation></ref><ref id="B232"><label>232</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zumla</surname><given-names>A</given-names></name><name><surname>Chan</surname><given-names>JFW</given-names></name><name><surname>Azhar</surname><given-names>EI</given-names></name><name><surname>Hui</surname><given-names>DSC</given-names></name><name><surname>Yuen K-Y</surname><given-names/></name></person-group><article-title>Coronaviruses - drug discovery and therapeutic
options</article-title><source>Nat Rev Drug Discov</source><year>2016</year><volume>15</volume><issue>5</issue><fpage>327</fpage><lpage>347</lpage><pub-id pub-id-type="pmid">26868298</pub-id></element-citation></ref><ref id="B233"><label>233</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chan JF-W</surname><given-names/></name><name><surname>Yao</surname><given-names>Y</given-names></name><name><surname>Yeung M-L</surname><given-names/></name><name><surname>Deng</surname><given-names>W</given-names></name><name><surname>Bao</surname><given-names>L</given-names></name><name><surname>Jia</surname><given-names>L</given-names></name></person-group><article-title>Treatment with lopinavir/ritonavir or interferon-&#x000df;1b improves
outcome of MERS-CoV infection in a nonhuman primate model of common
marmoset</article-title><source>J Infect Dis</source><year>2015</year><volume>212</volume><issue>12</issue><fpage>1904</fpage><lpage>1913</lpage><pub-id pub-id-type="pmid">26198719</pub-id></element-citation></ref><ref id="B234"><label>234</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nukoolkarn</surname><given-names>V</given-names></name><name><surname>Lee</surname><given-names>VS</given-names></name><name><surname>Malaisree</surname><given-names>M</given-names></name><name><surname>Aruksakulwong</surname><given-names>O</given-names></name><name><surname>Hannongbua</surname><given-names>S</given-names></name></person-group><article-title>Molecular dynamic simulations analysis of ritronavir and
lopinavir as SARS-CoV 3CLpro inhibitors</article-title><source>J Theor Biol</source><year>2008</year><volume>254</volume><issue>4</issue><fpage>861</fpage><lpage>867</lpage><pub-id pub-id-type="pmid">18706430</pub-id></element-citation></ref><ref id="B235"><label>235</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chu</surname><given-names>CM</given-names></name></person-group><article-title>Role of lopinavir/ritonavir in the treatment of SARS initial
virological and clinical findings</article-title><source>Thorax</source><year>2004</year><volume>59</volume><issue>3</issue><fpage>252</fpage><lpage>256</lpage><pub-id pub-id-type="pmid">14985565</pub-id></element-citation></ref><ref id="B236"><label>236</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sheahan</surname><given-names>TP</given-names></name><name><surname>Sims</surname><given-names>AC</given-names></name><name><surname>Leist</surname><given-names>SR</given-names></name><name><surname>Sch&#x000e4;fer</surname><given-names>A</given-names></name><name><surname>Won</surname><given-names>J</given-names></name><name><surname>Brown</surname><given-names>AJ</given-names></name></person-group><article-title>Comparative therapeutic efficacy of remdesivir and combination
lopinavir, ritonavir, and interferon beta against MERS-CoV</article-title><source>Nat Commun</source><year>2020</year><volume>11</volume><issue>1</issue><fpage>222</fpage><lpage>222</lpage><pub-id pub-id-type="pmid">31924756</pub-id></element-citation></ref><ref id="B237"><label>237</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gupta</surname><given-names>H</given-names></name><name><surname>Kumar</surname><given-names>S</given-names></name><name><surname>Roy</surname><given-names>S</given-names></name><name><surname>Gaud</surname><given-names>R</given-names></name></person-group><article-title>Patent protection strategies</article-title><source>J Pharm Bioallied Sci</source><year>2010</year><volume>2</volume><issue>1</issue><fpage>2</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">21814422</pub-id></element-citation></ref><ref id="B238"><label>238</label><element-citation publication-type="webpage"><person-group person-group-type="author"><name><surname>Gaessler</surname><given-names>F</given-names></name><name><surname>Wagner</surname><given-names>S</given-names></name></person-group><article-title>Patents, data exclusivity, and the development of new
drugs</article-title><year>2019</year><pub-id pub-id-type="doi">10.2139/ssrn.3401226</pub-id></element-citation></ref><ref id="B239"><label>239</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harrison</surname><given-names>C</given-names></name></person-group><article-title>Coronavirus puts drug repurposing on the fast
track</article-title><source>Nat Biotechnol</source><year>2020</year><volume>38</volume><issue>4</issue><fpage>379</fpage><lpage>381</lpage><pub-id pub-id-type="pmid">32205870</pub-id></element-citation></ref><ref id="B240"><label>240</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>C</given-names></name><name><surname>Zhou</surname><given-names>Q</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Garner</surname><given-names>LV</given-names></name><name><surname>Watkins</surname><given-names>SP</given-names></name><name><surname>Carter</surname><given-names>LJ</given-names></name></person-group><article-title>Research and development on therapeutic agents and vaccines for
COVID-19 and related human coronavirus diseases</article-title><source>ACS Cent Sci</source><year>2020</year><volume>6</volume><issue>3</issue><fpage>315</fpage><lpage>331</lpage><pub-id pub-id-type="pmid">32226821</pub-id></element-citation></ref><ref id="B241"><label>241</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>Inquartik [homepage on Internet]</collab></person-group><source>Coronavirus patents</source><year>2020</year><publisher-loc>Coronavirus patents</publisher-loc><publisher-name>China files for remdesivir patent, but Gilead Sciences will
still come out a winner</publisher-name></element-citation></ref><ref id="B242"><label>242</label><element-citation publication-type="webpage"><person-group person-group-type="author"><collab>Fierce Pharma</collab></person-group><article-title>Gilead turbocharges production of COVID-19 hopeful
remdesivir</article-title><year>2020</year><ext-link ext-link-type="uri" xlink:href="https://www.fiercepharma.com/manufacturing/gilead-to-donate-1-5m-doses-covid-19-hopeful-remdesivir-as-manufacturing-skyrockets">https://www.fiercepharma.com/manufacturing/gilead-to-donate-1-5m-doses-covid-19-hopeful-remdesivir-as-manufacturing-skyrockets</ext-link></element-citation></ref><ref id="B243"><label>243</label><element-citation publication-type="webpage"><person-group person-group-type="author"><collab>Incyte</collab></person-group><article-title>Lilly and Incyte announce collaboration for development and
commercialization of oral anti-inflammatory and autoimmune
therapies</article-title><year>2009</year><ext-link ext-link-type="uri" xlink:href="https://investor.incyte.com/news-releases/news-release-details/lilly-and-incyte-announce-collaboration-development-and">https://investor.incyte.com/news-releases/news-release-details/lilly-and-incyte-announce-collaboration-development-and</ext-link></element-citation></ref><ref id="B244"><label>244</label><element-citation publication-type="webpage"><person-group person-group-type="author"><collab>ClinicalTrials.gov</collab></person-group><article-title>Search results: baricitinib | COVID-19</article-title><year>2020</year><ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/results?cond=COVID-19&#x00026;term=baricitinib&#x00026;cntry=&#x00026;state=&#x00026;city=&#x00026;dist=">https://clinicaltrials.gov/ct2/results?cond=COVID-19&#x00026;term=baricitinib&#x00026;cntry=&#x00026;state=&#x00026;city=&#x00026;dist=</ext-link></element-citation></ref><ref id="B245"><label>245</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kobierski ME</surname><given-names>inventors</given-names></name><name><surname>Lilly</surname><given-names>Eli</given-names></name><collab>Company assignee</collab></person-group><year>2016</year><article-title>Processes and intermediates for the preparation of
{1(Ethylsulfonyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1yl]azetidin-3-yl}acetonitrile</article-title><source>International patent</source></element-citation></ref><ref id="B246"><label>246</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rodgers</surname><given-names>JD</given-names></name><name><surname>Shepard</surname><given-names>S</given-names></name><name><surname>Li</surname><given-names>Y-L</given-names></name><name><surname>Zhou</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>P</given-names></name><name><surname>Meloni</surname><given-names>D</given-names></name><etal/></person-group><year>2009</year><article-title>Azetidine and cyclobutane derivatives as JAK
inhibitors</article-title><source>United States patent</source></element-citation></ref><ref id="B247"><label>247</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hill</surname><given-names>A</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Levi</surname><given-names>J</given-names></name><name><surname>Heath</surname><given-names>K</given-names></name><name><surname>Fortunak</surname><given-names>J</given-names></name></person-group><article-title>Minimum costs to manufacture new treatments for
COVID-19</article-title><source>J Virus Erad</source><year>2020</year><volume>6</volume><issue>2</issue><fpage>61</fpage><lpage>69</lpage><pub-id pub-id-type="pmid">32405423</pub-id></element-citation></ref><ref id="B248"><label>248</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ledford</surname><given-names>H</given-names></name></person-group><article-title>Dozens of coronavirus drugs are in development - What happens
next</article-title><source>Nature</source><year>2020</year><volume>581</volume><issue>7808</issue><fpage>247</fpage><lpage>248</lpage><pub-id pub-id-type="pmid">32409766</pub-id></element-citation></ref><ref id="B249"><label>249</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sham</surname><given-names>HL</given-names></name><name><surname>Norbeck</surname><given-names>D</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Betebenner</surname><given-names>DA</given-names></name><name><surname>Kempf</surname><given-names>D</given-names></name><name><surname>Herrin</surname><given-names>TR</given-names></name><etal/></person-group><year>1997</year><article-title>Retroviral protease inhibiting compounds</article-title><source>International patent</source></element-citation></ref><ref id="B250"><label>250</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stuk</surname><given-names>T</given-names></name><name><surname>Kerdesky</surname><given-names>FAJ</given-names></name><name><surname>Likewski</surname><given-names>LM</given-names></name><name><surname>Norbeck</surname><given-names>DW</given-names></name><name><surname>Scarpetti</surname><given-names>D</given-names></name><name><surname>Tien</surname><given-names>JHJ</given-names></name><etal/></person-group><year>1995</year><article-title>Process for the preparations of a substituted
2,5-diamino-3-hydroxyhexane</article-title><source>International patent</source></element-citation></ref><ref id="B251"><label>251</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kempf</surname><given-names>DJ</given-names></name><name><surname>Sham</surname><given-names>HL</given-names></name><name><surname>Marsh</surname><given-names>KC</given-names></name><name><surname>Flentge</surname><given-names>CA</given-names></name><name><surname>Betebenner</surname><given-names>D</given-names></name><name><surname>Green</surname><given-names>BE</given-names></name></person-group><article-title>Discovery of ritonavir, a potent inhibitor of HIV protease with
high oral bioavailability and clinical efficacy</article-title><source>J Med Chem</source><year>1998</year><volume>41</volume><issue>4</issue><fpage>602</fpage><lpage>617</lpage><pub-id pub-id-type="pmid">9484509</pub-id></element-citation></ref><ref id="B252"><label>252</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ning</surname><given-names>Z</given-names></name><name><surname>Ran</surname><given-names>G</given-names></name><name><surname>Ren</surname><given-names>XU</given-names></name><name><surname>Zhang</surname><given-names>YI</given-names></name><name><surname>Zhou</surname><given-names>Z</given-names></name></person-group><year>2019</year><article-title>Preparation method of ritonavir</article-title><source>Chinese patent</source></element-citation></ref><ref id="B253"><label>253</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shoujun</surname><given-names>W</given-names></name><name><surname>Dequan</surname><given-names>WU</given-names></name><name><surname>Yuyou</surname><given-names>X</given-names></name><name><surname>Chao</surname><given-names>Z</given-names></name></person-group><year>2018</year><article-title>Method used for preparing lopinavir using one-pot
method</article-title><source>Chinese patent</source></element-citation></ref></ref-list></back></article>